{ "schema_version": "1.0.0", "run_id": "report-2d17662dd927", "mode": "calculated_only", "status": "passed", "report": { "id": "novartis-q4-fy2025-report-v1", "title": "Novartis Fourth Quarter and Full Year 2025 Financial Explorer", "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf", "pages": 54, "pdf_sha256": "96b1174acff58ba1cb1212ad7b9f74aecfbf966c126c437a65928f0ab2908543", "capture_method": "Reviewed transcription assisted by local PDF text extraction. Selected financial tables are normalized; this is not a general PDF ingestion system.", "inspected_on": "2026-10-15", "units_note": "Financial amounts are USD millions unless each row states a different unit. Blank source cells remain null.", "accounting_note": "Quarter statements are unaudited; annual statements and dated balance sheets are audited as labeled in the report. Core and free cash flow are company-defined non-IFRS measures." }, "periods": [ { "id": "quarter", "label": "Fourth quarter", "current": "2025-Q4", "prior": "2024-Q4" }, { "id": "full_year", "label": "Full year", "current": "2025-FY", "prior": "2024-FY" } ], "views": { "quarter": { "current_period": "2025-Q4", "prior_period": "2024-Q4", "income": { "rows": [ { "id": "net_sales", "label": "Net sales", "current": 13336, "prior": 13153, "delta": 183, "growth_percent": 1.3913175701360907, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.net_sales.2025-Q4", "income.net_sales.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 524, "prior": 405, "delta": 119, "growth_percent": 29.38271604938272, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_revenues.2025-Q4", "income.other_revenues.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -3611, "prior": -3324, "delta": -287, "growth_percent": -8.634175691937426, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.cost_of_goods_sold.2025-Q4", "income.cost_of_goods_sold.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "gross_profit", "label": "Gross profit", "current": 10249, "prior": 10234, "delta": 15, "growth_percent": 0.1465702560093805, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.gross_profit.2025-Q4", "income.gross_profit.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -3440, "prior": -3501, "delta": 61, "growth_percent": 1.7423593259068837, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.selling_general_administration.2025-Q4", "income.selling_general_administration.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -3163, "prior": -2842, "delta": -321, "growth_percent": -11.294862772695286, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.research_and_development.2025-Q4", "income.research_and_development.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 417, "prior": 298, "delta": 119, "growth_percent": 39.93288590604027, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_income.2025-Q4", "income.other_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -447, "prior": -659, "delta": 212, "growth_percent": 32.16995447647951, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_expense.2025-Q4", "income.other_expense.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "operating_income", "label": "Operating income", "current": 3616, "prior": 3530, "delta": 86, "growth_percent": 2.4362606232294617, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.operating_income.2025-Q4", "income.operating_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "associated_companies", "label": "Loss from associated companies", "current": -2, "prior": -3, "delta": 1, "growth_percent": 33.33333333333333, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.associated_companies.2025-Q4", "income.associated_companies.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "interest_expense", "label": "Interest expense", "current": -304, "prior": -275, "delta": -29, "growth_percent": -10.545454545454545, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.interest_expense.2025-Q4", "income.interest_expense.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_financial_income_expense", "label": "Other financial income and expense", "current": -92, "prior": 33, "delta": -125, "growth_percent": -378.7878787878788, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_financial_income_expense.2025-Q4", "income.other_financial_income_expense.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "income_before_taxes", "label": "Income before taxes", "current": 3218, "prior": 3285, "delta": -67, "growth_percent": -2.0395738203957383, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.income_before_taxes.2025-Q4", "income.income_before_taxes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "income_taxes", "label": "Income taxes", "current": -814, "prior": -465, "delta": -349, "growth_percent": -75.05376344086021, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.income_taxes.2025-Q4", "income.income_taxes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Net income", "current": 2404, "prior": 2820, "delta": -416, "growth_percent": -14.75177304964539, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.net_income.2025-Q4", "income.net_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "current": 2409, "prior": 2818, "delta": -409, "growth_percent": -14.513839602555004, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.net_income_shareholders.2025-Q4", "income.net_income_shareholders.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "current": -5, "prior": 2, "delta": -7, "growth_percent": -350.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.non_controlling_interests.2025-Q4", "income.non_controlling_interests.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "basic_shares", "label": "Weighted average basic shares", "current": 1913, "prior": 1987, "delta": -74, "growth_percent": -3.724207347760443, "unit": "million shares", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.basic_shares.2025-Q4", "income.basic_shares.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "basic_eps", "label": "Basic earnings per share", "current": 1.26, "prior": 1.42, "delta": -0.15999999999999992, "growth_percent": -11.26760563380281, "unit": "USD per share", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.basic_eps.2025-Q4", "income.basic_eps.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "diluted_shares", "label": "Weighted average diluted shares", "current": 1929, "prior": 2004, "delta": -75, "growth_percent": -3.74251497005988, "unit": "million shares", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.diluted_shares.2025-Q4", "income.diluted_shares.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "diluted_eps", "label": "Diluted earnings per share", "current": 1.25, "prior": 1.41, "delta": -0.15999999999999992, "growth_percent": -11.347517730496449, "unit": "USD per share", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.diluted_eps.2025-Q4", "income.diluted_eps.2024-Q4" ], "note": null, "dimensions": {} } ], "bridge": { "id": "operating_income", "title": "Year-on-year reported operating-income movement", "kind": "year_on_year", "prior": 3530, "current": 3616, "delta": 86, "residual": 0, "unit": "USD million", "prior_label": "2024-Q4", "current_label": "2025-Q4", "contributions": [ { "id": "net_sales", "label": "Net sales", "current": 13336, "prior": 13153, "delta": 183, "growth_percent": 1.3913175701360907, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.net_sales.2025-Q4", "income.net_sales.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 524, "prior": 405, "delta": 119, "growth_percent": 29.38271604938272, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_revenues.2025-Q4", "income.other_revenues.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -3611, "prior": -3324, "delta": -287, "growth_percent": -8.634175691937426, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.cost_of_goods_sold.2025-Q4", "income.cost_of_goods_sold.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -3440, "prior": -3501, "delta": 61, "growth_percent": 1.7423593259068837, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.selling_general_administration.2025-Q4", "income.selling_general_administration.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -3163, "prior": -2842, "delta": -321, "growth_percent": -11.294862772695286, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.research_and_development.2025-Q4", "income.research_and_development.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 417, "prior": 298, "delta": 119, "growth_percent": 39.93288590604027, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_income.2025-Q4", "income.other_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -447, "prior": -659, "delta": 212, "growth_percent": 32.16995447647951, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "income.other_expense.2025-Q4", "income.other_expense.2024-Q4" ], "note": null, "dimensions": {} } ], "source_pages": [ 17 ], "fact_ids": [ "income.net_sales.2025-Q4", "income.net_sales.2024-Q4", "income.other_revenues.2025-Q4", "income.other_revenues.2024-Q4", "income.cost_of_goods_sold.2025-Q4", "income.cost_of_goods_sold.2024-Q4", "income.selling_general_administration.2025-Q4", "income.selling_general_administration.2024-Q4", "income.research_and_development.2025-Q4", "income.research_and_development.2024-Q4", "income.other_income.2025-Q4", "income.other_income.2024-Q4", "income.other_expense.2025-Q4", "income.other_expense.2024-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Seven non-overlapping signed P&L changes; gross-profit subtotal is excluded. Arithmetic contributions do not establish operational causes." }, "ratios": [ { "id": "gross_margin", "label": "Gross margin", "current": 76.85212957408518, "prior": 77.80734433209153, "delta": -0.955214758006349, "unit": "%", "formula": "gross_profit / net_sales \u00d7 100", "source_pages": [ 17 ], "fact_ids": [ "income.gross_profit.2025-Q4", "income.net_sales.2025-Q4", "income.gross_profit.2024-Q4", "income.net_sales.2024-Q4" ] }, { "id": "operating_margin", "label": "Operating margin", "current": 27.114577084583086, "prior": 26.83798372994754, "delta": 0.2765933546355477, "unit": "%", "formula": "operating_income / net_sales \u00d7 100", "source_pages": [ 17 ], "fact_ids": [ "income.operating_income.2025-Q4", "income.net_sales.2025-Q4", "income.operating_income.2024-Q4", "income.net_sales.2024-Q4" ] }, { "id": "net_margin", "label": "Net margin", "current": 18.026394721055787, "prior": 21.439975670949593, "delta": -3.413580949893806, "unit": "%", "formula": "net_income / net_sales \u00d7 100", "source_pages": [ 17 ], "fact_ids": [ "income.net_income.2025-Q4", "income.net_sales.2025-Q4", "income.net_income.2024-Q4", "income.net_sales.2024-Q4" ] }, { "id": "rd_sales_ratio", "label": "R&D expense / net sales", "current": 23.717756448710258, "prior": 21.60723789249601, "delta": 2.1105185562142488, "unit": "%", "formula": "research_and_development / net_sales \u00d7 -100", "source_pages": [ 17 ], "fact_ids": [ "income.research_and_development.2025-Q4", "income.net_sales.2025-Q4", "income.research_and_development.2024-Q4", "income.net_sales.2024-Q4" ] }, { "id": "effective_tax_rate", "label": "Effective tax rate", "current": 25.295214418893725, "prior": 14.15525114155251, "delta": 11.139963277341215, "unit": "%", "formula": "income_taxes / income_before_taxes \u00d7 -100", "source_pages": [ 17 ], "fact_ids": [ "income.income_taxes.2025-Q4", "income.income_before_taxes.2025-Q4", "income.income_taxes.2024-Q4", "income.income_before_taxes.2024-Q4" ] } ] }, "sales": { "total_current": 13336, "total_prior": 13153, "unit": "USD million", "products": [ { "id": "entresto", "label": "Entresto", "current": 1253, "prior": 2180, "delta": -927, "growth_percent": -42.522935779816514, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.entresto.2025-Q4", "products.entresto.2024-Q4", "product_geography.entresto_us.2025-Q4", "product_geography.entresto_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 9.395620875824836, "share_prior_percent": 16.574165589599332, "share_change_pp": -7.178544713774496, "is_top20": true, "us_current": 95, "rest_world_current": 1158, "us_prior": null, "rest_world_prior": null }, { "id": "leqvio", "label": "Leqvio", "current": 335, "prior": 223, "delta": 112, "growth_percent": 50.224215246636774, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.leqvio.2025-Q4", "products.leqvio.2024-Q4", "product_geography.leqvio_us.2025-Q4", "product_geography.leqvio_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 2.511997600479904, "share_prior_percent": 1.695430700220482, "share_change_pp": 0.816566900259422, "is_top20": true, "us_current": 164, "rest_world_current": 171, "us_prior": null, "rest_world_prior": null }, { "id": "vanrafia", "label": "Vanrafia", "current": 13, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.vanrafia.2025-Q4", "products.vanrafia.2024-Q4" ], "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 0.09748050389922015, "share_prior_percent": null, "share_change_pp": null, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "cosentyx", "label": "Cosentyx", "current": 1807, "prior": 1596, "delta": 211, "growth_percent": 13.220551378446116, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.cosentyx.2025-Q4", "products.cosentyx.2024-Q4", "product_geography.cosentyx_us.2025-Q4", "product_geography.cosentyx_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 13.549790041991603, "share_prior_percent": 12.134113890367217, "share_change_pp": 1.4156761516243854, "is_top20": true, "us_current": 1098, "rest_world_current": 709, "us_prior": null, "rest_world_prior": null }, { "id": "ilaris", "label": "Ilaris", "current": 514, "prior": 413, "delta": 101, "growth_percent": 24.455205811138015, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.ilaris.2025-Q4", "products.ilaris.2024-Q4", "product_geography.ilaris_us.2025-Q4", "product_geography.ilaris_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 3.8542291541691664, "share_prior_percent": 3.139968068121341, "share_change_pp": 0.7142610860478253, "is_top20": true, "us_current": 294, "rest_world_current": 220, "us_prior": null, "rest_world_prior": null }, { "id": "xolair", "label": "Xolair", "current": 384, "prior": 399, "delta": -15, "growth_percent": -3.7593984962406015, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.xolair.2025-Q4", "products.xolair.2024-Q4", "product_geography.xolair_us.2025-Q4", "product_geography.xolair_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 2.8794241151769646, "share_prior_percent": 3.0335284725918044, "share_change_pp": -0.15410435741483974, "is_top20": true, "us_current": null, "rest_world_current": 384, "us_prior": null, "rest_world_prior": null }, { "id": "rhapsido", "label": "Rhapsido", "current": 19, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.rhapsido.2025-Q4", "products.rhapsido.2024-Q4" ], "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 0.14247150569886022, "share_prior_percent": null, "share_change_pp": null, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kesimpta", "label": "Kesimpta", "current": 1228, "prior": 950, "delta": 278, "growth_percent": 29.263157894736842, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.kesimpta.2025-Q4", "products.kesimpta.2024-Q4", "product_geography.kesimpta_us.2025-Q4", "product_geography.kesimpta_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 9.208158368326334, "share_prior_percent": 7.222686839504296, "share_change_pp": 1.9854715288220381, "is_top20": true, "us_current": 815, "rest_world_current": 413, "us_prior": null, "rest_world_prior": null }, { "id": "zolgensma", "label": "Zolgensma Group", "current": 307, "prior": 262, "delta": 45, "growth_percent": 17.17557251908397, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.zolgensma.2025-Q4", "products.zolgensma.2024-Q4", "product_geography.zolgensma_us.2025-Q4", "product_geography.zolgensma_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 2.3020395920815835, "share_prior_percent": 1.9919410020527637, "share_change_pp": 0.3100985900288198, "is_top20": true, "us_current": 91, "rest_world_current": 216, "us_prior": null, "rest_world_prior": null }, { "id": "aimovig", "label": "Aimovig", "current": 90, "prior": 80, "delta": 10, "growth_percent": 12.5, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.aimovig.2025-Q4", "products.aimovig.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 0.674865026994601, "share_prior_percent": 0.6082262601687828, "share_change_pp": 0.06663876682581826, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kisqali", "label": "Kisqali", "current": 1321, "prior": 902, "delta": 419, "growth_percent": 46.45232815964523, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.kisqali.2025-Q4", "products.kisqali.2024-Q4", "product_geography.kisqali_us.2025-Q4", "product_geography.kisqali_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 9.905518896220755, "share_prior_percent": 6.857751083403025, "share_change_pp": 3.04776781281773, "is_top20": true, "us_current": 795, "rest_world_current": 526, "us_prior": null, "rest_world_prior": null }, { "id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "current": 540, "prior": 527, "delta": 13, "growth_percent": 2.4667931688804554, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.tafinlar_mekinist.2025-Q4", "products.tafinlar_mekinist.2024-Q4", "product_geography.tafinlar_mekinist_us.2025-Q4", "product_geography.tafinlar_mekinist_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 4.049190161967607, "share_prior_percent": 4.006690488861857, "share_change_pp": 0.04249967310575009, "is_top20": true, "us_current": 181, "rest_world_current": 359, "us_prior": null, "rest_world_prior": null }, { "id": "jakavi", "label": "Jakavi", "current": 555, "prior": 487, "delta": 68, "growth_percent": 13.963039014373715, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.jakavi.2025-Q4", "products.jakavi.2024-Q4", "product_geography.jakavi_us.2025-Q4", "product_geography.jakavi_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 4.161667666466707, "share_prior_percent": 3.7025773587774653, "share_change_pp": 0.45909030768924186, "is_top20": true, "us_current": null, "rest_world_current": 555, "us_prior": null, "rest_world_prior": null }, { "id": "pluvicto", "label": "Pluvicto", "current": 605, "prior": 351, "delta": 254, "growth_percent": 72.36467236467237, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.pluvicto.2025-Q4", "products.pluvicto.2024-Q4", "product_geography.pluvicto_us.2025-Q4", "product_geography.pluvicto_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 4.536592681463707, "share_prior_percent": 2.6685927164905343, "share_change_pp": 1.867999964973173, "is_top20": true, "us_current": 491, "rest_world_current": 114, "us_prior": null, "rest_world_prior": null }, { "id": "promacta", "label": "Promacta / Revolade", "current": 226, "prior": 583, "delta": -357, "growth_percent": -61.23499142367067, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.promacta.2025-Q4", "products.promacta.2024-Q4", "product_geography.promacta_us.2025-Q4", "product_geography.promacta_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 1.6946610677864429, "share_prior_percent": 4.4324488709800045, "share_change_pp": -2.7377878031935614, "is_top20": true, "us_current": 33, "rest_world_current": 193, "us_prior": null, "rest_world_prior": null }, { "id": "scemblix", "label": "Scemblix", "current": 391, "prior": 207, "delta": 184, "growth_percent": 88.88888888888889, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.scemblix.2025-Q4", "products.scemblix.2024-Q4", "product_geography.scemblix_us.2025-Q4", "product_geography.scemblix_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 2.9319136172765448, "share_prior_percent": 1.5737854481867253, "share_change_pp": 1.3581281690898195, "is_top20": true, "us_current": 246, "rest_world_current": 145, "us_prior": null, "rest_world_prior": null }, { "id": "tasigna", "label": "Tasigna", "current": 179, "prior": 411, "delta": -232, "growth_percent": -56.447688564476884, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.tasigna.2025-Q4", "products.tasigna.2024-Q4", "product_geography.tasigna_us.2025-Q4", "product_geography.tasigna_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 1.3422315536892622, "share_prior_percent": 3.1247624116171218, "share_change_pp": -1.7825308579278596, "is_top20": true, "us_current": 48, "rest_world_current": 131, "us_prior": null, "rest_world_prior": null }, { "id": "lutathera", "label": "Lutathera", "current": 203, "prior": 190, "delta": 13, "growth_percent": 6.842105263157896, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.lutathera.2025-Q4", "products.lutathera.2024-Q4", "product_geography.lutathera_us.2025-Q4", "product_geography.lutathera_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 1.5221955608878224, "share_prior_percent": 1.444537367900859, "share_change_pp": 0.0776581929869633, "is_top20": true, "us_current": 147, "rest_world_current": 56, "us_prior": null, "rest_world_prior": null }, { "id": "fabhalta", "label": "Fabhalta", "current": 155, "prior": 57, "delta": 98, "growth_percent": 171.9298245614035, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.fabhalta.2025-Q4", "products.fabhalta.2024-Q4", "product_geography.fabhalta_us.2025-Q4", "product_geography.fabhalta_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 1.1622675464907017, "share_prior_percent": 0.43336121037025777, "share_change_pp": 0.728906336120444, "is_top20": true, "us_current": 95, "rest_world_current": 60, "us_prior": null, "rest_world_prior": null }, { "id": "piqray_vijoice", "label": "Piqray / Vijoice", "current": 81, "prior": 109, "delta": -28, "growth_percent": -25.688073394495415, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.piqray_vijoice.2025-Q4", "products.piqray_vijoice.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 0.6073785242951409, "share_prior_percent": 0.8287082794799665, "share_change_pp": -0.22132975518482556, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "sandostatin", "label": "Sandostatin Group", "current": 291, "prior": 306, "delta": -15, "growth_percent": -4.901960784313726, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.sandostatin.2025-Q4", "products.sandostatin.2024-Q4", "product_geography.sandostatin_us.2025-Q4", "product_geography.sandostatin_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 2.1820635872825433, "share_prior_percent": 2.326465445145594, "share_change_pp": -0.1444018578630506, "is_top20": true, "us_current": 169, "rest_world_current": 122, "us_prior": null, "rest_world_prior": null }, { "id": "exforge", "label": "Exforge Group", "current": 181, "prior": 159, "delta": 22, "growth_percent": 13.836477987421384, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.exforge.2025-Q4", "products.exforge.2024-Q4", "product_geography.exforge_us.2025-Q4", "product_geography.exforge_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 1.357228554289142, "share_prior_percent": 1.208849692085456, "share_change_pp": 0.14837886220368612, "is_top20": true, "us_current": 1, "rest_world_current": 180, "us_prior": null, "rest_world_prior": null }, { "id": "lucentis", "label": "Lucentis", "current": 133, "prior": 210, "delta": -77, "growth_percent": -36.666666666666664, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.lucentis.2025-Q4", "products.lucentis.2024-Q4", "product_geography.lucentis_us.2025-Q4", "product_geography.lucentis_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 0.9973005398920216, "share_prior_percent": 1.5965939329430547, "share_change_pp": -0.5992933930510331, "is_top20": true, "us_current": null, "rest_world_current": 133, "us_prior": null, "rest_world_prior": null }, { "id": "diovan", "label": "Diovan Group", "current": 157, "prior": 140, "delta": 17, "growth_percent": 12.142857142857142, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37, 39 ], "source_ids": [ "p37", "p39" ], "fact_ids": [ "products.diovan.2025-Q4", "products.diovan.2024-Q4", "product_geography.diovan_us.2025-Q4", "product_geography.diovan_row.2025-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 1.177264547090582, "share_prior_percent": 1.06439595529537, "share_change_pp": 0.11286859179521214, "is_top20": true, "us_current": 8, "rest_world_current": 149, "us_prior": null, "rest_world_prior": null }, { "id": "galvus", "label": "Galvus Group", "current": 114, "prior": 144, "delta": -30, "growth_percent": -20.833333333333336, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.galvus.2025-Q4", "products.galvus.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 0.8548290341931614, "share_prior_percent": 1.094807268303809, "share_change_pp": -0.23997823411064767, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kymriah", "label": "Kymriah", "current": 85, "prior": 108, "delta": -23, "growth_percent": -21.296296296296298, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.kymriah.2025-Q4", "products.kymriah.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 0.637372525494901, "share_prior_percent": 0.8211054512278567, "share_change_pp": -0.18373292573295574, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "contract_manufacturing", "label": "Contract manufacturing", "current": 404, "prior": 323, "delta": 81, "growth_percent": 25.077399380804955, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.contract_manufacturing.2025-Q4", "products.contract_manufacturing.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 3.029394121175765, "share_prior_percent": 2.4557135254314604, "share_change_pp": 0.5736805957443045, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "other", "label": "Other portfolio", "current": 1765, "prior": 1836, "delta": -71, "growth_percent": -3.867102396514161, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "products.other.2025-Q4", "products.other.2024-Q4" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 13.234853029394122, "share_prior_percent": 13.958792670873565, "share_change_pp": -0.7239396414794435, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null } ], "regions": [ { "id": "us", "label": "United States", "current": 5334, "prior": 6002, "delta": -668, "growth_percent": -11.129623458847052, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.us.2025-Q4", "regions.us.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 39.997000599880025, "share_prior_percent": 45.63217516916293, "share_change_pp": -5.635174569282903 }, { "id": "europe", "label": "Europe", "current": 4403, "prior": 3962, "delta": 441, "growth_percent": 11.130742049469964, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.europe.2025-Q4", "regions.europe.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 33.015896820635874, "share_prior_percent": 30.122405534858963, "share_change_pp": 2.8934912857769106 }, { "id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "current": 2646, "prior": 2313, "delta": 333, "growth_percent": 14.396887159533073, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.asia_africa_australasia.2025-Q4", "regions.asia_africa_australasia.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 19.84103179364127, "share_prior_percent": 17.58534174712993, "share_change_pp": 2.25569004651134 }, { "id": "canada_latin_america", "label": "Canada and Latin America", "current": 953, "prior": 876, "delta": 77, "growth_percent": 8.789954337899543, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.canada_latin_america.2025-Q4", "regions.canada_latin_america.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 7.146070785842832, "share_prior_percent": 6.660077548848172, "share_change_pp": 0.48599323699466 } ], "therapeutic_areas": [ { "id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "current": 1601, "prior": 2403, "delta": -802, "growth_percent": -33.37494798168956, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "therapeutic_areas.cardiovascular.2025-Q4", "therapeutic_areas.cardiovascular.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 12.00509898020396, "share_prior_percent": 18.269596289819813, "share_change_pp": -6.264497309615853 }, { "id": "immunology", "label": "Immunology", "current": 2724, "prior": 2408, "delta": 316, "growth_percent": 13.122923588039868, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "therapeutic_areas.immunology.2025-Q4", "therapeutic_areas.immunology.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 20.425914817036592, "share_prior_percent": 18.307610431080363, "share_change_pp": 2.118304385956229 }, { "id": "neuroscience", "label": "Neuroscience", "current": 1625, "prior": 1292, "delta": 333, "growth_percent": 25.773993808049532, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "therapeutic_areas.neuroscience.2025-Q4", "therapeutic_areas.neuroscience.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 12.185062987402521, "share_prior_percent": 9.822854101725842, "share_change_pp": 2.3622088856766794 }, { "id": "oncology", "label": "Oncology", "current": 4256, "prior": 3824, "delta": 432, "growth_percent": 11.297071129707113, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "therapeutic_areas.oncology.2025-Q4", "therapeutic_areas.oncology.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 31.91361727654469, "share_prior_percent": 29.073215236067817, "share_change_pp": 2.8404020404768744 }, { "id": "established", "label": "Established brands", "current": 3130, "prior": 3226, "delta": -96, "growth_percent": -2.9758214507129574, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 37 ], "source_ids": [ "p37" ], "fact_ids": [ "therapeutic_areas.established.2025-Q4", "therapeutic_areas.established.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 23.47030593881224, "share_prior_percent": 24.526723941306166, "share_change_pp": -1.0564180024939276 } ], "market_groups": [ { "id": "established", "label": "Established markets", "current": 9860, "prior": 10209, "delta": -349, "growth_percent": -3.4185522578117347, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "market_groups.established.2025-Q4", "market_groups.established.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 73.93521295740851, "share_prior_percent": 77.6172736257888, "share_change_pp": -3.682060668380288 }, { "id": "emerging", "label": "Emerging growth markets", "current": 3476, "prior": 2944, "delta": 532, "growth_percent": 18.070652173913043, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "market_groups.emerging.2025-Q4", "market_groups.emerging.2024-Q4" ], "note": null, "dimensions": {}, "share_current_percent": 26.06478704259148, "share_prior_percent": 22.382726374211206, "share_change_pp": 3.6820606683802737 } ], "top20_coverage": [ { "id": "top20_sales_share", "label": "2025 top-20 brand cohort / net sales", "current": 80.72135572885422, "prior": 80.23264654451457, "delta": 0.4887091843396547, "unit": "%", "formula": "sum of the same 20 brands' reported sales / company net sales \u00d7 100", "source_pages": [ 37, 39 ], "fact_ids": [ "products.entresto.2025-Q4", "products.entresto.2024-Q4", "product_geography.entresto_us.2025-Q4", "product_geography.entresto_row.2025-Q4", "products.leqvio.2025-Q4", "products.leqvio.2024-Q4", "product_geography.leqvio_us.2025-Q4", "product_geography.leqvio_row.2025-Q4", "products.cosentyx.2025-Q4", "products.cosentyx.2024-Q4", "product_geography.cosentyx_us.2025-Q4", "product_geography.cosentyx_row.2025-Q4", "products.ilaris.2025-Q4", "products.ilaris.2024-Q4", "product_geography.ilaris_us.2025-Q4", "product_geography.ilaris_row.2025-Q4", "products.xolair.2025-Q4", "products.xolair.2024-Q4", "product_geography.xolair_us.2025-Q4", "product_geography.xolair_row.2025-Q4", "products.kesimpta.2025-Q4", "products.kesimpta.2024-Q4", "product_geography.kesimpta_us.2025-Q4", "product_geography.kesimpta_row.2025-Q4", "products.zolgensma.2025-Q4", "products.zolgensma.2024-Q4", "product_geography.zolgensma_us.2025-Q4", "product_geography.zolgensma_row.2025-Q4", "products.kisqali.2025-Q4", "products.kisqali.2024-Q4", "product_geography.kisqali_us.2025-Q4", "product_geography.kisqali_row.2025-Q4", "products.tafinlar_mekinist.2025-Q4", "products.tafinlar_mekinist.2024-Q4", "product_geography.tafinlar_mekinist_us.2025-Q4", "product_geography.tafinlar_mekinist_row.2025-Q4", "products.jakavi.2025-Q4", "products.jakavi.2024-Q4", "product_geography.jakavi_us.2025-Q4", "product_geography.jakavi_row.2025-Q4", "products.pluvicto.2025-Q4", "products.pluvicto.2024-Q4", "product_geography.pluvicto_us.2025-Q4", "product_geography.pluvicto_row.2025-Q4", "products.promacta.2025-Q4", "products.promacta.2024-Q4", "product_geography.promacta_us.2025-Q4", "product_geography.promacta_row.2025-Q4", "products.scemblix.2025-Q4", "products.scemblix.2024-Q4", "product_geography.scemblix_us.2025-Q4", "product_geography.scemblix_row.2025-Q4", "products.tasigna.2025-Q4", "products.tasigna.2024-Q4", "product_geography.tasigna_us.2025-Q4", "product_geography.tasigna_row.2025-Q4", "products.lutathera.2025-Q4", "products.lutathera.2024-Q4", "product_geography.lutathera_us.2025-Q4", "product_geography.lutathera_row.2025-Q4", "products.fabhalta.2025-Q4", "products.fabhalta.2024-Q4", "product_geography.fabhalta_us.2025-Q4", "product_geography.fabhalta_row.2025-Q4", "products.sandostatin.2025-Q4", "products.sandostatin.2024-Q4", "product_geography.sandostatin_us.2025-Q4", "product_geography.sandostatin_row.2025-Q4", "products.exforge.2025-Q4", "products.exforge.2024-Q4", "product_geography.exforge_us.2025-Q4", "product_geography.exforge_row.2025-Q4", "products.lucentis.2025-Q4", "products.lucentis.2024-Q4", "product_geography.lucentis_us.2025-Q4", "product_geography.lucentis_row.2025-Q4", "products.diovan.2025-Q4", "products.diovan.2024-Q4", "product_geography.diovan_us.2025-Q4", "product_geography.diovan_row.2025-Q4" ] } ], "top20_totals": { "current": 10765, "prior": 10553, "rest_current": 2571, "rest_prior": 2600, "note": "Current top-20/rest totals cross-check pages 39/40. Prior totals are calculated from exact same-cohort brand amounts, not inferred from rounded growth rates." }, "notes": [ "Four geographic regions are one complete partition. Established/emerging markets are a separate alternative partition, not extra regions.", "Therapeutic areas are sales classifications; the company reports a single global operating segment.", "2024 therapeutic-area classifications conform to the 2025 presentation. New-brand blank comparatives remain unavailable.", "US/rest-of-world brand values are 2025 only; no exact 2024 split is reconstructed from growth rates. Xolair/Jakavi/Lucentis US blanks remain unavailable.", "Shares and USD growth are calculated from reported amounts; they are not reported constant-currency rates. These are two-year comparisons, not a multi-quarter time series." ] }, "cashflow": { "rows": [ { "id": "net_income", "label": "Net income", "current": 2404, "prior": 2820, "delta": -416, "growth_percent": -14.75177304964539, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.net_income.2025-Q4", "cashflow.net_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "current": 3302, "prior": 2709, "delta": 593, "growth_percent": 21.88999630860096, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.noncash_adjustments.2025-Q4", "cashflow.noncash_adjustments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "dividends_received", "label": "Dividends received from associated companies and others", "current": null, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.dividends_received.2025-Q4", "cashflow.dividends_received.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "interest_received", "label": "Interest received", "current": 88, "prior": 142, "delta": -54, "growth_percent": -38.028169014084504, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.interest_received.2025-Q4", "cashflow.interest_received.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "interest_paid", "label": "Interest paid", "current": -211, "prior": -214, "delta": 3, "growth_percent": 1.4018691588785046, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.interest_paid.2025-Q4", "cashflow.interest_paid.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "current": -50, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.other_financial_receipts.2025-Q4", "cashflow.other_financial_receipts.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "other_financial_payments", "label": "Other financial payments / change in payments", "current": -6, "prior": -85, "delta": 79, "growth_percent": 92.94117647058823, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.other_financial_payments.2025-Q4", "cashflow.other_financial_payments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "income_taxes_paid", "label": "Income taxes paid", "current": -981, "prior": -924, "delta": -57, "growth_percent": -6.1688311688311686, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.income_taxes_paid.2025-Q4", "cashflow.income_taxes_paid.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "current": 4546, "prior": 4448, "delta": 98, "growth_percent": 2.2032374100719423, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.operating_before_changes.2025-Q4", "cashflow.operating_before_changes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "current": -695, "prior": -260, "delta": -435, "growth_percent": -167.30769230769232, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.provision_payments.2025-Q4", "cashflow.provision_payments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "working_capital", "label": "Working capital and other operating cash-flow items", "current": -1587, "prior": 5, "delta": -1592, "growth_percent": -31839.999999999996, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.working_capital.2025-Q4", "cashflow.working_capital.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "current": 2264, "prior": 4193, "delta": -1929, "growth_percent": -46.00524683997138, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.operating_cash_flow.2025-Q4", "cashflow.operating_cash_flow.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "capex", "label": "Purchases of property, plant and equipment", "current": -609, "prior": -558, "delta": -51, "growth_percent": -9.13978494623656, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.capex.2025-Q4", "cashflow.capex.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "current": 1, "prior": 47, "delta": -46, "growth_percent": -97.87234042553192, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.property_sale_proceeds.2025-Q4", "cashflow.property_sale_proceeds.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "intangible_purchases", "label": "Purchases of intangible assets", "current": -408, "prior": -573, "delta": 165, "growth_percent": 28.79581151832461, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.intangible_purchases.2025-Q4", "cashflow.intangible_purchases.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "current": 112, "prior": 37, "delta": 75, "growth_percent": 202.7027027027027, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.intangible_sale_proceeds.2025-Q4", "cashflow.intangible_sale_proceeds.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "financial_asset_purchases", "label": "Purchases of financial assets", "current": -53, "prior": -48, "delta": -5, "growth_percent": -10.416666666666668, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.financial_asset_purchases.2025-Q4", "cashflow.financial_asset_purchases.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "current": 24, "prior": 21, "delta": 3, "growth_percent": 14.285714285714285, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.financial_asset_sale_proceeds.2025-Q4", "cashflow.financial_asset_sale_proceeds.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "business_acquisitions", "label": "Acquisitions of businesses", "current": -21, "prior": -426, "delta": 405, "growth_percent": 95.07042253521126, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.business_acquisitions.2025-Q4", "cashflow.business_acquisitions.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "current": -1138, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.asset_acquisitions.2025-Q4", "cashflow.asset_acquisitions.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "business_divestments", "label": "Divestments of businesses, net", "current": -9, "prior": 164, "delta": -173, "growth_percent": -105.48780487804879, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.business_divestments.2025-Q4", "cashflow.business_divestments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "current": -37, "prior": -2257, "delta": 2220, "growth_percent": 98.36065573770492, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.time_deposit_investments.2025-Q4", "cashflow.time_deposit_investments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "current": 48, "prior": 560, "delta": -512, "growth_percent": -91.42857142857143, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.time_deposit_proceeds.2025-Q4", "cashflow.time_deposit_proceeds.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_investing", "label": "Other investing cash flows, net", "current": -14, "prior": 0, "delta": -14, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.other_investing.2025-Q4", "cashflow.other_investing.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "current": -2104, "prior": -3033, "delta": 929, "growth_percent": 30.629739531816686, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.investing_cash_flow.2025-Q4", "cashflow.investing_cash_flow.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "current": null, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.dividends_paid.2025-Q4", "cashflow.dividends_paid.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "treasury_share_purchases", "label": "Purchases of treasury shares", "current": -1480, "prior": -2762, "delta": 1282, "growth_percent": 46.41564083997103, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.treasury_share_purchases.2025-Q4", "cashflow.treasury_share_purchases.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "current": 4, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.treasury_share_proceeds.2025-Q4", "cashflow.treasury_share_proceeds.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "current": 5963, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.debt_proceeds.2025-Q4", "cashflow.debt_proceeds.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "current": -1770, "prior": -10, "delta": -1760, "growth_percent": -17600.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.debt_repayments.2025-Q4", "cashflow.debt_repayments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "current_debt_change", "label": "Change in current financial debts", "current": -837, "prior": -24, "delta": -813, "growth_percent": -3387.5, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.current_debt_change.2025-Q4", "cashflow.current_debt_change.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_debt_repayments", "label": "Repayments of other current financial debts", "current": null, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.other_debt_repayments.2025-Q4", "cashflow.other_debt_repayments.2024-Q4" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "lease_payments", "label": "Payments of lease liabilities", "current": -73, "prior": -72, "delta": -1, "growth_percent": -1.3888888888888888, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.lease_payments.2025-Q4", "cashflow.lease_payments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "ownership_payments", "label": "Payments from changes in ownership interests", "current": -91, "prior": -156, "delta": 65, "growth_percent": 41.66666666666667, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.ownership_payments.2025-Q4", "cashflow.ownership_payments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_financing", "label": "Other financing cash flows, net", "current": -33, "prior": 28, "delta": -61, "growth_percent": -217.85714285714283, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.other_financing.2025-Q4", "cashflow.other_financing.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "current": 1683, "prior": -2996, "delta": 4679, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.financing_cash_flow.2025-Q4", "cashflow.financing_cash_flow.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "current": 1843, "prior": -1836, "delta": 3679, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.cash_change_before_fx.2025-Q4", "cashflow.cash_change_before_fx.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "current": 36, "prior": -314, "delta": 350, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.fx_effect.2025-Q4", "cashflow.fx_effect.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cash_change", "label": "Net change in cash and cash equivalents", "current": 1879, "prior": -2150, "delta": 4029, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.cash_change.2025-Q4", "cashflow.cash_change.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cash_start", "label": "Cash and cash equivalents at period start", "current": 9556, "prior": 13609, "delta": -4053, "growth_percent": -29.7817620692189, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.cash_start.2025-Q4", "cashflow.cash_start.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cash_end", "label": "Cash and cash equivalents at December 31", "current": 11435, "prior": 11459, "delta": -24, "growth_percent": -0.20944235971725284, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.cash_end.2025-Q4", "cashflow.cash_end.2024-Q4" ], "note": null, "dimensions": {} } ], "operating_bridge": { "id": "operating_cash_flow", "title": "Year-on-year operating-cash-flow movement", "kind": "year_on_year", "prior": 4193, "current": 2264, "delta": -1929, "residual": 0, "unit": "USD million", "prior_label": "2024-Q4", "current_label": "2025-Q4", "contributions": [ { "id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "current": 4546, "prior": 4448, "delta": 98, "growth_percent": 2.2032374100719423, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.operating_before_changes.2025-Q4", "cashflow.operating_before_changes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "current": -695, "prior": -260, "delta": -435, "growth_percent": -167.30769230769232, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.provision_payments.2025-Q4", "cashflow.provision_payments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "working_capital", "label": "Working capital and other operating cash-flow items", "current": -1587, "prior": 5, "delta": -1592, "growth_percent": -31839.999999999996, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.working_capital.2025-Q4", "cashflow.working_capital.2024-Q4" ], "note": null, "dimensions": {} } ], "source_pages": [ 23 ], "fact_ids": [ "cashflow.operating_before_changes.2025-Q4", "cashflow.operating_before_changes.2024-Q4", "cashflow.provision_payments.2025-Q4", "cashflow.provision_payments.2024-Q4", "cashflow.working_capital.2025-Q4", "cashflow.working_capital.2024-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Before-working-capital cash flow, provision payments and working-capital changes are non-overlapping components; their detailed child lines are not counted again." }, "change_bridge": { "id": "cash_rollforward", "title": "Cash balance rollforward", "kind": "cash_rollforward", "prior": 9556, "current": 11435, "delta": 1879, "residual": 0, "unit": "USD million", "prior_label": "Opening cash / 2025-Q4", "current_label": "Closing cash / 2025-Q4", "contributions": [ { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "prior": 0, "current": 2264, "delta": 2264, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.operating_cash_flow.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "prior": 0, "current": -2104, "delta": -2104, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.investing_cash_flow.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "prior": 0, "current": 1683, "delta": 1683, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.financing_cash_flow.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "prior": 0, "current": 36, "delta": 36, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.fx_effect.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 23 ], "fact_ids": [ "cashflow.operating_cash_flow.2025-Q4", "cashflow.investing_cash_flow.2025-Q4", "cashflow.financing_cash_flow.2025-Q4", "cashflow.fx_effect.2025-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Selected-period cash flows plus foreign-exchange effects bridge opening to closing cash; these endpoints are not prior-year/current-year totals." }, "change_bridge_comparative": { "id": "cash_rollforward", "title": "Cash balance rollforward", "kind": "cash_rollforward", "prior": 13609, "current": 11459, "delta": -2150, "residual": 0, "unit": "USD million", "prior_label": "Opening cash / 2024-Q4", "current_label": "Closing cash / 2024-Q4", "contributions": [ { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "prior": 0, "current": 4193, "delta": 4193, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.operating_cash_flow.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "prior": 0, "current": -3033, "delta": -3033, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.investing_cash_flow.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "prior": 0, "current": -2996, "delta": -2996, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.financing_cash_flow.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "prior": 0, "current": -314, "delta": -314, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.fx_effect.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 23 ], "fact_ids": [ "cashflow.operating_cash_flow.2024-Q4", "cashflow.investing_cash_flow.2024-Q4", "cashflow.financing_cash_flow.2024-Q4", "cashflow.fx_effect.2024-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Selected-period cash flows plus foreign-exchange effects bridge opening to closing cash; these endpoints are not prior-year/current-year totals." }, "fcf_bridge": { "id": "free_cash_flow", "title": "Operating cash flow to company-defined free cash flow", "kind": "non_ifrs_reconciliation", "prior": 2264, "current": 1655, "delta": -609, "residual": 0, "unit": "USD million", "prior_label": "Operating cash flow / 2025-Q4", "current_label": "Non-IFRS free cash flow / 2025-Q4", "contributions": [ { "id": "capex", "label": "Purchases of property, plant and equipment", "prior": 0, "current": -609, "delta": -609, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.capex.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 23, 49 ], "fact_ids": [ "cashflow.capex.2025-Q4", "free_cash_flow.free_cash_flow.2025-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Novartis defines FCF as operating cash flow less purchases of property, plant and equipment. Intangible purchases are not deducted in this company definition." }, "fcf_bridge_comparative": { "id": "free_cash_flow", "title": "Operating cash flow to company-defined free cash flow", "kind": "non_ifrs_reconciliation", "prior": 4193, "current": 3635, "delta": -558, "residual": 0, "unit": "USD million", "prior_label": "Operating cash flow / 2024-Q4", "current_label": "Non-IFRS free cash flow / 2024-Q4", "contributions": [ { "id": "capex", "label": "Purchases of property, plant and equipment", "prior": 0, "current": -558, "delta": -558, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 23 ], "source_ids": [ "p23" ], "fact_ids": [ "cashflow.capex.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 23, 49 ], "fact_ids": [ "cashflow.capex.2024-Q4", "free_cash_flow.free_cash_flow.2024-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Novartis defines FCF as operating cash flow less purchases of property, plant and equipment. Intangible purchases are not deducted in this company definition." }, "working_capital": [ { "id": "inventories", "label": "Decrease/(increase) in inventories", "current": 151, "prior": -169, "delta": 320, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.inventories.2025-Q4", "working_capital.inventories.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "trade_receivables", "label": "Increase/decrease in trade receivables", "current": -94, "prior": 162, "delta": -256, "growth_percent": -158.02469135802468, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.trade_receivables.2025-Q4", "working_capital.trade_receivables.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "trade_payables", "label": "Increase/(decrease) in trade payables", "current": 102, "prior": 555, "delta": -453, "growth_percent": -81.62162162162161, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.trade_payables.2025-Q4", "working_capital.trade_payables.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_assets", "label": "Change in other current and non-current assets", "current": -601, "prior": -73, "delta": -528, "growth_percent": -723.2876712328766, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.other_assets.2025-Q4", "working_capital.other_assets.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_liabilities", "label": "Change in other current liabilities", "current": -1145, "prior": -470, "delta": -675, "growth_percent": -143.61702127659575, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.other_liabilities.2025-Q4", "working_capital.other_liabilities.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "total", "label": "Total working-capital and other operating items", "current": -1587, "prior": 5, "delta": -1592, "growth_percent": -31839.999999999996, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.total.2025-Q4", "working_capital.total.2024-Q4" ], "note": null, "dimensions": {} } ], "free_cash_flow": { "id": "free_cash_flow", "label": "Free cash flow", "current": 1655, "prior": 3635, "delta": -1980, "growth_percent": -54.470426409903716, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "source_pages": [ 49 ], "source_ids": [ "p49" ], "fact_ids": [ "free_cash_flow.free_cash_flow.2025-Q4", "free_cash_flow.free_cash_flow.2024-Q4" ], "note": null, "dimensions": {} } }, "core": { "rows": [ { "id": "net_sales", "label": "Net sales", "current": 13336, "prior": 13153, "delta": 183, "growth_percent": 1.3913175701360907, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 17 ], "source_ids": [ "p17" ], "fact_ids": [ "core.net_sales.2025-Q4", "core.net_sales.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 524, "prior": 405, "delta": 119, "growth_percent": 29.38271604938272, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.other_revenues.2025-Q4", "core.other_revenues.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -2853, "prior": -2584, "delta": -269, "growth_percent": -10.410216718266254, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.cost_of_goods_sold.2025-Q4", "core.cost_of_goods_sold.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "gross_profit", "label": "Gross profit", "current": 11007, "prior": 10974, "delta": 33, "growth_percent": 0.30071077091306725, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.gross_profit.2025-Q4", "core.gross_profit.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -3436, "prior": -3501, "delta": 65, "growth_percent": 1.8566123964581547, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.selling_general_administration.2025-Q4", "core.selling_general_administration.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -2763, "prior": -2502, "delta": -261, "growth_percent": -10.431654676258994, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.research_and_development.2025-Q4", "core.research_and_development.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 298, "prior": 26, "delta": 272, "growth_percent": 1046.1538461538462, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.other_income.2025-Q4", "core.other_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -177, "prior": -138, "delta": -39, "growth_percent": -28.26086956521739, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.other_expense.2025-Q4", "core.other_expense.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "operating_income", "label": "Core operating income", "current": 4929, "prior": 4859, "delta": 70, "growth_percent": 1.440625643136448, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.operating_income.2025-Q4", "core.operating_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "income_before_taxes", "label": "Core income before taxes", "current": 4641, "prior": 4664, "delta": -23, "growth_percent": -0.49313893653516294, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.income_before_taxes.2025-Q4", "core.income_before_taxes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "income_taxes", "label": "Core income taxes", "current": -752, "prior": -731, "delta": -21, "growth_percent": -2.8727770177838576, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.income_taxes.2025-Q4", "core.income_taxes.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Core net income", "current": 3889, "prior": 3933, "delta": -44, "growth_percent": -1.1187388761759471, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.net_income.2025-Q4", "core.net_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "current": 3894, "prior": 3932, "delta": -38, "growth_percent": -0.9664292980671414, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.net_income_shareholders.2025-Q4", "core.net_income_shareholders.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "non_controlling_interests", "label": "Core non-controlling interests", "current": -5, "prior": 1, "delta": -6, "growth_percent": -600.0, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.non_controlling_interests.2025-Q4", "core.non_controlling_interests.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "basic_eps", "label": "Core basic earnings per share", "current": 2.03, "prior": 1.98, "delta": 0.04999999999999982, "growth_percent": 2.525252525252516, "unit": "USD per share", "basis": "Core non-IFRS", "source_pages": [ 47 ], "source_ids": [ "p47" ], "fact_ids": [ "core.basic_eps.2025-Q4", "core.basic_eps.2024-Q4" ], "note": null, "dimensions": {} } ], "adjustments": [ { "id": "amortization", "label": "Amortization of intangible assets", "current": 763, "prior": 800, "delta": -37, "growth_percent": -4.625, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.amortization.2025-Q4", "core_adjustments.amortization.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "impairments", "label": "Total impairment charges", "current": 364, "prior": 425, "delta": -61, "growth_percent": -14.352941176470587, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.impairments.2025-Q4", "core_adjustments.impairments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "current": 50, "prior": -15, "delta": 65, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.acquisition_divestment.2025-Q4", "core_adjustments.acquisition_divestment.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_adjustments", "label": "Total other adjustment items", "current": 136, "prior": 119, "delta": 17, "growth_percent": 14.285714285714285, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.other_adjustments.2025-Q4", "core_adjustments.other_adjustments.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "total_adjustments", "label": "Total adjustments", "current": 1313, "prior": 1329, "delta": -16, "growth_percent": -1.203912716328066, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.total_adjustments.2025-Q4", "core_adjustments.total_adjustments.2024-Q4" ], "note": null, "dimensions": {} } ], "bridge": { "id": "ifrs_to_core", "title": "Reported IFRS to core operating income", "kind": "non_ifrs_reconciliation", "prior": 3616, "current": 4929, "delta": 1313, "residual": 0, "unit": "USD million", "prior_label": "IFRS operating income / 2025-Q4", "current_label": "Core operating income / 2025-Q4", "contributions": [ { "id": "amortization", "label": "Amortization of intangible assets", "prior": 0, "current": 763, "delta": 763, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.amortization.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "impairments", "label": "Total impairment charges", "prior": 0, "current": 364, "delta": 364, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.impairments.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "prior": 0, "current": 50, "delta": 50, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.acquisition_divestment.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_adjustments", "label": "Total other adjustment items", "prior": 0, "current": 136, "delta": 136, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.other_adjustments.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 46 ], "fact_ids": [ "core_adjustments.amortization.2025-Q4", "core_adjustments.impairments.2025-Q4", "core_adjustments.acquisition_divestment.2025-Q4", "core_adjustments.other_adjustments.2025-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Four non-overlapping company-defined adjustments. Core is a non-IFRS measure, not a replacement for reported IFRS results." }, "ratios": [ { "id": "core_operating_margin", "label": "Core operating margin", "current": 36.960107978404324, "prior": 36.94214247700145, "delta": 0.017965501402876782, "unit": "%", "formula": "operating_income / net_sales \u00d7 100", "source_pages": [ 17, 47 ], "fact_ids": [ "core.operating_income.2025-Q4", "core.net_sales.2025-Q4", "core.operating_income.2024-Q4", "core.net_sales.2024-Q4" ] }, { "id": "core_net_margin", "label": "Core net margin", "current": 29.161667666466705, "prior": 29.901923515547786, "delta": -0.7402558490810804, "unit": "%", "formula": "net_income / net_sales \u00d7 100", "source_pages": [ 17, 47 ], "fact_ids": [ "core.net_income.2025-Q4", "core.net_sales.2025-Q4", "core.net_income.2024-Q4", "core.net_sales.2024-Q4" ] } ] }, "other_revenues": [ { "id": "profit_sharing", "label": "Profit sharing income", "current": 373, "prior": 305, "delta": 68, "growth_percent": 22.295081967213115, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.profit_sharing.2025-Q4", "other_revenues.profit_sharing.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "royalties", "label": "Royalty income", "current": 27, "prior": 7, "delta": 20, "growth_percent": 285.7142857142857, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.royalties.2025-Q4", "other_revenues.royalties.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "milestones", "label": "Milestone income", "current": 21, "prior": 2, "delta": 19, "growth_percent": 950.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.milestones.2025-Q4", "other_revenues.milestones.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other", "label": "Other revenue", "current": 103, "prior": 91, "delta": 12, "growth_percent": 13.186813186813188, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.other.2025-Q4", "other_revenues.other.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "total", "label": "Total other revenues", "current": 524, "prior": 405, "delta": 119, "growth_percent": 29.38271604938272, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.total.2025-Q4", "other_revenues.total.2024-Q4" ], "note": null, "dimensions": {} } ], "equity": { "rows": [ { "id": "equity_start", "label": "Total equity at start of period", "current": 44752, "prior": 43441, "delta": 1311, "growth_percent": 3.017886328583596, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.equity_start.2025-Q4", "equity.equity_start.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Net income", "current": 2404, "prior": 2820, "delta": -416, "growth_percent": -14.75177304964539, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.net_income.2025-Q4", "equity.net_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "current": 595, "prior": 477, "delta": 118, "growth_percent": 24.737945492662476, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_comprehensive_income.2025-Q4", "equity.other_comprehensive_income.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "other_movements", "label": "Total other equity movements", "current": -1202, "prior": -2612, "delta": 1410, "growth_percent": 53.98162327718224, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_movements.2025-Q4", "equity.other_movements.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "equity_end", "label": "Total equity at end of period", "current": 46549, "prior": 44126, "delta": 2423, "growth_percent": 5.491093686262068, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.equity_end.2025-Q4", "equity.equity_end.2024-Q4" ], "note": null, "dimensions": {} } ], "bridge": { "id": "equity_rollforward", "title": "Total-equity rollforward", "kind": "equity_rollforward", "prior": 44752, "current": 46549, "delta": 1797, "residual": 0, "unit": "USD million", "prior_label": "Opening total equity / 2025-Q4", "current_label": "Closing total equity / 2025-Q4", "contributions": [ { "id": "net_income", "label": "Net income", "prior": 0, "current": 2404, "delta": 2404, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.net_income.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "prior": 0, "current": 595, "delta": 595, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_comprehensive_income.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_movements", "label": "Total other equity movements", "prior": 0, "current": -1202, "delta": -1202, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_movements.2025-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 21 ], "fact_ids": [ "equity.net_income.2025-Q4", "equity.other_comprehensive_income.2025-Q4", "equity.other_movements.2025-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Total equity includes non-controlling interests; shareholder-only equity is a different measure." }, "bridge_comparative": { "id": "equity_rollforward", "title": "Total-equity rollforward", "kind": "equity_rollforward", "prior": 43441, "current": 44126, "delta": 685, "residual": 0, "unit": "USD million", "prior_label": "Opening total equity / 2024-Q4", "current_label": "Closing total equity / 2024-Q4", "contributions": [ { "id": "net_income", "label": "Net income", "prior": 0, "current": 2820, "delta": 2820, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.net_income.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "prior": 0, "current": 477, "delta": 477, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_comprehensive_income.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_movements", "label": "Total other equity movements", "prior": 0, "current": -2612, "delta": -2612, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 21 ], "source_ids": [ "p21" ], "fact_ids": [ "equity.other_movements.2024-Q4" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 21 ], "fact_ids": [ "equity.net_income.2024-Q4", "equity.other_comprehensive_income.2024-Q4", "equity.other_movements.2024-Q4" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Total equity includes non-controlling interests; shareholder-only equity is a different measure." } }, "currency_rates": [ { "id": "chf", "label": "CHF", "current": 1.251, "prior": 1.14, "delta": 0.11099999999999999, "growth_percent": 9.736842105263158, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.chf.2025-Q4", "currency_rates.chf.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "cny", "label": "CNY", "current": 0.141, "prior": 0.139, "delta": 0.001999999999999974, "growth_percent": 1.4388489208632904, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.cny.2025-Q4", "currency_rates.cny.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "eur", "label": "EUR", "current": 1.164, "prior": 1.067, "delta": 0.09699999999999998, "growth_percent": 9.090909090909088, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.eur.2025-Q4", "currency_rates.eur.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "gbp", "label": "GBP", "current": 1.329, "prior": 1.282, "delta": 0.04699999999999993, "growth_percent": 3.6661466458658287, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.gbp.2025-Q4", "currency_rates.gbp.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "jpy100", "label": "100 JPY", "current": 0.649, "prior": 0.657, "delta": -0.008000000000000007, "growth_percent": -1.2176560121765612, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.jpy100.2025-Q4", "currency_rates.jpy100.2024-Q4" ], "note": null, "dimensions": {} }, { "id": "rub100", "label": "100 RUB", "current": 1.252, "prior": 0.997, "delta": 0.255, "growth_percent": 25.576730190571716, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.rub100.2025-Q4", "currency_rates.rub100.2024-Q4" ], "note": null, "dimensions": {} } ] }, "full_year": { "current_period": "2025-FY", "prior_period": "2024-FY", "income": { "rows": [ { "id": "net_sales", "label": "Net sales", "current": 54532, "prior": 50317, "delta": 4215, "growth_percent": 8.376890514140351, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.net_sales.2025-FY", "income.net_sales.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 2142, "prior": 1405, "delta": 737, "growth_percent": 52.455516014234874, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_revenues.2025-FY", "income.other_revenues.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -13699, "prior": -12827, "delta": -872, "growth_percent": -6.798160130973726, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.cost_of_goods_sold.2025-FY", "income.cost_of_goods_sold.2024-FY" ], "note": null, "dimensions": {} }, { "id": "gross_profit", "label": "Gross profit", "current": 42975, "prior": 38895, "delta": 4080, "growth_percent": 10.489780177400695, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.gross_profit.2025-FY", "income.gross_profit.2024-FY" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -13248, "prior": -12566, "delta": -682, "growth_percent": -5.427343625656533, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.selling_general_administration.2025-FY", "income.selling_general_administration.2024-FY" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -11200, "prior": -10022, "delta": -1178, "growth_percent": -11.754140890041906, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.research_and_development.2025-FY", "income.research_and_development.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 1460, "prior": 1175, "delta": 285, "growth_percent": 24.25531914893617, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_income.2025-FY", "income.other_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -2343, "prior": -2938, "delta": 595, "growth_percent": 20.251872021783527, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_expense.2025-FY", "income.other_expense.2024-FY" ], "note": null, "dimensions": {} }, { "id": "operating_income", "label": "Operating income", "current": 17644, "prior": 14544, "delta": 3100, "growth_percent": 21.314631463146313, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.operating_income.2025-FY", "income.operating_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "associated_companies", "label": "Loss from associated companies", "current": -12, "prior": -38, "delta": 26, "growth_percent": 68.42105263157895, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.associated_companies.2025-FY", "income.associated_companies.2024-FY" ], "note": null, "dimensions": {} }, { "id": "interest_expense", "label": "Interest expense", "current": -1144, "prior": -1006, "delta": -138, "growth_percent": -13.717693836978132, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.interest_expense.2025-FY", "income.interest_expense.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_financial_income_expense", "label": "Other financial income and expense", "current": -136, "prior": 140, "delta": -276, "growth_percent": -197.14285714285717, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_financial_income_expense.2025-FY", "income.other_financial_income_expense.2024-FY" ], "note": null, "dimensions": {} }, { "id": "income_before_taxes", "label": "Income before taxes", "current": 16352, "prior": 13640, "delta": 2712, "growth_percent": 19.882697947214076, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.income_before_taxes.2025-FY", "income.income_before_taxes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "income_taxes", "label": "Income taxes", "current": -2385, "prior": -1701, "delta": -684, "growth_percent": -40.21164021164021, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.income_taxes.2025-FY", "income.income_taxes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Net income", "current": 13967, "prior": 11939, "delta": 2028, "growth_percent": 16.9863472652651, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.net_income.2025-FY", "income.net_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "current": 13984, "prior": 11941, "delta": 2043, "growth_percent": 17.10911983920945, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.net_income_shareholders.2025-FY", "income.net_income_shareholders.2024-FY" ], "note": null, "dimensions": {} }, { "id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "current": -17, "prior": -2, "delta": -15, "growth_percent": -750.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.non_controlling_interests.2025-FY", "income.non_controlling_interests.2024-FY" ], "note": null, "dimensions": {} }, { "id": "basic_shares", "label": "Weighted average basic shares", "current": 1939, "prior": 2018, "delta": -79, "growth_percent": -3.914767096134787, "unit": "million shares", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.basic_shares.2025-FY", "income.basic_shares.2024-FY" ], "note": null, "dimensions": {} }, { "id": "basic_eps", "label": "Basic earnings per share", "current": 7.21, "prior": 5.92, "delta": 1.29, "growth_percent": 21.79054054054054, "unit": "USD per share", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.basic_eps.2025-FY", "income.basic_eps.2024-FY" ], "note": null, "dimensions": {} }, { "id": "diluted_shares", "label": "Weighted average diluted shares", "current": 1955, "prior": 2035, "delta": -80, "growth_percent": -3.9312039312039313, "unit": "million shares", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.diluted_shares.2025-FY", "income.diluted_shares.2024-FY" ], "note": null, "dimensions": {} }, { "id": "diluted_eps", "label": "Diluted earnings per share", "current": 7.15, "prior": 5.87, "delta": 1.2800000000000002, "growth_percent": 21.805792163543444, "unit": "USD per share", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.diluted_eps.2025-FY", "income.diluted_eps.2024-FY" ], "note": null, "dimensions": {} } ], "bridge": { "id": "operating_income", "title": "Year-on-year reported operating-income movement", "kind": "year_on_year", "prior": 14544, "current": 17644, "delta": 3100, "residual": 0, "unit": "USD million", "prior_label": "2024-FY", "current_label": "2025-FY", "contributions": [ { "id": "net_sales", "label": "Net sales", "current": 54532, "prior": 50317, "delta": 4215, "growth_percent": 8.376890514140351, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.net_sales.2025-FY", "income.net_sales.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 2142, "prior": 1405, "delta": 737, "growth_percent": 52.455516014234874, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_revenues.2025-FY", "income.other_revenues.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -13699, "prior": -12827, "delta": -872, "growth_percent": -6.798160130973726, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.cost_of_goods_sold.2025-FY", "income.cost_of_goods_sold.2024-FY" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -13248, "prior": -12566, "delta": -682, "growth_percent": -5.427343625656533, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.selling_general_administration.2025-FY", "income.selling_general_administration.2024-FY" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -11200, "prior": -10022, "delta": -1178, "growth_percent": -11.754140890041906, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.research_and_development.2025-FY", "income.research_and_development.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 1460, "prior": 1175, "delta": 285, "growth_percent": 24.25531914893617, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_income.2025-FY", "income.other_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -2343, "prior": -2938, "delta": 595, "growth_percent": 20.251872021783527, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "income.other_expense.2025-FY", "income.other_expense.2024-FY" ], "note": null, "dimensions": {} } ], "source_pages": [ 18 ], "fact_ids": [ "income.net_sales.2025-FY", "income.net_sales.2024-FY", "income.other_revenues.2025-FY", "income.other_revenues.2024-FY", "income.cost_of_goods_sold.2025-FY", "income.cost_of_goods_sold.2024-FY", "income.selling_general_administration.2025-FY", "income.selling_general_administration.2024-FY", "income.research_and_development.2025-FY", "income.research_and_development.2024-FY", "income.other_income.2025-FY", "income.other_income.2024-FY", "income.other_expense.2025-FY", "income.other_expense.2024-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Seven non-overlapping signed P&L changes; gross-profit subtotal is excluded. Arithmetic contributions do not establish operational causes." }, "ratios": [ { "id": "gross_margin", "label": "Gross margin", "current": 78.80693904496442, "prior": 77.29991851660472, "delta": 1.5070205283597033, "unit": "%", "formula": "gross_profit / net_sales \u00d7 100", "source_pages": [ 18 ], "fact_ids": [ "income.gross_profit.2025-FY", "income.net_sales.2025-FY", "income.gross_profit.2024-FY", "income.net_sales.2024-FY" ] }, { "id": "operating_margin", "label": "Operating margin", "current": 32.35531431086335, "prior": 28.90474392352485, "delta": 3.450570387338498, "unit": "%", "formula": "operating_income / net_sales \u00d7 100", "source_pages": [ 18 ], "fact_ids": [ "income.operating_income.2025-FY", "income.net_sales.2025-FY", "income.operating_income.2024-FY", "income.net_sales.2024-FY" ] }, { "id": "net_margin", "label": "Net margin", "current": 25.61248441282183, "prior": 23.727567223801103, "delta": 1.884917189020726, "unit": "%", "formula": "net_income / net_sales \u00d7 100", "source_pages": [ 18 ], "fact_ids": [ "income.net_income.2025-FY", "income.net_sales.2025-FY", "income.net_income.2024-FY", "income.net_sales.2024-FY" ] }, { "id": "rd_sales_ratio", "label": "R&D expense / net sales", "current": 20.538399471869727, "prior": 19.917721644772143, "delta": 0.6206778270975839, "unit": "%", "formula": "research_and_development / net_sales \u00d7 -100", "source_pages": [ 18 ], "fact_ids": [ "income.research_and_development.2025-FY", "income.net_sales.2025-FY", "income.research_and_development.2024-FY", "income.net_sales.2024-FY" ] }, { "id": "effective_tax_rate", "label": "Effective tax rate", "current": 14.58537181996086, "prior": 12.470674486803519, "delta": 2.1146973331573413, "unit": "%", "formula": "income_taxes / income_before_taxes \u00d7 -100", "source_pages": [ 18 ], "fact_ids": [ "income.income_taxes.2025-FY", "income.income_before_taxes.2025-FY", "income.income_taxes.2024-FY", "income.income_before_taxes.2024-FY" ] } ] }, "sales": { "total_current": 54532, "total_prior": 50317, "unit": "USD million", "products": [ { "id": "entresto", "label": "Entresto", "current": 7748, "prior": 7822, "delta": -74, "growth_percent": -0.9460496036819227, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.entresto.2025-FY", "products.entresto.2024-FY", "product_geography.entresto_us.2025-FY", "product_geography.entresto_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 14.208171348932735, "share_prior_percent": 15.54544189836437, "share_change_pp": -1.3372705494316346, "is_top20": true, "us_current": 3285, "rest_world_current": 4463, "us_prior": null, "rest_world_prior": null }, { "id": "leqvio", "label": "Leqvio", "current": 1198, "prior": 754, "delta": 444, "growth_percent": 58.88594164456234, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.leqvio.2025-FY", "products.leqvio.2024-FY", "product_geography.leqvio_us.2025-FY", "product_geography.leqvio_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 2.1968752292232083, "share_prior_percent": 1.4984995130870282, "share_change_pp": 0.6983757161361801, "is_top20": true, "us_current": 575, "rest_world_current": 623, "us_prior": null, "rest_world_prior": null }, { "id": "vanrafia", "label": "Vanrafia", "current": 13, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.vanrafia.2025-FY", "products.vanrafia.2024-FY" ], "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred.", "dimensions": { "therapeutic_area": "cardiovascular" }, "share_current_percent": 0.023839213672705934, "share_prior_percent": null, "share_change_pp": null, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "cosentyx", "label": "Cosentyx", "current": 6668, "prior": 6141, "delta": 527, "growth_percent": 8.581664224067742, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.cosentyx.2025-FY", "products.cosentyx.2024-FY", "product_geography.cosentyx_us.2025-FY", "product_geography.cosentyx_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 12.227682828431014, "share_prior_percent": 12.204622692131883, "share_change_pp": 0.023060136299131173, "is_top20": true, "us_current": 3839, "rest_world_current": 2829, "us_prior": null, "rest_world_prior": null }, { "id": "ilaris", "label": "Ilaris", "current": 1883, "prior": 1509, "delta": 374, "growth_percent": 24.784625579854207, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.ilaris.2025-FY", "products.ilaris.2024-FY", "product_geography.ilaris_us.2025-FY", "product_geography.ilaris_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 3.4530184112080984, "share_prior_percent": 2.9989864260587873, "share_change_pp": 0.4540319851493111, "is_top20": true, "us_current": 1041, "rest_world_current": 842, "us_prior": null, "rest_world_prior": null }, { "id": "xolair", "label": "Xolair", "current": 1723, "prior": 1643, "delta": 80, "growth_percent": 4.869141813755325, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.xolair.2025-FY", "products.xolair.2024-FY", "product_geography.xolair_us.2025-FY", "product_geography.xolair_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 3.1596127044671016, "share_prior_percent": 3.265298010612715, "share_change_pp": -0.10568530614561356, "is_top20": true, "us_current": null, "rest_world_current": 1723, "us_prior": null, "rest_world_prior": null }, { "id": "rhapsido", "label": "Rhapsido", "current": 19, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.rhapsido.2025-FY", "products.rhapsido.2024-FY" ], "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred.", "dimensions": { "therapeutic_area": "immunology" }, "share_current_percent": 0.03484192767549329, "share_prior_percent": null, "share_change_pp": null, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kesimpta", "label": "Kesimpta", "current": 4426, "prior": 3224, "delta": 1202, "growth_percent": 37.28287841191067, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.kesimpta.2025-FY", "products.kesimpta.2024-FY", "product_geography.kesimpta_us.2025-FY", "product_geography.kesimpta_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 8.116335362722806, "share_prior_percent": 6.4073772283721215, "share_change_pp": 1.7089581343506843, "is_top20": true, "us_current": 2943, "rest_world_current": 1483, "us_prior": null, "rest_world_prior": null }, { "id": "zolgensma", "label": "Zolgensma Group", "current": 1232, "prior": 1214, "delta": 18, "growth_percent": 1.4827018121911038, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.zolgensma.2025-FY", "products.zolgensma.2024-FY", "product_geography.zolgensma_us.2025-FY", "product_geography.zolgensma_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 2.25922394190567, "share_prior_percent": 2.4127034600631996, "share_change_pp": -0.1534795181575297, "is_top20": true, "us_current": 413, "rest_world_current": 819, "us_prior": null, "rest_world_prior": null }, { "id": "aimovig", "label": "Aimovig", "current": 335, "prior": 312, "delta": 23, "growth_percent": 7.371794871794872, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.aimovig.2025-FY", "products.aimovig.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "neuroscience" }, "share_current_percent": 0.6143181984889606, "share_prior_percent": 0.6200687640360117, "share_change_pp": -0.005750565547051112, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kisqali", "label": "Kisqali", "current": 4783, "prior": 3033, "delta": 1750, "growth_percent": 57.698648203099246, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.kisqali.2025-FY", "products.kisqali.2024-FY", "product_geography.kisqali_us.2025-FY", "product_geography.kisqali_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 8.770996845888652, "share_prior_percent": 6.027783850388537, "share_change_pp": 2.743212995500115, "is_top20": true, "us_current": 2975, "rest_world_current": 1808, "us_prior": null, "rest_world_prior": null }, { "id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "current": 2215, "prior": 2058, "delta": 157, "growth_percent": 7.628765792031097, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.tafinlar_mekinist.2025-FY", "products.tafinlar_mekinist.2024-FY", "product_geography.tafinlar_mekinist_us.2025-FY", "product_geography.tafinlar_mekinist_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 4.061835252695665, "share_prior_percent": 4.090068962776, "share_change_pp": -0.02823371008033515, "is_top20": true, "us_current": 867, "rest_world_current": 1348, "us_prior": null, "rest_world_prior": null }, { "id": "jakavi", "label": "Jakavi", "current": 2110, "prior": 1936, "delta": 174, "growth_percent": 8.987603305785125, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.jakavi.2025-FY", "products.jakavi.2024-FY", "product_geography.jakavi_us.2025-FY", "product_geography.jakavi_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 3.869287757646886, "share_prior_percent": 3.847606176838841, "share_change_pp": 0.02168158080804483, "is_top20": true, "us_current": null, "rest_world_current": 2110, "us_prior": null, "rest_world_prior": null }, { "id": "pluvicto", "label": "Pluvicto", "current": 1994, "prior": 1392, "delta": 602, "growth_percent": 43.247126436781606, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.pluvicto.2025-FY", "products.pluvicto.2024-FY", "product_geography.pluvicto_us.2025-FY", "product_geography.pluvicto_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 3.656568620259664, "share_prior_percent": 2.766460639545283, "share_change_pp": 0.8901079807143812, "is_top20": true, "us_current": 1596, "rest_world_current": 398, "us_prior": null, "rest_world_prior": null }, { "id": "promacta", "label": "Promacta / Revolade", "current": 1636, "prior": 2216, "delta": -580, "growth_percent": -26.173285198555956, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.promacta.2025-FY", "products.promacta.2024-FY", "product_geography.promacta_us.2025-FY", "product_geography.promacta_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 3.0000733514266855, "share_prior_percent": 4.404078144563468, "share_change_pp": -1.4040047931367825, "is_top20": true, "us_current": 636, "rest_world_current": 1000, "us_prior": null, "rest_world_prior": null }, { "id": "scemblix", "label": "Scemblix", "current": 1285, "prior": 689, "delta": 596, "growth_percent": 86.5021770682148, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.scemblix.2025-FY", "products.scemblix.2024-FY", "product_geography.scemblix_us.2025-FY", "product_geography.scemblix_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 2.356414582263625, "share_prior_percent": 1.3693185205795257, "share_change_pp": 0.9870960616840991, "is_top20": true, "us_current": 824, "rest_world_current": 461, "us_prior": null, "rest_world_prior": null }, { "id": "tasigna", "label": "Tasigna", "current": 1104, "prior": 1671, "delta": -567, "growth_percent": -33.931777378815084, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.tasigna.2025-FY", "products.tasigna.2024-FY", "product_geography.tasigna_us.2025-FY", "product_geography.tasigna_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 2.024499376512873, "share_prior_percent": 3.320945207385178, "share_change_pp": -1.296445830872305, "is_top20": true, "us_current": 486, "rest_world_current": 618, "us_prior": null, "rest_world_prior": null }, { "id": "lutathera", "label": "Lutathera", "current": 816, "prior": 724, "delta": 92, "growth_percent": 12.70718232044199, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.lutathera.2025-FY", "products.lutathera.2024-FY", "product_geography.lutathera_us.2025-FY", "product_geography.lutathera_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 1.49636910437908, "share_prior_percent": 1.4388775165451042, "share_change_pp": 0.0574915878339759, "is_top20": true, "us_current": 588, "rest_world_current": 228, "us_prior": null, "rest_world_prior": null }, { "id": "fabhalta", "label": "Fabhalta", "current": 505, "prior": 129, "delta": 376, "growth_percent": 291.47286821705427, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.fabhalta.2025-FY", "products.fabhalta.2024-FY", "product_geography.fabhalta_us.2025-FY", "product_geography.fabhalta_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 0.9260617619012691, "share_prior_percent": 0.25637458513027406, "share_change_pp": 0.6696871767709951, "is_top20": true, "us_current": 317, "rest_world_current": 188, "us_prior": null, "rest_world_prior": null }, { "id": "piqray_vijoice", "label": "Piqray / Vijoice", "current": 382, "prior": 449, "delta": -67, "growth_percent": -14.92204899777283, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.piqray_vijoice.2025-FY", "products.piqray_vijoice.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "oncology" }, "share_current_percent": 0.7005061248441282, "share_prior_percent": 0.8923425482441322, "share_change_pp": -0.19183642340000395, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "sandostatin", "label": "Sandostatin Group", "current": 1213, "prior": 1279, "delta": -66, "growth_percent": -5.160281469898358, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.sandostatin.2025-FY", "products.sandostatin.2024-FY", "product_geography.sandostatin_us.2025-FY", "product_geography.sandostatin_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 2.224382014230177, "share_prior_percent": 2.541884452570702, "share_change_pp": -0.31750243834052494, "is_top20": true, "us_current": 729, "rest_world_current": 484, "us_prior": null, "rest_world_prior": null }, { "id": "exforge", "label": "Exforge Group", "current": 727, "prior": 703, "delta": 24, "growth_percent": 3.4139402560455197, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.exforge.2025-FY", "products.exforge.2024-FY", "product_geography.exforge_us.2025-FY", "product_geography.exforge_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 1.3331621800044011, "share_prior_percent": 1.3971421189657571, "share_change_pp": -0.06397993896135601, "is_top20": true, "us_current": 5, "rest_world_current": 722, "us_prior": null, "rest_world_prior": null }, { "id": "lucentis", "label": "Lucentis", "current": 643, "prior": 1044, "delta": -401, "growth_percent": -38.40996168582376, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.lucentis.2025-FY", "products.lucentis.2024-FY", "product_geography.lucentis_us.2025-FY", "product_geography.lucentis_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 1.179124183965378, "share_prior_percent": 2.074845479658962, "share_change_pp": -0.895721295693584, "is_top20": true, "us_current": null, "rest_world_current": 643, "us_prior": null, "rest_world_prior": null }, { "id": "diovan", "label": "Diovan Group", "current": 604, "prior": 590, "delta": 14, "growth_percent": 2.3728813559322033, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38, 40 ], "source_ids": [ "p38", "p40" ], "fact_ids": [ "products.diovan.2025-FY", "products.diovan.2024-FY", "product_geography.diovan_us.2025-FY", "product_geography.diovan_row.2025-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 1.1076065429472604, "share_prior_percent": 1.1725659319911759, "share_change_pp": -0.06495938904391552, "is_top20": true, "us_current": 35, "rest_world_current": 569, "us_prior": null, "rest_world_prior": null }, { "id": "galvus", "label": "Galvus Group", "current": 487, "prior": 602, "delta": -115, "growth_percent": -19.102990033222593, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.galvus.2025-FY", "products.galvus.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 0.8930536198929069, "share_prior_percent": 1.1964147306079456, "share_change_pp": -0.3033611107150387, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "kymriah", "label": "Kymriah", "current": 381, "prior": 443, "delta": -62, "growth_percent": -13.99548532731377, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.kymriah.2025-FY", "products.kymriah.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 0.698672339176997, "share_prior_percent": 0.8804181489357474, "share_change_pp": -0.18174580975875043, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "contract_manufacturing", "label": "Contract manufacturing", "current": 1419, "prior": 1152, "delta": 267, "growth_percent": 23.177083333333336, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.contract_manufacturing.2025-FY", "products.contract_manufacturing.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 2.6021418616592094, "share_prior_percent": 2.2894846672098894, "share_change_pp": 0.31265719444931994, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null }, { "id": "other", "label": "Other portfolio", "current": 6983, "prior": 7588, "delta": -605, "growth_percent": -7.973115445440168, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "products.other.2025-FY", "products.other.2024-FY" ], "note": "2024 classifications conform to the 2025 presentation.", "dimensions": { "therapeutic_area": "established" }, "share_current_percent": 12.805325313577349, "share_prior_percent": 15.080390325337362, "share_change_pp": -2.275065011760013, "is_top20": false, "us_current": null, "rest_world_current": null, "us_prior": null, "rest_world_prior": null } ], "regions": [ { "id": "us", "label": "United States", "current": 23331, "prior": 21146, "delta": 2185, "growth_percent": 10.33292348434692, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.us.2025-FY", "regions.us.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 42.784053399838626, "share_prior_percent": 42.02555796251764, "share_change_pp": 0.7584954373209882 }, { "id": "europe", "label": "Europe", "current": 16729, "prior": 15557, "delta": 1172, "growth_percent": 7.533586166998779, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.europe.2025-FY", "regions.europe.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 30.67740042543827, "share_prior_percent": 30.917980006757162, "share_change_pp": -0.24057958131889023 }, { "id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "current": 10797, "prior": 10021, "delta": 776, "growth_percent": 7.743738149885241, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.asia_africa_australasia.2025-FY", "regions.asia_africa_australasia.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 19.799383848015843, "share_prior_percent": 19.915734244887414, "share_change_pp": -0.1163503968715709 }, { "id": "canada_latin_america", "label": "Canada and Latin America", "current": 3675, "prior": 3593, "delta": 82, "growth_percent": 2.282215418870025, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "regions.canada_latin_america.2025-FY", "regions.canada_latin_america.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 6.7391623267072545, "share_prior_percent": 7.140727785837789, "share_change_pp": -0.4015654591305342 } ], "therapeutic_areas": [ { "id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "current": 8959, "prior": 8576, "delta": 383, "growth_percent": 4.465951492537314, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "therapeutic_areas.cardiovascular.2025-FY", "therapeutic_areas.cardiovascular.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 16.42888579182865, "share_prior_percent": 17.0439414114514, "share_change_pp": -0.6150556196227477 }, { "id": "immunology", "label": "Immunology", "current": 10293, "prior": 9293, "delta": 1000, "growth_percent": 10.760787689658883, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "therapeutic_areas.immunology.2025-FY", "therapeutic_areas.immunology.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 18.875155871781708, "share_prior_percent": 18.468907128803387, "share_change_pp": 0.40624874297832037 }, { "id": "neuroscience", "label": "Neuroscience", "current": 5993, "prior": 4750, "delta": 1243, "growth_percent": 26.16842105263158, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "therapeutic_areas.neuroscience.2025-FY", "therapeutic_areas.neuroscience.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 10.989877503117436, "share_prior_percent": 9.440149452471331, "share_change_pp": 1.5497280506461042 }, { "id": "oncology", "label": "Oncology", "current": 16830, "prior": 14297, "delta": 2533, "growth_percent": 17.717003567181926, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "therapeutic_areas.oncology.2025-FY", "therapeutic_areas.oncology.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 30.862612777818526, "share_prior_percent": 28.41385615199634, "share_change_pp": 2.4487566258221847 }, { "id": "established", "label": "Established brands", "current": 12457, "prior": 13401, "delta": -944, "growth_percent": -7.0442504290724575, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 38 ], "source_ids": [ "p38" ], "fact_ids": [ "therapeutic_areas.established.2025-FY", "therapeutic_areas.established.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 22.843468055453677, "share_prior_percent": 26.63314585527754, "share_change_pp": -3.7896777998238633 } ], "market_groups": [ { "id": "established", "label": "Established markets", "current": 40555, "prior": 37371, "delta": 3184, "growth_percent": 8.51997538198068, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "market_groups.established.2025-FY", "market_groups.established.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 74.36917773050686, "share_prior_percent": 74.27112109227497, "share_change_pp": 0.09805663823189548 }, { "id": "emerging", "label": "Emerging growth markets", "current": 13977, "prior": 12946, "delta": 1031, "growth_percent": 7.963849837787734, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 36 ], "source_ids": [ "p36" ], "fact_ids": [ "market_groups.emerging.2025-FY", "market_groups.emerging.2024-FY" ], "note": null, "dimensions": {}, "share_current_percent": 25.63082226949314, "share_prior_percent": 25.728878907725022, "share_change_pp": -0.09805663823188127 } ], "top20_coverage": [ { "id": "top20_sales_share", "label": "2025 top-20 brand cohort / net sales", "current": 81.62730140101225, "prior": 79.04088081562891, "delta": 2.586420585383337, "unit": "%", "formula": "sum of the same 20 brands' reported sales / company net sales \u00d7 100", "source_pages": [ 38, 40 ], "fact_ids": [ "products.entresto.2025-FY", "products.entresto.2024-FY", "product_geography.entresto_us.2025-FY", "product_geography.entresto_row.2025-FY", "products.leqvio.2025-FY", "products.leqvio.2024-FY", "product_geography.leqvio_us.2025-FY", "product_geography.leqvio_row.2025-FY", "products.cosentyx.2025-FY", "products.cosentyx.2024-FY", "product_geography.cosentyx_us.2025-FY", "product_geography.cosentyx_row.2025-FY", "products.ilaris.2025-FY", "products.ilaris.2024-FY", "product_geography.ilaris_us.2025-FY", "product_geography.ilaris_row.2025-FY", "products.xolair.2025-FY", "products.xolair.2024-FY", "product_geography.xolair_us.2025-FY", "product_geography.xolair_row.2025-FY", "products.kesimpta.2025-FY", "products.kesimpta.2024-FY", "product_geography.kesimpta_us.2025-FY", "product_geography.kesimpta_row.2025-FY", "products.zolgensma.2025-FY", "products.zolgensma.2024-FY", "product_geography.zolgensma_us.2025-FY", "product_geography.zolgensma_row.2025-FY", "products.kisqali.2025-FY", "products.kisqali.2024-FY", "product_geography.kisqali_us.2025-FY", "product_geography.kisqali_row.2025-FY", "products.tafinlar_mekinist.2025-FY", "products.tafinlar_mekinist.2024-FY", "product_geography.tafinlar_mekinist_us.2025-FY", "product_geography.tafinlar_mekinist_row.2025-FY", "products.jakavi.2025-FY", "products.jakavi.2024-FY", "product_geography.jakavi_us.2025-FY", "product_geography.jakavi_row.2025-FY", "products.pluvicto.2025-FY", "products.pluvicto.2024-FY", "product_geography.pluvicto_us.2025-FY", "product_geography.pluvicto_row.2025-FY", "products.promacta.2025-FY", "products.promacta.2024-FY", "product_geography.promacta_us.2025-FY", "product_geography.promacta_row.2025-FY", "products.scemblix.2025-FY", "products.scemblix.2024-FY", "product_geography.scemblix_us.2025-FY", "product_geography.scemblix_row.2025-FY", "products.tasigna.2025-FY", "products.tasigna.2024-FY", "product_geography.tasigna_us.2025-FY", "product_geography.tasigna_row.2025-FY", "products.lutathera.2025-FY", "products.lutathera.2024-FY", "product_geography.lutathera_us.2025-FY", "product_geography.lutathera_row.2025-FY", "products.fabhalta.2025-FY", "products.fabhalta.2024-FY", "product_geography.fabhalta_us.2025-FY", "product_geography.fabhalta_row.2025-FY", "products.sandostatin.2025-FY", "products.sandostatin.2024-FY", "product_geography.sandostatin_us.2025-FY", "product_geography.sandostatin_row.2025-FY", "products.exforge.2025-FY", "products.exforge.2024-FY", "product_geography.exforge_us.2025-FY", "product_geography.exforge_row.2025-FY", "products.lucentis.2025-FY", "products.lucentis.2024-FY", "product_geography.lucentis_us.2025-FY", "product_geography.lucentis_row.2025-FY", "products.diovan.2025-FY", "products.diovan.2024-FY", "product_geography.diovan_us.2025-FY", "product_geography.diovan_row.2025-FY" ] } ], "top20_totals": { "current": 44513, "prior": 39771, "rest_current": 10019, "rest_prior": 10546, "note": "Current top-20/rest totals cross-check pages 39/40. Prior totals are calculated from exact same-cohort brand amounts, not inferred from rounded growth rates." }, "notes": [ "Four geographic regions are one complete partition. Established/emerging markets are a separate alternative partition, not extra regions.", "Therapeutic areas are sales classifications; the company reports a single global operating segment.", "2024 therapeutic-area classifications conform to the 2025 presentation. New-brand blank comparatives remain unavailable.", "US/rest-of-world brand values are 2025 only; no exact 2024 split is reconstructed from growth rates. Xolair/Jakavi/Lucentis US blanks remain unavailable.", "Shares and USD growth are calculated from reported amounts; they are not reported constant-currency rates. These are two-year comparisons, not a multi-quarter time series." ] }, "cashflow": { "rows": [ { "id": "net_income", "label": "Net income", "current": 13967, "prior": 11939, "delta": 2028, "growth_percent": 16.9863472652651, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.net_income.2025-FY", "cashflow.net_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "current": 11229, "prior": 10232, "delta": 997, "growth_percent": 9.743940578577014, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.noncash_adjustments.2025-FY", "cashflow.noncash_adjustments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "dividends_received", "label": "Dividends received from associated companies and others", "current": 1, "prior": 1, "delta": 0, "growth_percent": 0.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.dividends_received.2025-FY", "cashflow.dividends_received.2024-FY" ], "note": null, "dimensions": {} }, { "id": "interest_received", "label": "Interest received", "current": 310, "prior": 489, "delta": -179, "growth_percent": -36.60531697341513, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.interest_received.2025-FY", "cashflow.interest_received.2024-FY" ], "note": null, "dimensions": {} }, { "id": "interest_paid", "label": "Interest paid", "current": -981, "prior": -855, "delta": -126, "growth_percent": -14.736842105263156, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.interest_paid.2025-FY", "cashflow.interest_paid.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "current": 266, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.other_financial_receipts.2025-FY", "cashflow.other_financial_receipts.2024-FY" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "other_financial_payments", "label": "Other financial payments / change in payments", "current": -26, "prior": -116, "delta": 90, "growth_percent": 77.58620689655173, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.other_financial_payments.2025-FY", "cashflow.other_financial_payments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "income_taxes_paid", "label": "Income taxes paid", "current": -2562, "prior": -2258, "delta": -304, "growth_percent": -13.46324180690877, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.income_taxes_paid.2025-FY", "cashflow.income_taxes_paid.2024-FY" ], "note": null, "dimensions": {} }, { "id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "current": 22204, "prior": 19432, "delta": 2772, "growth_percent": 14.265129682997118, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.operating_before_changes.2025-FY", "cashflow.operating_before_changes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "current": -1483, "prior": -1107, "delta": -376, "growth_percent": -33.96567299006323, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.provision_payments.2025-FY", "cashflow.provision_payments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "working_capital", "label": "Working capital and other operating cash-flow items", "current": -1577, "prior": -706, "delta": -871, "growth_percent": -123.37110481586402, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.working_capital.2025-FY", "cashflow.working_capital.2024-FY" ], "note": null, "dimensions": {} }, { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "current": 19144, "prior": 17619, "delta": 1525, "growth_percent": 8.655428798456212, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.operating_cash_flow.2025-FY", "cashflow.operating_cash_flow.2024-FY" ], "note": null, "dimensions": {} }, { "id": "capex", "label": "Purchases of property, plant and equipment", "current": -1548, "prior": -1366, "delta": -182, "growth_percent": -13.323572474377746, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.capex.2025-FY", "cashflow.capex.2024-FY" ], "note": null, "dimensions": {} }, { "id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "current": 13, "prior": 86, "delta": -73, "growth_percent": -84.88372093023256, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.property_sale_proceeds.2025-FY", "cashflow.property_sale_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "intangible_purchases", "label": "Purchases of intangible assets", "current": -2352, "prior": -2448, "delta": 96, "growth_percent": 3.9215686274509802, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.intangible_purchases.2025-FY", "cashflow.intangible_purchases.2024-FY" ], "note": null, "dimensions": {} }, { "id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "current": 164, "prior": 80, "delta": 84, "growth_percent": 105.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.intangible_sale_proceeds.2025-FY", "cashflow.intangible_sale_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "financial_asset_purchases", "label": "Purchases of financial assets", "current": -116, "prior": -193, "delta": 77, "growth_percent": 39.89637305699482, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.financial_asset_purchases.2025-FY", "cashflow.financial_asset_purchases.2024-FY" ], "note": null, "dimensions": {} }, { "id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "current": 209, "prior": 957, "delta": -748, "growth_percent": -78.16091954022988, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.financial_asset_sale_proceeds.2025-FY", "cashflow.financial_asset_sale_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "business_acquisitions", "label": "Acquisitions of businesses", "current": -147, "prior": -4018, "delta": 3871, "growth_percent": 96.34146341463415, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.business_acquisitions.2025-FY", "cashflow.business_acquisitions.2024-FY" ], "note": null, "dimensions": {} }, { "id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "current": -2769, "prior": null, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.asset_acquisitions.2025-FY", "cashflow.asset_acquisitions.2024-FY" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "business_divestments", "label": "Divestments of businesses, net", "current": -88, "prior": 107, "delta": -195, "growth_percent": -182.2429906542056, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.business_divestments.2025-FY", "cashflow.business_divestments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "current": -187, "prior": -3455, "delta": 3268, "growth_percent": 94.58755426917511, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.time_deposit_investments.2025-FY", "cashflow.time_deposit_investments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "current": 1968, "prior": 2744, "delta": -776, "growth_percent": -28.279883381924197, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.time_deposit_proceeds.2025-FY", "cashflow.time_deposit_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_investing", "label": "Other investing cash flows, net", "current": -24, "prior": -7, "delta": -17, "growth_percent": -242.85714285714283, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.other_investing.2025-FY", "cashflow.other_investing.2024-FY" ], "note": null, "dimensions": {} }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "current": -4877, "prior": -7513, "delta": 2636, "growth_percent": 35.08585119126847, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.investing_cash_flow.2025-FY", "cashflow.investing_cash_flow.2024-FY" ], "note": null, "dimensions": {} }, { "id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "current": -7818, "prior": -7624, "delta": -194, "growth_percent": -2.5445960125918154, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.dividends_paid.2025-FY", "cashflow.dividends_paid.2024-FY" ], "note": null, "dimensions": {} }, { "id": "treasury_share_purchases", "label": "Purchases of treasury shares", "current": -9212, "prior": -8331, "delta": -881, "growth_percent": -10.57496098907694, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.treasury_share_purchases.2025-FY", "cashflow.treasury_share_purchases.2024-FY" ], "note": null, "dimensions": {} }, { "id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "current": 27, "prior": 30, "delta": -3, "growth_percent": -10.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.treasury_share_proceeds.2025-FY", "cashflow.treasury_share_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "current": 6098, "prior": 6143, "delta": -45, "growth_percent": -0.7325411036952629, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.debt_proceeds.2025-FY", "cashflow.debt_proceeds.2024-FY" ], "note": null, "dimensions": {} }, { "id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "current": -3392, "prior": -2160, "delta": -1232, "growth_percent": -57.03703703703704, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.debt_repayments.2025-FY", "cashflow.debt_repayments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "current_debt_change", "label": "Change in current financial debts", "current": 5, "prior": 958, "delta": -953, "growth_percent": -99.47807933194154, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.current_debt_change.2025-FY", "cashflow.current_debt_change.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_debt_repayments", "label": "Repayments of other current financial debts", "current": null, "prior": -289, "delta": null, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.other_debt_repayments.2025-FY", "cashflow.other_debt_repayments.2024-FY" ], "note": "Blank or unavailable source cell; not a measured zero.", "dimensions": {} }, { "id": "lease_payments", "label": "Payments of lease liabilities", "current": -281, "prior": -262, "delta": -19, "growth_percent": -7.251908396946565, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.lease_payments.2025-FY", "cashflow.lease_payments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "ownership_payments", "label": "Payments from changes in ownership interests", "current": -91, "prior": -293, "delta": 202, "growth_percent": 68.94197952218431, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.ownership_payments.2025-FY", "cashflow.ownership_payments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_financing", "label": "Other financing cash flows, net", "current": -203, "prior": 86, "delta": -289, "growth_percent": -336.046511627907, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.other_financing.2025-FY", "cashflow.other_financing.2024-FY" ], "note": null, "dimensions": {} }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "current": -14867, "prior": -11742, "delta": -3125, "growth_percent": -26.61386475898484, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.financing_cash_flow.2025-FY", "cashflow.financing_cash_flow.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "current": -600, "prior": -1636, "delta": 1036, "growth_percent": 63.325183374083124, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.cash_change_before_fx.2025-FY", "cashflow.cash_change_before_fx.2024-FY" ], "note": null, "dimensions": {} }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "current": 576, "prior": -298, "delta": 874, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.fx_effect.2025-FY", "cashflow.fx_effect.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cash_change", "label": "Net change in cash and cash equivalents", "current": -24, "prior": -1934, "delta": 1910, "growth_percent": 98.75904860392967, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.cash_change.2025-FY", "cashflow.cash_change.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cash_start", "label": "Cash and cash equivalents at period start", "current": 11459, "prior": 13393, "delta": -1934, "growth_percent": -14.440379302620773, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.cash_start.2025-FY", "cashflow.cash_start.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cash_end", "label": "Cash and cash equivalents at December 31", "current": 11435, "prior": 11459, "delta": -24, "growth_percent": -0.20944235971725284, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.cash_end.2025-FY", "cashflow.cash_end.2024-FY" ], "note": null, "dimensions": {} } ], "operating_bridge": { "id": "operating_cash_flow", "title": "Year-on-year operating-cash-flow movement", "kind": "year_on_year", "prior": 17619, "current": 19144, "delta": 1525, "residual": 0, "unit": "USD million", "prior_label": "2024-FY", "current_label": "2025-FY", "contributions": [ { "id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "current": 22204, "prior": 19432, "delta": 2772, "growth_percent": 14.265129682997118, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.operating_before_changes.2025-FY", "cashflow.operating_before_changes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "current": -1483, "prior": -1107, "delta": -376, "growth_percent": -33.96567299006323, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.provision_payments.2025-FY", "cashflow.provision_payments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "working_capital", "label": "Working capital and other operating cash-flow items", "current": -1577, "prior": -706, "delta": -871, "growth_percent": -123.37110481586402, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.working_capital.2025-FY", "cashflow.working_capital.2024-FY" ], "note": null, "dimensions": {} } ], "source_pages": [ 24 ], "fact_ids": [ "cashflow.operating_before_changes.2025-FY", "cashflow.operating_before_changes.2024-FY", "cashflow.provision_payments.2025-FY", "cashflow.provision_payments.2024-FY", "cashflow.working_capital.2025-FY", "cashflow.working_capital.2024-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Before-working-capital cash flow, provision payments and working-capital changes are non-overlapping components; their detailed child lines are not counted again." }, "change_bridge": { "id": "cash_rollforward", "title": "Cash balance rollforward", "kind": "cash_rollforward", "prior": 11459, "current": 11435, "delta": -24, "residual": 0, "unit": "USD million", "prior_label": "Opening cash / 2025-FY", "current_label": "Closing cash / 2025-FY", "contributions": [ { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "prior": 0, "current": 19144, "delta": 19144, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.operating_cash_flow.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "prior": 0, "current": -4877, "delta": -4877, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.investing_cash_flow.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "prior": 0, "current": -14867, "delta": -14867, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.financing_cash_flow.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "prior": 0, "current": 576, "delta": 576, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.fx_effect.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 24 ], "fact_ids": [ "cashflow.operating_cash_flow.2025-FY", "cashflow.investing_cash_flow.2025-FY", "cashflow.financing_cash_flow.2025-FY", "cashflow.fx_effect.2025-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Selected-period cash flows plus foreign-exchange effects bridge opening to closing cash; these endpoints are not prior-year/current-year totals." }, "change_bridge_comparative": { "id": "cash_rollforward", "title": "Cash balance rollforward", "kind": "cash_rollforward", "prior": 13393, "current": 11459, "delta": -1934, "residual": 0, "unit": "USD million", "prior_label": "Opening cash / 2024-FY", "current_label": "Closing cash / 2024-FY", "contributions": [ { "id": "operating_cash_flow", "label": "Net cash flows from operating activities", "prior": 0, "current": 17619, "delta": 17619, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.operating_cash_flow.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "prior": 0, "current": -7513, "delta": -7513, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.investing_cash_flow.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "prior": 0, "current": -11742, "delta": -11742, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.financing_cash_flow.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "fx_effect", "label": "Exchange-rate effects on cash", "prior": 0, "current": -298, "delta": -298, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.fx_effect.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 24 ], "fact_ids": [ "cashflow.operating_cash_flow.2024-FY", "cashflow.investing_cash_flow.2024-FY", "cashflow.financing_cash_flow.2024-FY", "cashflow.fx_effect.2024-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Selected-period cash flows plus foreign-exchange effects bridge opening to closing cash; these endpoints are not prior-year/current-year totals." }, "fcf_bridge": { "id": "free_cash_flow", "title": "Operating cash flow to company-defined free cash flow", "kind": "non_ifrs_reconciliation", "prior": 19144, "current": 17596, "delta": -1548, "residual": 0, "unit": "USD million", "prior_label": "Operating cash flow / 2025-FY", "current_label": "Non-IFRS free cash flow / 2025-FY", "contributions": [ { "id": "capex", "label": "Purchases of property, plant and equipment", "prior": 0, "current": -1548, "delta": -1548, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.capex.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 24, 50 ], "fact_ids": [ "cashflow.capex.2025-FY", "free_cash_flow.free_cash_flow.2025-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Novartis defines FCF as operating cash flow less purchases of property, plant and equipment. Intangible purchases are not deducted in this company definition." }, "fcf_bridge_comparative": { "id": "free_cash_flow", "title": "Operating cash flow to company-defined free cash flow", "kind": "non_ifrs_reconciliation", "prior": 17619, "current": 16253, "delta": -1366, "residual": 0, "unit": "USD million", "prior_label": "Operating cash flow / 2024-FY", "current_label": "Non-IFRS free cash flow / 2024-FY", "contributions": [ { "id": "capex", "label": "Purchases of property, plant and equipment", "prior": 0, "current": -1366, "delta": -1366, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 24 ], "source_ids": [ "p24" ], "fact_ids": [ "cashflow.capex.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 24, 50 ], "fact_ids": [ "cashflow.capex.2024-FY", "free_cash_flow.free_cash_flow.2024-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Novartis defines FCF as operating cash flow less purchases of property, plant and equipment. Intangible purchases are not deducted in this company definition." }, "working_capital": [ { "id": "inventories", "label": "Decrease/(increase) in inventories", "current": 34, "prior": -225, "delta": 259, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.inventories.2025-FY", "working_capital.inventories.2024-FY" ], "note": null, "dimensions": {} }, { "id": "trade_receivables", "label": "Increase/decrease in trade receivables", "current": -1124, "prior": -931, "delta": -193, "growth_percent": -20.730397422126746, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.trade_receivables.2025-FY", "working_capital.trade_receivables.2024-FY" ], "note": null, "dimensions": {} }, { "id": "trade_payables", "label": "Increase/(decrease) in trade payables", "current": -273, "prior": -105, "delta": -168, "growth_percent": -160.0, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.trade_payables.2025-FY", "working_capital.trade_payables.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_assets", "label": "Change in other current and non-current assets", "current": -461, "prior": -502, "delta": 41, "growth_percent": 8.167330677290837, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.other_assets.2025-FY", "working_capital.other_assets.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_liabilities", "label": "Change in other current liabilities", "current": 247, "prior": 1057, "delta": -810, "growth_percent": -76.63197729422895, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.other_liabilities.2025-FY", "working_capital.other_liabilities.2024-FY" ], "note": null, "dimensions": {} }, { "id": "total", "label": "Total working-capital and other operating items", "current": -1577, "prior": -706, "delta": -871, "growth_percent": -123.37110481586402, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 32 ], "source_ids": [ "p32" ], "fact_ids": [ "working_capital.total.2025-FY", "working_capital.total.2024-FY" ], "note": null, "dimensions": {} } ], "free_cash_flow": { "id": "free_cash_flow", "label": "Free cash flow", "current": 17596, "prior": 16253, "delta": 1343, "growth_percent": 8.263089891097028, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "source_pages": [ 50 ], "source_ids": [ "p50" ], "fact_ids": [ "free_cash_flow.free_cash_flow.2025-FY", "free_cash_flow.free_cash_flow.2024-FY" ], "note": null, "dimensions": {} } }, "core": { "rows": [ { "id": "net_sales", "label": "Net sales", "current": 54532, "prior": 50317, "delta": 4215, "growth_percent": 8.376890514140351, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 18 ], "source_ids": [ "p18" ], "fact_ids": [ "core.net_sales.2025-FY", "core.net_sales.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_revenues", "label": "Other revenues", "current": 1798, "prior": 1405, "delta": 393, "growth_percent": 27.971530249110323, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.other_revenues.2025-FY", "core.other_revenues.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cost_of_goods_sold", "label": "Cost of goods sold", "current": -10815, "prior": -9850, "delta": -965, "growth_percent": -9.796954314720812, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.cost_of_goods_sold.2025-FY", "core.cost_of_goods_sold.2024-FY" ], "note": null, "dimensions": {} }, { "id": "gross_profit", "label": "Gross profit", "current": 45515, "prior": 41872, "delta": 3643, "growth_percent": 8.700324799388612, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.gross_profit.2025-FY", "core.gross_profit.2024-FY" ], "note": null, "dimensions": {} }, { "id": "selling_general_administration", "label": "Selling, general and administration", "current": -13238, "prior": -12564, "delta": -674, "growth_percent": -5.36453358802929, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.selling_general_administration.2025-FY", "core.selling_general_administration.2024-FY" ], "note": null, "dimensions": {} }, { "id": "research_and_development", "label": "Research and development", "current": -10295, "prior": -9302, "delta": -993, "growth_percent": -10.675123629327027, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.research_and_development.2025-FY", "core.research_and_development.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_income", "label": "Other income", "current": 667, "prior": 273, "delta": 394, "growth_percent": 144.32234432234432, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.other_income.2025-FY", "core.other_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_expense", "label": "Other expense", "current": -760, "prior": -785, "delta": 25, "growth_percent": 3.1847133757961785, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.other_expense.2025-FY", "core.other_expense.2024-FY" ], "note": null, "dimensions": {} }, { "id": "operating_income", "label": "Core operating income", "current": 21889, "prior": 19494, "delta": 2395, "growth_percent": 12.2858315379091, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.operating_income.2025-FY", "core.operating_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "income_before_taxes", "label": "Core income before taxes", "current": 20777, "prior": 18771, "delta": 2006, "growth_percent": 10.686697565393425, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.income_before_taxes.2025-FY", "core.income_before_taxes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "income_taxes", "label": "Core income taxes", "current": -3366, "prior": -3016, "delta": -350, "growth_percent": -11.60477453580902, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.income_taxes.2025-FY", "core.income_taxes.2024-FY" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Core net income", "current": 17411, "prior": 15755, "delta": 1656, "growth_percent": 10.510948905109489, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.net_income.2025-FY", "core.net_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "current": 17411, "prior": 15757, "delta": 1654, "growth_percent": 10.496922002919337, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.net_income_shareholders.2025-FY", "core.net_income_shareholders.2024-FY" ], "note": null, "dimensions": {} }, { "id": "non_controlling_interests", "label": "Core non-controlling interests", "current": 0, "prior": -2, "delta": 2, "growth_percent": 100.0, "unit": "USD million", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.non_controlling_interests.2025-FY", "core.non_controlling_interests.2024-FY" ], "note": null, "dimensions": {} }, { "id": "basic_eps", "label": "Core basic earnings per share", "current": 8.98, "prior": 7.81, "delta": 1.1700000000000008, "growth_percent": 14.980793854033303, "unit": "USD per share", "basis": "Core non-IFRS", "source_pages": [ 48 ], "source_ids": [ "p48" ], "fact_ids": [ "core.basic_eps.2025-FY", "core.basic_eps.2024-FY" ], "note": null, "dimensions": {} } ], "adjustments": [ { "id": "amortization", "label": "Amortization of intangible assets", "current": 3197, "prior": 3174, "delta": 23, "growth_percent": 0.7246376811594203, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.amortization.2025-FY", "core_adjustments.amortization.2024-FY" ], "note": null, "dimensions": {} }, { "id": "impairments", "label": "Total impairment charges", "current": 552, "prior": 1428, "delta": -876, "growth_percent": -61.34453781512605, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.impairments.2025-FY", "core_adjustments.impairments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "current": 71, "prior": 25, "delta": 46, "growth_percent": 184.0, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.acquisition_divestment.2025-FY", "core_adjustments.acquisition_divestment.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_adjustments", "label": "Total other adjustment items", "current": 425, "prior": 323, "delta": 102, "growth_percent": 31.57894736842105, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.other_adjustments.2025-FY", "core_adjustments.other_adjustments.2024-FY" ], "note": null, "dimensions": {} }, { "id": "total_adjustments", "label": "Total adjustments", "current": 4245, "prior": 4950, "delta": -705, "growth_percent": -14.242424242424242, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.total_adjustments.2025-FY", "core_adjustments.total_adjustments.2024-FY" ], "note": null, "dimensions": {} } ], "bridge": { "id": "ifrs_to_core", "title": "Reported IFRS to core operating income", "kind": "non_ifrs_reconciliation", "prior": 17644, "current": 21889, "delta": 4245, "residual": 0, "unit": "USD million", "prior_label": "IFRS operating income / 2025-FY", "current_label": "Core operating income / 2025-FY", "contributions": [ { "id": "amortization", "label": "Amortization of intangible assets", "prior": 0, "current": 3197, "delta": 3197, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.amortization.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "impairments", "label": "Total impairment charges", "prior": 0, "current": 552, "delta": 552, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.impairments.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "prior": 0, "current": 71, "delta": 71, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.acquisition_divestment.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_adjustments", "label": "Total other adjustment items", "prior": 0, "current": 425, "delta": 425, "growth_percent": null, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "source_pages": [ 46 ], "source_ids": [ "p46" ], "fact_ids": [ "core_adjustments.other_adjustments.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 46 ], "fact_ids": [ "core_adjustments.amortization.2025-FY", "core_adjustments.impairments.2025-FY", "core_adjustments.acquisition_divestment.2025-FY", "core_adjustments.other_adjustments.2025-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Four non-overlapping company-defined adjustments. Core is a non-IFRS measure, not a replacement for reported IFRS results." }, "ratios": [ { "id": "core_operating_margin", "label": "Core operating margin", "current": 40.139734467835396, "prior": 38.742373352942344, "delta": 1.3973611148930516, "unit": "%", "formula": "operating_income / net_sales \u00d7 100", "source_pages": [ 18, 48 ], "fact_ids": [ "core.operating_income.2025-FY", "core.net_sales.2025-FY", "core.operating_income.2024-FY", "core.net_sales.2024-FY" ] }, { "id": "core_net_margin", "label": "Core net margin", "current": 31.928042250421772, "prior": 31.311485183933858, "delta": 0.6165570664879141, "unit": "%", "formula": "net_income / net_sales \u00d7 100", "source_pages": [ 18, 48 ], "fact_ids": [ "core.net_income.2025-FY", "core.net_sales.2025-FY", "core.net_income.2024-FY", "core.net_sales.2024-FY" ] } ] }, "other_revenues": [ { "id": "profit_sharing", "label": "Profit sharing income", "current": 1341, "prior": 1063, "delta": 278, "growth_percent": 26.152398871119477, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.profit_sharing.2025-FY", "other_revenues.profit_sharing.2024-FY" ], "note": null, "dimensions": {} }, { "id": "royalties", "label": "Royalty income", "current": 379, "prior": 37, "delta": 342, "growth_percent": 924.3243243243244, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.royalties.2025-FY", "other_revenues.royalties.2024-FY" ], "note": null, "dimensions": {} }, { "id": "milestones", "label": "Milestone income", "current": 117, "prior": 28, "delta": 89, "growth_percent": 317.85714285714283, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.milestones.2025-FY", "other_revenues.milestones.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other", "label": "Other revenue", "current": 305, "prior": 277, "delta": 28, "growth_percent": 10.108303249097473, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.other.2025-FY", "other_revenues.other.2024-FY" ], "note": null, "dimensions": {} }, { "id": "total", "label": "Total other revenues", "current": 2142, "prior": 1405, "delta": 737, "growth_percent": 52.455516014234874, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 41 ], "source_ids": [ "p41" ], "fact_ids": [ "other_revenues.total.2025-FY", "other_revenues.total.2024-FY" ], "note": null, "dimensions": {} } ], "equity": { "rows": [ { "id": "equity_start", "label": "Total equity at start of period", "current": 44126, "prior": 46750, "delta": -2624, "growth_percent": -5.61283422459893, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.equity_start.2025-FY", "equity.equity_start.2024-FY" ], "note": null, "dimensions": {} }, { "id": "net_income", "label": "Net income", "current": 13967, "prior": 11939, "delta": 2028, "growth_percent": 16.9863472652651, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.net_income.2025-FY", "equity.net_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "current": 3990, "prior": 589, "delta": 3401, "growth_percent": 577.4193548387098, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_comprehensive_income.2025-FY", "equity.other_comprehensive_income.2024-FY" ], "note": null, "dimensions": {} }, { "id": "other_movements", "label": "Total other equity movements", "current": -15534, "prior": -15152, "delta": -382, "growth_percent": -2.521119324181626, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_movements.2025-FY", "equity.other_movements.2024-FY" ], "note": null, "dimensions": {} }, { "id": "equity_end", "label": "Total equity at end of period", "current": 46549, "prior": 44126, "delta": 2423, "growth_percent": 5.491093686262068, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.equity_end.2025-FY", "equity.equity_end.2024-FY" ], "note": null, "dimensions": {} } ], "bridge": { "id": "equity_rollforward", "title": "Total-equity rollforward", "kind": "equity_rollforward", "prior": 44126, "current": 46549, "delta": 2423, "residual": 0, "unit": "USD million", "prior_label": "Opening total equity / 2025-FY", "current_label": "Closing total equity / 2025-FY", "contributions": [ { "id": "net_income", "label": "Net income", "prior": 0, "current": 13967, "delta": 13967, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.net_income.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "prior": 0, "current": 3990, "delta": 3990, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_comprehensive_income.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_movements", "label": "Total other equity movements", "prior": 0, "current": -15534, "delta": -15534, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_movements.2025-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 22 ], "fact_ids": [ "equity.net_income.2025-FY", "equity.other_comprehensive_income.2025-FY", "equity.other_movements.2025-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Total equity includes non-controlling interests; shareholder-only equity is a different measure." }, "bridge_comparative": { "id": "equity_rollforward", "title": "Total-equity rollforward", "kind": "equity_rollforward", "prior": 46750, "current": 44126, "delta": -2624, "residual": 0, "unit": "USD million", "prior_label": "Opening total equity / 2024-FY", "current_label": "Closing total equity / 2024-FY", "contributions": [ { "id": "net_income", "label": "Net income", "prior": 0, "current": 11939, "delta": 11939, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.net_income.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_comprehensive_income", "label": "Other comprehensive income", "prior": 0, "current": 589, "delta": 589, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_comprehensive_income.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." }, { "id": "other_movements", "label": "Total other equity movements", "prior": 0, "current": -15152, "delta": -15152, "growth_percent": null, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 22 ], "source_ids": [ "p22" ], "fact_ids": [ "equity.other_movements.2024-FY" ], "note": "Zero is the diagram contribution origin, not a prior-year reported value." } ], "source_pages": [ 22 ], "fact_ids": [ "equity.net_income.2024-FY", "equity.other_comprehensive_income.2024-FY", "equity.other_movements.2024-FY" ], "formula": "current \u2212 prior = sum of signed contributions", "note": "Total equity includes non-controlling interests; shareholder-only equity is a different measure." } }, "currency_rates": [ { "id": "chf", "label": "CHF", "current": 1.205, "prior": 1.136, "delta": 0.06900000000000017, "growth_percent": 6.073943661971846, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.chf.2025-FY", "currency_rates.chf.2024-FY" ], "note": null, "dimensions": {} }, { "id": "cny", "label": "CNY", "current": 0.139, "prior": 0.139, "delta": 0.0, "growth_percent": 0.0, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.cny.2025-FY", "currency_rates.cny.2024-FY" ], "note": null, "dimensions": {} }, { "id": "eur", "label": "EUR", "current": 1.129, "prior": 1.082, "delta": 0.04699999999999993, "growth_percent": 4.343807763401102, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.eur.2025-FY", "currency_rates.eur.2024-FY" ], "note": null, "dimensions": {} }, { "id": "gbp", "label": "GBP", "current": 1.318, "prior": 1.278, "delta": 0.040000000000000036, "growth_percent": 3.129890453834119, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.gbp.2025-FY", "currency_rates.gbp.2024-FY" ], "note": null, "dimensions": {} }, { "id": "jpy100", "label": "100 JPY", "current": 0.669, "prior": 0.661, "delta": 0.008000000000000007, "growth_percent": 1.2102874432677773, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.jpy100.2025-FY", "currency_rates.jpy100.2024-FY" ], "note": null, "dimensions": {} }, { "id": "rub100", "label": "100 RUB", "current": 1.2, "prior": 1.08, "delta": 0.11999999999999988, "growth_percent": 11.1111111111111, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.rub100.2025-FY", "currency_rates.rub100.2024-FY" ], "note": null, "dimensions": {} } ] } }, "balance_sheet": { "current_date": "2025-12-31", "prior_date": "2024-12-31", "rows": [ { "id": "property_plant_equipment", "label": "Property, plant and equipment", "current": 10782, "prior": 9458, "delta": 1324, "growth_percent": 13.998731232818779, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.property_plant_equipment.2025-12-31", "balance_sheet.property_plant_equipment.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "right_of_use_assets", "label": "Right-of-use assets", "current": 1570, "prior": 1415, "delta": 155, "growth_percent": 10.954063604240282, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.right_of_use_assets.2025-12-31", "balance_sheet.right_of_use_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "goodwill", "label": "Goodwill", "current": 25567, "prior": 24756, "delta": 811, "growth_percent": 3.2759735013734046, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.goodwill.2025-12-31", "balance_sheet.goodwill.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "other_intangibles", "label": "Intangible assets other than goodwill", "current": 29411, "prior": 26915, "delta": 2496, "growth_percent": 9.273639234627531, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.other_intangibles.2025-12-31", "balance_sheet.other_intangibles.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "associated_company_investments", "label": "Investments in associated companies", "current": 98, "prior": 119, "delta": -21, "growth_percent": -17.647058823529413, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.associated_company_investments.2025-12-31", "balance_sheet.associated_company_investments.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "deferred_tax_assets", "label": "Deferred tax assets", "current": 5438, "prior": 4359, "delta": 1079, "growth_percent": 24.753383803624686, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.deferred_tax_assets.2025-12-31", "balance_sheet.deferred_tax_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "financial_assets", "label": "Financial assets", "current": 2348, "prior": 2015, "delta": 333, "growth_percent": 16.52605459057072, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.financial_assets.2025-12-31", "balance_sheet.financial_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "other_noncurrent_assets", "label": "Other non-current assets", "current": 5275, "prior": 3505, "delta": 1770, "growth_percent": 50.499286733238236, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.other_noncurrent_assets.2025-12-31", "balance_sheet.other_noncurrent_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "noncurrent_assets", "label": "Total non-current assets", "current": 80489, "prior": 72542, "delta": 7947, "growth_percent": 10.955032946431032, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.noncurrent_assets.2025-12-31", "balance_sheet.noncurrent_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "inventories", "label": "Inventories", "current": 6269, "prior": 5723, "delta": 546, "growth_percent": 9.54045081251092, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.inventories.2025-12-31", "balance_sheet.inventories.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "trade_receivables", "label": "Trade receivables", "current": 8937, "prior": 7423, "delta": 1514, "growth_percent": 20.39606628047959, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.trade_receivables.2025-12-31", "balance_sheet.trade_receivables.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "income_tax_receivables", "label": "Income tax receivables", "current": 205, "prior": 133, "delta": 72, "growth_percent": 54.13533834586466, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.income_tax_receivables.2025-12-31", "balance_sheet.income_tax_receivables.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "current": 155, "prior": 1998, "delta": -1843, "growth_percent": -92.24224224224224, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.marketable_securities.2025-12-31", "balance_sheet.marketable_securities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "cash_and_cash_equivalents", "label": "Cash and cash equivalents", "current": 11435, "prior": 11459, "delta": -24, "growth_percent": -0.20944235971725284, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.cash_and_cash_equivalents.2025-12-31", "balance_sheet.cash_and_cash_equivalents.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "other_current_assets", "label": "Other current assets", "current": 3459, "prior": 2968, "delta": 491, "growth_percent": 16.54312668463612, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.other_current_assets.2025-12-31", "balance_sheet.other_current_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_assets", "label": "Total current assets", "current": 30460, "prior": 29704, "delta": 756, "growth_percent": 2.545111769458659, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.current_assets.2025-12-31", "balance_sheet.current_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "total_assets", "label": "Total assets", "current": 110949, "prior": 102246, "delta": 8703, "growth_percent": 8.511824423449328, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.total_assets.2025-12-31", "balance_sheet.total_assets.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "share_capital", "label": "Share capital", "current": 766, "prior": 793, "delta": -27, "growth_percent": -3.4047919293820934, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.share_capital.2025-12-31", "balance_sheet.share_capital.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "treasury_shares", "label": "Treasury shares", "current": -50, "prior": -53, "delta": 3, "growth_percent": 5.660377358490567, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.treasury_shares.2025-12-31", "balance_sheet.treasury_shares.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "reserves", "label": "Reserves", "current": 45414, "prior": 43306, "delta": 2108, "growth_percent": 4.8676857710248, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.reserves.2025-12-31", "balance_sheet.reserves.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "shareholders_equity", "label": "Equity attributable to Novartis AG shareholders", "current": 46130, "prior": 44046, "delta": 2084, "growth_percent": 4.731417154792716, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.shareholders_equity.2025-12-31", "balance_sheet.shareholders_equity.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "non_controlling_interests", "label": "Non-controlling interests", "current": 419, "prior": 80, "delta": 339, "growth_percent": 423.75, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.non_controlling_interests.2025-12-31", "balance_sheet.non_controlling_interests.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "total_equity", "label": "Total equity", "current": 46549, "prior": 44126, "delta": 2423, "growth_percent": 5.491093686262068, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.total_equity.2025-12-31", "balance_sheet.total_equity.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "noncurrent_financial_debts", "label": "Non-current financial debts", "current": 27935, "prior": 21366, "delta": 6569, "growth_percent": 30.745109051764487, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.noncurrent_financial_debts.2025-12-31", "balance_sheet.noncurrent_financial_debts.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "noncurrent_lease_liabilities", "label": "Non-current lease liabilities", "current": 1657, "prior": 1568, "delta": 89, "growth_percent": 5.676020408163265, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.noncurrent_lease_liabilities.2025-12-31", "balance_sheet.noncurrent_lease_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "deferred_tax_liabilities", "label": "Deferred tax liabilities", "current": 3397, "prior": 2419, "delta": 978, "growth_percent": 40.42992972302604, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.deferred_tax_liabilities.2025-12-31", "balance_sheet.deferred_tax_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "other_noncurrent_liabilities", "label": "Provisions and other non-current liabilities", "current": 4133, "prior": 4075, "delta": 58, "growth_percent": 1.4233128834355828, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.other_noncurrent_liabilities.2025-12-31", "balance_sheet.other_noncurrent_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "noncurrent_liabilities", "label": "Total non-current liabilities", "current": 37122, "prior": 29428, "delta": 7694, "growth_percent": 26.145167867337232, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.noncurrent_liabilities.2025-12-31", "balance_sheet.noncurrent_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "trade_payables", "label": "Trade payables", "current": 4456, "prior": 4572, "delta": -116, "growth_percent": -2.537182852143482, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.trade_payables.2025-12-31", "balance_sheet.trade_payables.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_financial_debts", "label": "Current financial debts and derivatives", "current": 5602, "prior": 8232, "delta": -2630, "growth_percent": -31.94849368318756, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.current_financial_debts.2025-12-31", "balance_sheet.current_financial_debts.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_lease_liabilities", "label": "Current lease liabilities", "current": 263, "prior": 235, "delta": 28, "growth_percent": 11.914893617021278, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.current_lease_liabilities.2025-12-31", "balance_sheet.current_lease_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_tax_liabilities", "label": "Current income tax liabilities", "current": 1969, "prior": 1599, "delta": 370, "growth_percent": 23.139462163852407, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.current_tax_liabilities.2025-12-31", "balance_sheet.current_tax_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "other_current_liabilities", "label": "Provisions and other current liabilities", "current": 14988, "prior": 14054, "delta": 934, "growth_percent": 6.645794791518429, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.other_current_liabilities.2025-12-31", "balance_sheet.other_current_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_liabilities", "label": "Total current liabilities", "current": 27278, "prior": 28692, "delta": -1414, "growth_percent": -4.92820298341001, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.current_liabilities.2025-12-31", "balance_sheet.current_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "total_liabilities", "label": "Total liabilities", "current": 64400, "prior": 58120, "delta": 6280, "growth_percent": 10.80523055746731, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.total_liabilities.2025-12-31", "balance_sheet.total_liabilities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "equity_and_liabilities", "label": "Total equity and liabilities", "current": 110949, "prior": 102246, "delta": 8703, "growth_percent": 8.511824423449328, "unit": "USD million", "basis": "IFRS reported", "source_pages": [ 20 ], "source_ids": [ "p20" ], "fact_ids": [ "balance_sheet.equity_and_liabilities.2025-12-31", "balance_sheet.equity_and_liabilities.2024-12-31" ], "note": null, "dimensions": {} } ], "ratios": [ { "id": "current_ratio", "label": "Current assets / current liabilities", "current": 1.1166507808490358, "prior": 1.0352711557228496, "delta": 0.08137962512618624, "unit": "times", "formula": "current_assets / current_liabilities", "source_pages": [ 20 ], "fact_ids": [ "balance_sheet.current_assets.2025-12-31", "balance_sheet.current_liabilities.2025-12-31", "balance_sheet.current_assets.2024-12-31", "balance_sheet.current_liabilities.2024-12-31" ] }, { "id": "equity_assets", "label": "Equity / total assets", "current": 41.95531280137721, "prior": 43.156700506621284, "delta": -1.2013877052440733, "unit": "%", "formula": "total_equity / total_assets \u00d7 100", "source_pages": [ 20 ], "fact_ids": [ "balance_sheet.total_equity.2025-12-31", "balance_sheet.total_assets.2025-12-31", "balance_sheet.total_equity.2024-12-31", "balance_sheet.total_assets.2024-12-31" ] } ], "net_debt": [ { "id": "noncurrent_debts", "label": "Non-current financial debts", "current": -27935, "prior": -21366, "delta": -6569, "growth_percent": -30.745109051764487, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.noncurrent_debts.2025-12-31", "net_debt.noncurrent_debts.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "current_debts", "label": "Current financial debts and derivatives", "current": -5602, "prior": -8232, "delta": 2630, "growth_percent": 31.94849368318756, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.current_debts.2025-12-31", "net_debt.current_debts.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "financial_debts", "label": "Total financial debts", "current": -33537, "prior": -29598, "delta": -3939, "growth_percent": -13.308331644030002, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.financial_debts.2025-12-31", "net_debt.financial_debts.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "cash", "label": "Cash and cash equivalents", "current": 11435, "prior": 11459, "delta": -24, "growth_percent": -0.20944235971725284, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.cash.2025-12-31", "net_debt.cash.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "current": 155, "prior": 1998, "delta": -1843, "growth_percent": -92.24224224224224, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.marketable_securities.2025-12-31", "net_debt.marketable_securities.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "liquidity", "label": "Total liquidity", "current": 11590, "prior": 13457, "delta": -1867, "growth_percent": -13.87382031656387, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.liquidity.2025-12-31", "net_debt.liquidity.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "signed_net_debt", "label": "Signed net debt", "current": -21947, "prior": -16141, "delta": -5806, "growth_percent": -35.9705098816678, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "net_debt.signed_net_debt.2025-12-31", "net_debt.signed_net_debt.2024-12-31" ], "note": null, "dimensions": {} } ], "share_information": [ { "id": "shares_outstanding", "label": "Number of shares outstanding", "current": 1908151679, "prior": 1975089248, "delta": -66937569, "growth_percent": -3.3890908508454403, "unit": "shares", "basis": "Reported year-end market information", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "share_information.shares_outstanding.2025-12-31", "share_information.shares_outstanding.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "registered_share_price", "label": "Registered share price", "current": 109.6, "prior": 88.7, "delta": 20.89999999999999, "growth_percent": 23.562570462232234, "unit": "CHF per share", "basis": "Reported year-end market information", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "share_information.registered_share_price.2025-12-31", "share_information.registered_share_price.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "adr_price", "label": "ADR price", "current": 137.87, "prior": 97.31, "delta": 40.56, "growth_percent": 41.68122495118693, "unit": "USD per ADR", "basis": "Reported year-end market information", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "share_information.adr_price.2025-12-31", "share_information.adr_price.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "market_cap_usd", "label": "Market capitalization, USD", "current": 263.7, "prior": 193.9, "delta": 69.79999999999998, "growth_percent": 35.997937080969564, "unit": "USD billion", "basis": "Reported year-end market information", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "share_information.market_cap_usd.2025-12-31", "share_information.market_cap_usd.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "market_cap_chf", "label": "Market capitalization, CHF", "current": 209.1, "prior": 175.2, "delta": 33.900000000000006, "growth_percent": 19.349315068493155, "unit": "CHF billion", "basis": "Reported year-end market information", "source_pages": [ 51 ], "source_ids": [ "p51" ], "fact_ids": [ "share_information.market_cap_chf.2025-12-31", "share_information.market_cap_chf.2024-12-31" ], "note": null, "dimensions": {} } ], "currency_spot_rates": [ { "id": "chf", "label": "CHF", "current": 1.261, "prior": 1.107, "delta": 0.15399999999999991, "growth_percent": 13.911472448057808, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.chf.2025-12-31", "currency_rates.chf.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "cny", "label": "CNY", "current": 0.143, "prior": 0.137, "delta": 0.005999999999999978, "growth_percent": 4.3795620437956035, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.cny.2025-12-31", "currency_rates.cny.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "eur", "label": "EUR", "current": 1.174, "prior": 1.041, "delta": 0.133, "growth_percent": 12.776176753121998, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.eur.2025-12-31", "currency_rates.eur.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "gbp", "label": "GBP", "current": 1.346, "prior": 1.256, "delta": 0.09000000000000008, "growth_percent": 7.165605095541408, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.gbp.2025-12-31", "currency_rates.gbp.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "jpy100", "label": "100 JPY", "current": 0.639, "prior": 0.64, "delta": -0.0010000000000000009, "growth_percent": -0.15625000000000014, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.jpy100.2025-12-31", "currency_rates.jpy100.2024-12-31" ], "note": null, "dimensions": {} }, { "id": "rub100", "label": "100 RUB", "current": 1.255, "prior": 0.889, "delta": 0.3659999999999999, "growth_percent": 41.169853768278955, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "source_pages": [ 52 ], "source_ids": [ "p52" ], "fact_ids": [ "currency_rates.rub100.2025-12-31", "currency_rates.rub100.2024-12-31" ], "note": null, "dimensions": {} } ], "note": "Dated year-end balances, not quarterly flows. Net debt retains the report's negative-debt convention. Share counts and market-capitalization units are explicit." }, "facts": [ { "id": "income.net_sales.2025-Q4", "section": "income", "metric_id": "net_sales", "label": "Net sales", "period": "2025-Q4", "value": 13336, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_sales.2024-Q4", "section": "income", "metric_id": "net_sales", "label": "Net sales", "period": "2024-Q4", "value": 13153, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_sales.2025-FY", "section": "income", "metric_id": "net_sales", "label": "Net sales", "period": "2025-FY", "value": 54532, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_sales.2024-FY", "section": "income", "metric_id": "net_sales", "label": "Net sales", "period": "2024-FY", "value": 50317, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_revenues.2025-Q4", "section": "income", "metric_id": "other_revenues", "label": "Other revenues", "period": "2025-Q4", "value": 524, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_revenues.2024-Q4", "section": "income", "metric_id": "other_revenues", "label": "Other revenues", "period": "2024-Q4", "value": 405, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_revenues.2025-FY", "section": "income", "metric_id": "other_revenues", "label": "Other revenues", "period": "2025-FY", "value": 2142, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_revenues.2024-FY", "section": "income", "metric_id": "other_revenues", "label": "Other revenues", "period": "2024-FY", "value": 1405, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.cost_of_goods_sold.2025-Q4", "section": "income", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2025-Q4", "value": -3611, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.cost_of_goods_sold.2024-Q4", "section": "income", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2024-Q4", "value": -3324, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.cost_of_goods_sold.2025-FY", "section": "income", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2025-FY", "value": -13699, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.cost_of_goods_sold.2024-FY", "section": "income", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2024-FY", "value": -12827, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.gross_profit.2025-Q4", "section": "income", "metric_id": "gross_profit", "label": "Gross profit", "period": "2025-Q4", "value": 10249, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.gross_profit.2024-Q4", "section": "income", "metric_id": "gross_profit", "label": "Gross profit", "period": "2024-Q4", "value": 10234, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.gross_profit.2025-FY", "section": "income", "metric_id": "gross_profit", "label": "Gross profit", "period": "2025-FY", "value": 42975, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.gross_profit.2024-FY", "section": "income", "metric_id": "gross_profit", "label": "Gross profit", "period": "2024-FY", "value": 38895, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.selling_general_administration.2025-Q4", "section": "income", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2025-Q4", "value": -3440, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.selling_general_administration.2024-Q4", "section": "income", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2024-Q4", "value": -3501, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.selling_general_administration.2025-FY", "section": "income", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2025-FY", "value": -13248, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.selling_general_administration.2024-FY", "section": "income", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2024-FY", "value": -12566, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.research_and_development.2025-Q4", "section": "income", "metric_id": "research_and_development", "label": "Research and development", "period": "2025-Q4", "value": -3163, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.research_and_development.2024-Q4", "section": "income", "metric_id": "research_and_development", "label": "Research and development", "period": "2024-Q4", "value": -2842, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.research_and_development.2025-FY", "section": "income", "metric_id": "research_and_development", "label": "Research and development", "period": "2025-FY", "value": -11200, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.research_and_development.2024-FY", "section": "income", "metric_id": "research_and_development", "label": "Research and development", "period": "2024-FY", "value": -10022, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_income.2025-Q4", "section": "income", "metric_id": "other_income", "label": "Other income", "period": "2025-Q4", "value": 417, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_income.2024-Q4", "section": "income", "metric_id": "other_income", "label": "Other income", "period": "2024-Q4", "value": 298, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_income.2025-FY", "section": "income", "metric_id": "other_income", "label": "Other income", "period": "2025-FY", "value": 1460, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_income.2024-FY", "section": "income", "metric_id": "other_income", "label": "Other income", "period": "2024-FY", "value": 1175, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_expense.2025-Q4", "section": "income", "metric_id": "other_expense", "label": "Other expense", "period": "2025-Q4", "value": -447, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_expense.2024-Q4", "section": "income", "metric_id": "other_expense", "label": "Other expense", "period": "2024-Q4", "value": -659, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_expense.2025-FY", "section": "income", "metric_id": "other_expense", "label": "Other expense", "period": "2025-FY", "value": -2343, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_expense.2024-FY", "section": "income", "metric_id": "other_expense", "label": "Other expense", "period": "2024-FY", "value": -2938, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.operating_income.2025-Q4", "section": "income", "metric_id": "operating_income", "label": "Operating income", "period": "2025-Q4", "value": 3616, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.operating_income.2024-Q4", "section": "income", "metric_id": "operating_income", "label": "Operating income", "period": "2024-Q4", "value": 3530, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.operating_income.2025-FY", "section": "income", "metric_id": "operating_income", "label": "Operating income", "period": "2025-FY", "value": 17644, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.operating_income.2024-FY", "section": "income", "metric_id": "operating_income", "label": "Operating income", "period": "2024-FY", "value": 14544, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.associated_companies.2025-Q4", "section": "income", "metric_id": "associated_companies", "label": "Loss from associated companies", "period": "2025-Q4", "value": -2, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.associated_companies.2024-Q4", "section": "income", "metric_id": "associated_companies", "label": "Loss from associated companies", "period": "2024-Q4", "value": -3, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.associated_companies.2025-FY", "section": "income", "metric_id": "associated_companies", "label": "Loss from associated companies", "period": "2025-FY", "value": -12, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.associated_companies.2024-FY", "section": "income", "metric_id": "associated_companies", "label": "Loss from associated companies", "period": "2024-FY", "value": -38, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.interest_expense.2025-Q4", "section": "income", "metric_id": "interest_expense", "label": "Interest expense", "period": "2025-Q4", "value": -304, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.interest_expense.2024-Q4", "section": "income", "metric_id": "interest_expense", "label": "Interest expense", "period": "2024-Q4", "value": -275, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.interest_expense.2025-FY", "section": "income", "metric_id": "interest_expense", "label": "Interest expense", "period": "2025-FY", "value": -1144, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.interest_expense.2024-FY", "section": "income", "metric_id": "interest_expense", "label": "Interest expense", "period": "2024-FY", "value": -1006, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_financial_income_expense.2025-Q4", "section": "income", "metric_id": "other_financial_income_expense", "label": "Other financial income and expense", "period": "2025-Q4", "value": -92, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_financial_income_expense.2024-Q4", "section": "income", "metric_id": "other_financial_income_expense", "label": "Other financial income and expense", "period": "2024-Q4", "value": 33, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_financial_income_expense.2025-FY", "section": "income", "metric_id": "other_financial_income_expense", "label": "Other financial income and expense", "period": "2025-FY", "value": -136, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.other_financial_income_expense.2024-FY", "section": "income", "metric_id": "other_financial_income_expense", "label": "Other financial income and expense", "period": "2024-FY", "value": 140, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_before_taxes.2025-Q4", "section": "income", "metric_id": "income_before_taxes", "label": "Income before taxes", "period": "2025-Q4", "value": 3218, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_before_taxes.2024-Q4", "section": "income", "metric_id": "income_before_taxes", "label": "Income before taxes", "period": "2024-Q4", "value": 3285, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_before_taxes.2025-FY", "section": "income", "metric_id": "income_before_taxes", "label": "Income before taxes", "period": "2025-FY", "value": 16352, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_before_taxes.2024-FY", "section": "income", "metric_id": "income_before_taxes", "label": "Income before taxes", "period": "2024-FY", "value": 13640, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_taxes.2025-Q4", "section": "income", "metric_id": "income_taxes", "label": "Income taxes", "period": "2025-Q4", "value": -814, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_taxes.2024-Q4", "section": "income", "metric_id": "income_taxes", "label": "Income taxes", "period": "2024-Q4", "value": -465, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_taxes.2025-FY", "section": "income", "metric_id": "income_taxes", "label": "Income taxes", "period": "2025-FY", "value": -2385, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.income_taxes.2024-FY", "section": "income", "metric_id": "income_taxes", "label": "Income taxes", "period": "2024-FY", "value": -1701, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income.2025-Q4", "section": "income", "metric_id": "net_income", "label": "Net income", "period": "2025-Q4", "value": 2404, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income.2024-Q4", "section": "income", "metric_id": "net_income", "label": "Net income", "period": "2024-Q4", "value": 2820, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income.2025-FY", "section": "income", "metric_id": "net_income", "label": "Net income", "period": "2025-FY", "value": 13967, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income.2024-FY", "section": "income", "metric_id": "net_income", "label": "Net income", "period": "2024-FY", "value": 11939, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income_shareholders.2025-Q4", "section": "income", "metric_id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "period": "2025-Q4", "value": 2409, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income_shareholders.2024-Q4", "section": "income", "metric_id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "period": "2024-Q4", "value": 2818, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income_shareholders.2025-FY", "section": "income", "metric_id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "period": "2025-FY", "value": 13984, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.net_income_shareholders.2024-FY", "section": "income", "metric_id": "net_income_shareholders", "label": "Net income attributable to Novartis AG shareholders", "period": "2024-FY", "value": 11941, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.non_controlling_interests.2025-Q4", "section": "income", "metric_id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "period": "2025-Q4", "value": -5, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.non_controlling_interests.2024-Q4", "section": "income", "metric_id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "period": "2024-Q4", "value": 2, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.non_controlling_interests.2025-FY", "section": "income", "metric_id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "period": "2025-FY", "value": -17, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.non_controlling_interests.2024-FY", "section": "income", "metric_id": "non_controlling_interests", "label": "Net income attributable to non-controlling interests", "period": "2024-FY", "value": -2, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_shares.2025-Q4", "section": "income", "metric_id": "basic_shares", "label": "Weighted average basic shares", "period": "2025-Q4", "value": 1913, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_shares.2024-Q4", "section": "income", "metric_id": "basic_shares", "label": "Weighted average basic shares", "period": "2024-Q4", "value": 1987, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_shares.2025-FY", "section": "income", "metric_id": "basic_shares", "label": "Weighted average basic shares", "period": "2025-FY", "value": 1939, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_shares.2024-FY", "section": "income", "metric_id": "basic_shares", "label": "Weighted average basic shares", "period": "2024-FY", "value": 2018, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_eps.2025-Q4", "section": "income", "metric_id": "basic_eps", "label": "Basic earnings per share", "period": "2025-Q4", "value": 1.26, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_eps.2024-Q4", "section": "income", "metric_id": "basic_eps", "label": "Basic earnings per share", "period": "2024-Q4", "value": 1.42, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_eps.2025-FY", "section": "income", "metric_id": "basic_eps", "label": "Basic earnings per share", "period": "2025-FY", "value": 7.21, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.basic_eps.2024-FY", "section": "income", "metric_id": "basic_eps", "label": "Basic earnings per share", "period": "2024-FY", "value": 5.92, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_shares.2025-Q4", "section": "income", "metric_id": "diluted_shares", "label": "Weighted average diluted shares", "period": "2025-Q4", "value": 1929, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_shares.2024-Q4", "section": "income", "metric_id": "diluted_shares", "label": "Weighted average diluted shares", "period": "2024-Q4", "value": 2004, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_shares.2025-FY", "section": "income", "metric_id": "diluted_shares", "label": "Weighted average diluted shares", "period": "2025-FY", "value": 1955, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_shares.2024-FY", "section": "income", "metric_id": "diluted_shares", "label": "Weighted average diluted shares", "period": "2024-FY", "value": 2035, "unit": "million shares", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_eps.2025-Q4", "section": "income", "metric_id": "diluted_eps", "label": "Diluted earnings per share", "period": "2025-Q4", "value": 1.25, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_eps.2024-Q4", "section": "income", "metric_id": "diluted_eps", "label": "Diluted earnings per share", "period": "2024-Q4", "value": 1.41, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_eps.2025-FY", "section": "income", "metric_id": "diluted_eps", "label": "Diluted earnings per share", "period": "2025-FY", "value": 7.15, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "income.diluted_eps.2024-FY", "section": "income", "metric_id": "diluted_eps", "label": "Diluted earnings per share", "period": "2024-FY", "value": 5.87, "unit": "USD per share", "basis": "IFRS reported", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.property_plant_equipment.2025-12-31", "section": "balance_sheet", "metric_id": "property_plant_equipment", "label": "Property, plant and equipment", "period": "2025-12-31", "value": 10782, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.property_plant_equipment.2024-12-31", "section": "balance_sheet", "metric_id": "property_plant_equipment", "label": "Property, plant and equipment", "period": "2024-12-31", "value": 9458, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.right_of_use_assets.2025-12-31", "section": "balance_sheet", "metric_id": "right_of_use_assets", "label": "Right-of-use assets", "period": "2025-12-31", "value": 1570, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.right_of_use_assets.2024-12-31", "section": "balance_sheet", "metric_id": "right_of_use_assets", "label": "Right-of-use assets", "period": "2024-12-31", "value": 1415, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.goodwill.2025-12-31", "section": "balance_sheet", "metric_id": "goodwill", "label": "Goodwill", "period": "2025-12-31", "value": 25567, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.goodwill.2024-12-31", "section": "balance_sheet", "metric_id": "goodwill", "label": "Goodwill", "period": "2024-12-31", "value": 24756, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_intangibles.2025-12-31", "section": "balance_sheet", "metric_id": "other_intangibles", "label": "Intangible assets other than goodwill", "period": "2025-12-31", "value": 29411, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_intangibles.2024-12-31", "section": "balance_sheet", "metric_id": "other_intangibles", "label": "Intangible assets other than goodwill", "period": "2024-12-31", "value": 26915, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.associated_company_investments.2025-12-31", "section": "balance_sheet", "metric_id": "associated_company_investments", "label": "Investments in associated companies", "period": "2025-12-31", "value": 98, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.associated_company_investments.2024-12-31", "section": "balance_sheet", "metric_id": "associated_company_investments", "label": "Investments in associated companies", "period": "2024-12-31", "value": 119, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.deferred_tax_assets.2025-12-31", "section": "balance_sheet", "metric_id": "deferred_tax_assets", "label": "Deferred tax assets", "period": "2025-12-31", "value": 5438, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.deferred_tax_assets.2024-12-31", "section": "balance_sheet", "metric_id": "deferred_tax_assets", "label": "Deferred tax assets", "period": "2024-12-31", "value": 4359, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.financial_assets.2025-12-31", "section": "balance_sheet", "metric_id": "financial_assets", "label": "Financial assets", "period": "2025-12-31", "value": 2348, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.financial_assets.2024-12-31", "section": "balance_sheet", "metric_id": "financial_assets", "label": "Financial assets", "period": "2024-12-31", "value": 2015, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_noncurrent_assets.2025-12-31", "section": "balance_sheet", "metric_id": "other_noncurrent_assets", "label": "Other non-current assets", "period": "2025-12-31", "value": 5275, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_noncurrent_assets.2024-12-31", "section": "balance_sheet", "metric_id": "other_noncurrent_assets", "label": "Other non-current assets", "period": "2024-12-31", "value": 3505, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_assets.2025-12-31", "section": "balance_sheet", "metric_id": "noncurrent_assets", "label": "Total non-current assets", "period": "2025-12-31", "value": 80489, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_assets.2024-12-31", "section": "balance_sheet", "metric_id": "noncurrent_assets", "label": "Total non-current assets", "period": "2024-12-31", "value": 72542, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.inventories.2025-12-31", "section": "balance_sheet", "metric_id": "inventories", "label": "Inventories", "period": "2025-12-31", "value": 6269, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.inventories.2024-12-31", "section": "balance_sheet", "metric_id": "inventories", "label": "Inventories", "period": "2024-12-31", "value": 5723, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.trade_receivables.2025-12-31", "section": "balance_sheet", "metric_id": "trade_receivables", "label": "Trade receivables", "period": "2025-12-31", "value": 8937, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.trade_receivables.2024-12-31", "section": "balance_sheet", "metric_id": "trade_receivables", "label": "Trade receivables", "period": "2024-12-31", "value": 7423, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.income_tax_receivables.2025-12-31", "section": "balance_sheet", "metric_id": "income_tax_receivables", "label": "Income tax receivables", "period": "2025-12-31", "value": 205, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.income_tax_receivables.2024-12-31", "section": "balance_sheet", "metric_id": "income_tax_receivables", "label": "Income tax receivables", "period": "2024-12-31", "value": 133, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.marketable_securities.2025-12-31", "section": "balance_sheet", "metric_id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "period": "2025-12-31", "value": 155, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.marketable_securities.2024-12-31", "section": "balance_sheet", "metric_id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "period": "2024-12-31", "value": 1998, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.cash_and_cash_equivalents.2025-12-31", "section": "balance_sheet", "metric_id": "cash_and_cash_equivalents", "label": "Cash and cash equivalents", "period": "2025-12-31", "value": 11435, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.cash_and_cash_equivalents.2024-12-31", "section": "balance_sheet", "metric_id": "cash_and_cash_equivalents", "label": "Cash and cash equivalents", "period": "2024-12-31", "value": 11459, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_current_assets.2025-12-31", "section": "balance_sheet", "metric_id": "other_current_assets", "label": "Other current assets", "period": "2025-12-31", "value": 3459, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_current_assets.2024-12-31", "section": "balance_sheet", "metric_id": "other_current_assets", "label": "Other current assets", "period": "2024-12-31", "value": 2968, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_assets.2025-12-31", "section": "balance_sheet", "metric_id": "current_assets", "label": "Total current assets", "period": "2025-12-31", "value": 30460, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_assets.2024-12-31", "section": "balance_sheet", "metric_id": "current_assets", "label": "Total current assets", "period": "2024-12-31", "value": 29704, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_assets.2025-12-31", "section": "balance_sheet", "metric_id": "total_assets", "label": "Total assets", "period": "2025-12-31", "value": 110949, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_assets.2024-12-31", "section": "balance_sheet", "metric_id": "total_assets", "label": "Total assets", "period": "2024-12-31", "value": 102246, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.share_capital.2025-12-31", "section": "balance_sheet", "metric_id": "share_capital", "label": "Share capital", "period": "2025-12-31", "value": 766, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.share_capital.2024-12-31", "section": "balance_sheet", "metric_id": "share_capital", "label": "Share capital", "period": "2024-12-31", "value": 793, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.treasury_shares.2025-12-31", "section": "balance_sheet", "metric_id": "treasury_shares", "label": "Treasury shares", "period": "2025-12-31", "value": -50, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.treasury_shares.2024-12-31", "section": "balance_sheet", "metric_id": "treasury_shares", "label": "Treasury shares", "period": "2024-12-31", "value": -53, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.reserves.2025-12-31", "section": "balance_sheet", "metric_id": "reserves", "label": "Reserves", "period": "2025-12-31", "value": 45414, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.reserves.2024-12-31", "section": "balance_sheet", "metric_id": "reserves", "label": "Reserves", "period": "2024-12-31", "value": 43306, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.shareholders_equity.2025-12-31", "section": "balance_sheet", "metric_id": "shareholders_equity", "label": "Equity attributable to Novartis AG shareholders", "period": "2025-12-31", "value": 46130, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.shareholders_equity.2024-12-31", "section": "balance_sheet", "metric_id": "shareholders_equity", "label": "Equity attributable to Novartis AG shareholders", "period": "2024-12-31", "value": 44046, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.non_controlling_interests.2025-12-31", "section": "balance_sheet", "metric_id": "non_controlling_interests", "label": "Non-controlling interests", "period": "2025-12-31", "value": 419, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.non_controlling_interests.2024-12-31", "section": "balance_sheet", "metric_id": "non_controlling_interests", "label": "Non-controlling interests", "period": "2024-12-31", "value": 80, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_equity.2025-12-31", "section": "balance_sheet", "metric_id": "total_equity", "label": "Total equity", "period": "2025-12-31", "value": 46549, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_equity.2024-12-31", "section": "balance_sheet", "metric_id": "total_equity", "label": "Total equity", "period": "2024-12-31", "value": 44126, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_financial_debts.2025-12-31", "section": "balance_sheet", "metric_id": "noncurrent_financial_debts", "label": "Non-current financial debts", "period": "2025-12-31", "value": 27935, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_financial_debts.2024-12-31", "section": "balance_sheet", "metric_id": "noncurrent_financial_debts", "label": "Non-current financial debts", "period": "2024-12-31", "value": 21366, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_lease_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "noncurrent_lease_liabilities", "label": "Non-current lease liabilities", "period": "2025-12-31", "value": 1657, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_lease_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "noncurrent_lease_liabilities", "label": "Non-current lease liabilities", "period": "2024-12-31", "value": 1568, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.deferred_tax_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "deferred_tax_liabilities", "label": "Deferred tax liabilities", "period": "2025-12-31", "value": 3397, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.deferred_tax_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "deferred_tax_liabilities", "label": "Deferred tax liabilities", "period": "2024-12-31", "value": 2419, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_noncurrent_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "other_noncurrent_liabilities", "label": "Provisions and other non-current liabilities", "period": "2025-12-31", "value": 4133, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_noncurrent_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "other_noncurrent_liabilities", "label": "Provisions and other non-current liabilities", "period": "2024-12-31", "value": 4075, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "noncurrent_liabilities", "label": "Total non-current liabilities", "period": "2025-12-31", "value": 37122, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.noncurrent_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "noncurrent_liabilities", "label": "Total non-current liabilities", "period": "2024-12-31", "value": 29428, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.trade_payables.2025-12-31", "section": "balance_sheet", "metric_id": "trade_payables", "label": "Trade payables", "period": "2025-12-31", "value": 4456, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.trade_payables.2024-12-31", "section": "balance_sheet", "metric_id": "trade_payables", "label": "Trade payables", "period": "2024-12-31", "value": 4572, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_financial_debts.2025-12-31", "section": "balance_sheet", "metric_id": "current_financial_debts", "label": "Current financial debts and derivatives", "period": "2025-12-31", "value": 5602, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_financial_debts.2024-12-31", "section": "balance_sheet", "metric_id": "current_financial_debts", "label": "Current financial debts and derivatives", "period": "2024-12-31", "value": 8232, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_lease_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "current_lease_liabilities", "label": "Current lease liabilities", "period": "2025-12-31", "value": 263, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_lease_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "current_lease_liabilities", "label": "Current lease liabilities", "period": "2024-12-31", "value": 235, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_tax_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "current_tax_liabilities", "label": "Current income tax liabilities", "period": "2025-12-31", "value": 1969, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_tax_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "current_tax_liabilities", "label": "Current income tax liabilities", "period": "2024-12-31", "value": 1599, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_current_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "other_current_liabilities", "label": "Provisions and other current liabilities", "period": "2025-12-31", "value": 14988, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.other_current_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "other_current_liabilities", "label": "Provisions and other current liabilities", "period": "2024-12-31", "value": 14054, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "current_liabilities", "label": "Total current liabilities", "period": "2025-12-31", "value": 27278, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.current_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "current_liabilities", "label": "Total current liabilities", "period": "2024-12-31", "value": 28692, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "total_liabilities", "label": "Total liabilities", "period": "2025-12-31", "value": 64400, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.total_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "total_liabilities", "label": "Total liabilities", "period": "2024-12-31", "value": 58120, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.equity_and_liabilities.2025-12-31", "section": "balance_sheet", "metric_id": "equity_and_liabilities", "label": "Total equity and liabilities", "period": "2025-12-31", "value": 110949, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "balance_sheet.equity_and_liabilities.2024-12-31", "section": "balance_sheet", "metric_id": "equity_and_liabilities", "label": "Total equity and liabilities", "period": "2024-12-31", "value": 102246, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 20, "pdf_page_index": 19, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.net_income.2025-Q4", "section": "cashflow", "metric_id": "net_income", "label": "Net income", "period": "2025-Q4", "value": 2404, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.net_income.2024-Q4", "section": "cashflow", "metric_id": "net_income", "label": "Net income", "period": "2024-Q4", "value": 2820, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.net_income.2025-FY", "section": "cashflow", "metric_id": "net_income", "label": "Net income", "period": "2025-FY", "value": 13967, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.net_income.2024-FY", "section": "cashflow", "metric_id": "net_income", "label": "Net income", "period": "2024-FY", "value": 11939, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.noncash_adjustments.2025-Q4", "section": "cashflow", "metric_id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "period": "2025-Q4", "value": 3302, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.noncash_adjustments.2024-Q4", "section": "cashflow", "metric_id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "period": "2024-Q4", "value": 2709, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.noncash_adjustments.2025-FY", "section": "cashflow", "metric_id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "period": "2025-FY", "value": 11229, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.noncash_adjustments.2024-FY", "section": "cashflow", "metric_id": "noncash_adjustments", "label": "Reversal of non-cash items and other adjustments", "period": "2024-FY", "value": 10232, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.dividends_received.2025-Q4", "section": "cashflow", "metric_id": "dividends_received", "label": "Dividends received from associated companies and others", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.dividends_received.2024-Q4", "section": "cashflow", "metric_id": "dividends_received", "label": "Dividends received from associated companies and others", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.dividends_received.2025-FY", "section": "cashflow", "metric_id": "dividends_received", "label": "Dividends received from associated companies and others", "period": "2025-FY", "value": 1, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.dividends_received.2024-FY", "section": "cashflow", "metric_id": "dividends_received", "label": "Dividends received from associated companies and others", "period": "2024-FY", "value": 1, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_received.2025-Q4", "section": "cashflow", "metric_id": "interest_received", "label": "Interest received", "period": "2025-Q4", "value": 88, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_received.2024-Q4", "section": "cashflow", "metric_id": "interest_received", "label": "Interest received", "period": "2024-Q4", "value": 142, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_received.2025-FY", "section": "cashflow", "metric_id": "interest_received", "label": "Interest received", "period": "2025-FY", "value": 310, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_received.2024-FY", "section": "cashflow", "metric_id": "interest_received", "label": "Interest received", "period": "2024-FY", "value": 489, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_paid.2025-Q4", "section": "cashflow", "metric_id": "interest_paid", "label": "Interest paid", "period": "2025-Q4", "value": -211, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_paid.2024-Q4", "section": "cashflow", "metric_id": "interest_paid", "label": "Interest paid", "period": "2024-Q4", "value": -214, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_paid.2025-FY", "section": "cashflow", "metric_id": "interest_paid", "label": "Interest paid", "period": "2025-FY", "value": -981, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.interest_paid.2024-FY", "section": "cashflow", "metric_id": "interest_paid", "label": "Interest paid", "period": "2024-FY", "value": -855, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_receipts.2025-Q4", "section": "cashflow", "metric_id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "period": "2025-Q4", "value": -50, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_receipts.2024-Q4", "section": "cashflow", "metric_id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.other_financial_receipts.2025-FY", "section": "cashflow", "metric_id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "period": "2025-FY", "value": 266, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_receipts.2024-FY", "section": "cashflow", "metric_id": "other_financial_receipts", "label": "Other financial receipts / change in receipts", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.other_financial_payments.2025-Q4", "section": "cashflow", "metric_id": "other_financial_payments", "label": "Other financial payments / change in payments", "period": "2025-Q4", "value": -6, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_payments.2024-Q4", "section": "cashflow", "metric_id": "other_financial_payments", "label": "Other financial payments / change in payments", "period": "2024-Q4", "value": -85, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_payments.2025-FY", "section": "cashflow", "metric_id": "other_financial_payments", "label": "Other financial payments / change in payments", "period": "2025-FY", "value": -26, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financial_payments.2024-FY", "section": "cashflow", "metric_id": "other_financial_payments", "label": "Other financial payments / change in payments", "period": "2024-FY", "value": -116, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.income_taxes_paid.2025-Q4", "section": "cashflow", "metric_id": "income_taxes_paid", "label": "Income taxes paid", "period": "2025-Q4", "value": -981, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.income_taxes_paid.2024-Q4", "section": "cashflow", "metric_id": "income_taxes_paid", "label": "Income taxes paid", "period": "2024-Q4", "value": -924, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.income_taxes_paid.2025-FY", "section": "cashflow", "metric_id": "income_taxes_paid", "label": "Income taxes paid", "period": "2025-FY", "value": -2562, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.income_taxes_paid.2024-FY", "section": "cashflow", "metric_id": "income_taxes_paid", "label": "Income taxes paid", "period": "2024-FY", "value": -2258, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_before_changes.2025-Q4", "section": "cashflow", "metric_id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "period": "2025-Q4", "value": 4546, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_before_changes.2024-Q4", "section": "cashflow", "metric_id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "period": "2024-Q4", "value": 4448, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_before_changes.2025-FY", "section": "cashflow", "metric_id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "period": "2025-FY", "value": 22204, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_before_changes.2024-FY", "section": "cashflow", "metric_id": "operating_before_changes", "label": "Operating cash flow before working capital and provision changes", "period": "2024-FY", "value": 19432, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.provision_payments.2025-Q4", "section": "cashflow", "metric_id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "period": "2025-Q4", "value": -695, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.provision_payments.2024-Q4", "section": "cashflow", "metric_id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "period": "2024-Q4", "value": -260, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.provision_payments.2025-FY", "section": "cashflow", "metric_id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "period": "2025-FY", "value": -1483, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.provision_payments.2024-FY", "section": "cashflow", "metric_id": "provision_payments", "label": "Payments out of provisions and other non-current movements", "period": "2024-FY", "value": -1107, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.working_capital.2025-Q4", "section": "cashflow", "metric_id": "working_capital", "label": "Working capital and other operating cash-flow items", "period": "2025-Q4", "value": -1587, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.working_capital.2024-Q4", "section": "cashflow", "metric_id": "working_capital", "label": "Working capital and other operating cash-flow items", "period": "2024-Q4", "value": 5, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.working_capital.2025-FY", "section": "cashflow", "metric_id": "working_capital", "label": "Working capital and other operating cash-flow items", "period": "2025-FY", "value": -1577, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.working_capital.2024-FY", "section": "cashflow", "metric_id": "working_capital", "label": "Working capital and other operating cash-flow items", "period": "2024-FY", "value": -706, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_cash_flow.2025-Q4", "section": "cashflow", "metric_id": "operating_cash_flow", "label": "Net cash flows from operating activities", "period": "2025-Q4", "value": 2264, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_cash_flow.2024-Q4", "section": "cashflow", "metric_id": "operating_cash_flow", "label": "Net cash flows from operating activities", "period": "2024-Q4", "value": 4193, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_cash_flow.2025-FY", "section": "cashflow", "metric_id": "operating_cash_flow", "label": "Net cash flows from operating activities", "period": "2025-FY", "value": 19144, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.operating_cash_flow.2024-FY", "section": "cashflow", "metric_id": "operating_cash_flow", "label": "Net cash flows from operating activities", "period": "2024-FY", "value": 17619, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.capex.2025-Q4", "section": "cashflow", "metric_id": "capex", "label": "Purchases of property, plant and equipment", "period": "2025-Q4", "value": -609, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.capex.2024-Q4", "section": "cashflow", "metric_id": "capex", "label": "Purchases of property, plant and equipment", "period": "2024-Q4", "value": -558, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.capex.2025-FY", "section": "cashflow", "metric_id": "capex", "label": "Purchases of property, plant and equipment", "period": "2025-FY", "value": -1548, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.capex.2024-FY", "section": "cashflow", "metric_id": "capex", "label": "Purchases of property, plant and equipment", "period": "2024-FY", "value": -1366, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.property_sale_proceeds.2025-Q4", "section": "cashflow", "metric_id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "period": "2025-Q4", "value": 1, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.property_sale_proceeds.2024-Q4", "section": "cashflow", "metric_id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "period": "2024-Q4", "value": 47, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.property_sale_proceeds.2025-FY", "section": "cashflow", "metric_id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "period": "2025-FY", "value": 13, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.property_sale_proceeds.2024-FY", "section": "cashflow", "metric_id": "property_sale_proceeds", "label": "Proceeds from sale of property, plant and equipment", "period": "2024-FY", "value": 86, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_purchases.2025-Q4", "section": "cashflow", "metric_id": "intangible_purchases", "label": "Purchases of intangible assets", "period": "2025-Q4", "value": -408, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_purchases.2024-Q4", "section": "cashflow", "metric_id": "intangible_purchases", "label": "Purchases of intangible assets", "period": "2024-Q4", "value": -573, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_purchases.2025-FY", "section": "cashflow", "metric_id": "intangible_purchases", "label": "Purchases of intangible assets", "period": "2025-FY", "value": -2352, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_purchases.2024-FY", "section": "cashflow", "metric_id": "intangible_purchases", "label": "Purchases of intangible assets", "period": "2024-FY", "value": -2448, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_sale_proceeds.2025-Q4", "section": "cashflow", "metric_id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "period": "2025-Q4", "value": 112, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_sale_proceeds.2024-Q4", "section": "cashflow", "metric_id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "period": "2024-Q4", "value": 37, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_sale_proceeds.2025-FY", "section": "cashflow", "metric_id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "period": "2025-FY", "value": 164, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.intangible_sale_proceeds.2024-FY", "section": "cashflow", "metric_id": "intangible_sale_proceeds", "label": "Proceeds from sale of intangible assets", "period": "2024-FY", "value": 80, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_purchases.2025-Q4", "section": "cashflow", "metric_id": "financial_asset_purchases", "label": "Purchases of financial assets", "period": "2025-Q4", "value": -53, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_purchases.2024-Q4", "section": "cashflow", "metric_id": "financial_asset_purchases", "label": "Purchases of financial assets", "period": "2024-Q4", "value": -48, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_purchases.2025-FY", "section": "cashflow", "metric_id": "financial_asset_purchases", "label": "Purchases of financial assets", "period": "2025-FY", "value": -116, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_purchases.2024-FY", "section": "cashflow", "metric_id": "financial_asset_purchases", "label": "Purchases of financial assets", "period": "2024-FY", "value": -193, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_sale_proceeds.2025-Q4", "section": "cashflow", "metric_id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "period": "2025-Q4", "value": 24, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_sale_proceeds.2024-Q4", "section": "cashflow", "metric_id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "period": "2024-Q4", "value": 21, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_sale_proceeds.2025-FY", "section": "cashflow", "metric_id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "period": "2025-FY", "value": 209, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financial_asset_sale_proceeds.2024-FY", "section": "cashflow", "metric_id": "financial_asset_sale_proceeds", "label": "Proceeds from sale of financial assets", "period": "2024-FY", "value": 957, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_acquisitions.2025-Q4", "section": "cashflow", "metric_id": "business_acquisitions", "label": "Acquisitions of businesses", "period": "2025-Q4", "value": -21, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_acquisitions.2024-Q4", "section": "cashflow", "metric_id": "business_acquisitions", "label": "Acquisitions of businesses", "period": "2024-Q4", "value": -426, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_acquisitions.2025-FY", "section": "cashflow", "metric_id": "business_acquisitions", "label": "Acquisitions of businesses", "period": "2025-FY", "value": -147, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_acquisitions.2024-FY", "section": "cashflow", "metric_id": "business_acquisitions", "label": "Acquisitions of businesses", "period": "2024-FY", "value": -4018, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.asset_acquisitions.2025-Q4", "section": "cashflow", "metric_id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "period": "2025-Q4", "value": -1138, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.asset_acquisitions.2024-Q4", "section": "cashflow", "metric_id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.asset_acquisitions.2025-FY", "section": "cashflow", "metric_id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "period": "2025-FY", "value": -2769, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.asset_acquisitions.2024-FY", "section": "cashflow", "metric_id": "asset_acquisitions", "label": "Acquisitions applying the optional concentration test", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.business_divestments.2025-Q4", "section": "cashflow", "metric_id": "business_divestments", "label": "Divestments of businesses, net", "period": "2025-Q4", "value": -9, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_divestments.2024-Q4", "section": "cashflow", "metric_id": "business_divestments", "label": "Divestments of businesses, net", "period": "2024-Q4", "value": 164, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_divestments.2025-FY", "section": "cashflow", "metric_id": "business_divestments", "label": "Divestments of businesses, net", "period": "2025-FY", "value": -88, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.business_divestments.2024-FY", "section": "cashflow", "metric_id": "business_divestments", "label": "Divestments of businesses, net", "period": "2024-FY", "value": 107, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_investments.2025-Q4", "section": "cashflow", "metric_id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "period": "2025-Q4", "value": -37, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_investments.2024-Q4", "section": "cashflow", "metric_id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "period": "2024-Q4", "value": -2257, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_investments.2025-FY", "section": "cashflow", "metric_id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "period": "2025-FY", "value": -187, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_investments.2024-FY", "section": "cashflow", "metric_id": "time_deposit_investments", "label": "Investments in time deposits and marketable securities", "period": "2024-FY", "value": -3455, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_proceeds.2025-Q4", "section": "cashflow", "metric_id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "period": "2025-Q4", "value": 48, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_proceeds.2024-Q4", "section": "cashflow", "metric_id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "period": "2024-Q4", "value": 560, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_proceeds.2025-FY", "section": "cashflow", "metric_id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "period": "2025-FY", "value": 1968, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.time_deposit_proceeds.2024-FY", "section": "cashflow", "metric_id": "time_deposit_proceeds", "label": "Proceeds from time deposits, marketable securities and commodities", "period": "2024-FY", "value": 2744, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_investing.2025-Q4", "section": "cashflow", "metric_id": "other_investing", "label": "Other investing cash flows, net", "period": "2025-Q4", "value": -14, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_investing.2024-Q4", "section": "cashflow", "metric_id": "other_investing", "label": "Other investing cash flows, net", "period": "2024-Q4", "value": 0, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_investing.2025-FY", "section": "cashflow", "metric_id": "other_investing", "label": "Other investing cash flows, net", "period": "2025-FY", "value": -24, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_investing.2024-FY", "section": "cashflow", "metric_id": "other_investing", "label": "Other investing cash flows, net", "period": "2024-FY", "value": -7, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.investing_cash_flow.2025-Q4", "section": "cashflow", "metric_id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "period": "2025-Q4", "value": -2104, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.investing_cash_flow.2024-Q4", "section": "cashflow", "metric_id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "period": "2024-Q4", "value": -3033, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.investing_cash_flow.2025-FY", "section": "cashflow", "metric_id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "period": "2025-FY", "value": -4877, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.investing_cash_flow.2024-FY", "section": "cashflow", "metric_id": "investing_cash_flow", "label": "Net cash flows used in investing activities", "period": "2024-FY", "value": -7513, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.dividends_paid.2025-Q4", "section": "cashflow", "metric_id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.dividends_paid.2024-Q4", "section": "cashflow", "metric_id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.dividends_paid.2025-FY", "section": "cashflow", "metric_id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "period": "2025-FY", "value": -7818, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.dividends_paid.2024-FY", "section": "cashflow", "metric_id": "dividends_paid", "label": "Dividends paid to Novartis AG shareholders", "period": "2024-FY", "value": -7624, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_purchases.2025-Q4", "section": "cashflow", "metric_id": "treasury_share_purchases", "label": "Purchases of treasury shares", "period": "2025-Q4", "value": -1480, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_purchases.2024-Q4", "section": "cashflow", "metric_id": "treasury_share_purchases", "label": "Purchases of treasury shares", "period": "2024-Q4", "value": -2762, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_purchases.2025-FY", "section": "cashflow", "metric_id": "treasury_share_purchases", "label": "Purchases of treasury shares", "period": "2025-FY", "value": -9212, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_purchases.2024-FY", "section": "cashflow", "metric_id": "treasury_share_purchases", "label": "Purchases of treasury shares", "period": "2024-FY", "value": -8331, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_proceeds.2025-Q4", "section": "cashflow", "metric_id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "period": "2025-Q4", "value": 4, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_proceeds.2024-Q4", "section": "cashflow", "metric_id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.treasury_share_proceeds.2025-FY", "section": "cashflow", "metric_id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "period": "2025-FY", "value": 27, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.treasury_share_proceeds.2024-FY", "section": "cashflow", "metric_id": "treasury_share_proceeds", "label": "Proceeds from options and other treasury transactions", "period": "2024-FY", "value": 30, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_proceeds.2025-Q4", "section": "cashflow", "metric_id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "period": "2025-Q4", "value": 5963, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_proceeds.2024-Q4", "section": "cashflow", "metric_id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.debt_proceeds.2025-FY", "section": "cashflow", "metric_id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "period": "2025-FY", "value": 6098, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_proceeds.2024-FY", "section": "cashflow", "metric_id": "debt_proceeds", "label": "Proceeds from non-current financial debts", "period": "2024-FY", "value": 6143, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_repayments.2025-Q4", "section": "cashflow", "metric_id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "period": "2025-Q4", "value": -1770, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_repayments.2024-Q4", "section": "cashflow", "metric_id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "period": "2024-Q4", "value": -10, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_repayments.2025-FY", "section": "cashflow", "metric_id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "period": "2025-FY", "value": -3392, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.debt_repayments.2024-FY", "section": "cashflow", "metric_id": "debt_repayments", "label": "Repayments of current portion of non-current debts", "period": "2024-FY", "value": -2160, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.current_debt_change.2025-Q4", "section": "cashflow", "metric_id": "current_debt_change", "label": "Change in current financial debts", "period": "2025-Q4", "value": -837, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.current_debt_change.2024-Q4", "section": "cashflow", "metric_id": "current_debt_change", "label": "Change in current financial debts", "period": "2024-Q4", "value": -24, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.current_debt_change.2025-FY", "section": "cashflow", "metric_id": "current_debt_change", "label": "Change in current financial debts", "period": "2025-FY", "value": 5, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.current_debt_change.2024-FY", "section": "cashflow", "metric_id": "current_debt_change", "label": "Change in current financial debts", "period": "2024-FY", "value": 958, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_debt_repayments.2025-Q4", "section": "cashflow", "metric_id": "other_debt_repayments", "label": "Repayments of other current financial debts", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.other_debt_repayments.2024-Q4", "section": "cashflow", "metric_id": "other_debt_repayments", "label": "Repayments of other current financial debts", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.other_debt_repayments.2025-FY", "section": "cashflow", "metric_id": "other_debt_repayments", "label": "Repayments of other current financial debts", "period": "2025-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Blank or unavailable source cell; not a measured zero." }, { "id": "cashflow.other_debt_repayments.2024-FY", "section": "cashflow", "metric_id": "other_debt_repayments", "label": "Repayments of other current financial debts", "period": "2024-FY", "value": -289, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.lease_payments.2025-Q4", "section": "cashflow", "metric_id": "lease_payments", "label": "Payments of lease liabilities", "period": "2025-Q4", "value": -73, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.lease_payments.2024-Q4", "section": "cashflow", "metric_id": "lease_payments", "label": "Payments of lease liabilities", "period": "2024-Q4", "value": -72, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.lease_payments.2025-FY", "section": "cashflow", "metric_id": "lease_payments", "label": "Payments of lease liabilities", "period": "2025-FY", "value": -281, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.lease_payments.2024-FY", "section": "cashflow", "metric_id": "lease_payments", "label": "Payments of lease liabilities", "period": "2024-FY", "value": -262, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.ownership_payments.2025-Q4", "section": "cashflow", "metric_id": "ownership_payments", "label": "Payments from changes in ownership interests", "period": "2025-Q4", "value": -91, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.ownership_payments.2024-Q4", "section": "cashflow", "metric_id": "ownership_payments", "label": "Payments from changes in ownership interests", "period": "2024-Q4", "value": -156, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.ownership_payments.2025-FY", "section": "cashflow", "metric_id": "ownership_payments", "label": "Payments from changes in ownership interests", "period": "2025-FY", "value": -91, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.ownership_payments.2024-FY", "section": "cashflow", "metric_id": "ownership_payments", "label": "Payments from changes in ownership interests", "period": "2024-FY", "value": -293, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financing.2025-Q4", "section": "cashflow", "metric_id": "other_financing", "label": "Other financing cash flows, net", "period": "2025-Q4", "value": -33, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financing.2024-Q4", "section": "cashflow", "metric_id": "other_financing", "label": "Other financing cash flows, net", "period": "2024-Q4", "value": 28, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financing.2025-FY", "section": "cashflow", "metric_id": "other_financing", "label": "Other financing cash flows, net", "period": "2025-FY", "value": -203, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.other_financing.2024-FY", "section": "cashflow", "metric_id": "other_financing", "label": "Other financing cash flows, net", "period": "2024-FY", "value": 86, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financing_cash_flow.2025-Q4", "section": "cashflow", "metric_id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "period": "2025-Q4", "value": 1683, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financing_cash_flow.2024-Q4", "section": "cashflow", "metric_id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "period": "2024-Q4", "value": -2996, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financing_cash_flow.2025-FY", "section": "cashflow", "metric_id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "period": "2025-FY", "value": -14867, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.financing_cash_flow.2024-FY", "section": "cashflow", "metric_id": "financing_cash_flow", "label": "Net cash flows from/(used in) financing activities", "period": "2024-FY", "value": -11742, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change_before_fx.2025-Q4", "section": "cashflow", "metric_id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "period": "2025-Q4", "value": 1843, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change_before_fx.2024-Q4", "section": "cashflow", "metric_id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "period": "2024-Q4", "value": -1836, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change_before_fx.2025-FY", "section": "cashflow", "metric_id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "period": "2025-FY", "value": -600, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change_before_fx.2024-FY", "section": "cashflow", "metric_id": "cash_change_before_fx", "label": "Net change in cash before exchange-rate effects", "period": "2024-FY", "value": -1636, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.fx_effect.2025-Q4", "section": "cashflow", "metric_id": "fx_effect", "label": "Exchange-rate effects on cash", "period": "2025-Q4", "value": 36, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.fx_effect.2024-Q4", "section": "cashflow", "metric_id": "fx_effect", "label": "Exchange-rate effects on cash", "period": "2024-Q4", "value": -314, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.fx_effect.2025-FY", "section": "cashflow", "metric_id": "fx_effect", "label": "Exchange-rate effects on cash", "period": "2025-FY", "value": 576, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.fx_effect.2024-FY", "section": "cashflow", "metric_id": "fx_effect", "label": "Exchange-rate effects on cash", "period": "2024-FY", "value": -298, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change.2025-Q4", "section": "cashflow", "metric_id": "cash_change", "label": "Net change in cash and cash equivalents", "period": "2025-Q4", "value": 1879, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change.2024-Q4", "section": "cashflow", "metric_id": "cash_change", "label": "Net change in cash and cash equivalents", "period": "2024-Q4", "value": -2150, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change.2025-FY", "section": "cashflow", "metric_id": "cash_change", "label": "Net change in cash and cash equivalents", "period": "2025-FY", "value": -24, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_change.2024-FY", "section": "cashflow", "metric_id": "cash_change", "label": "Net change in cash and cash equivalents", "period": "2024-FY", "value": -1934, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_start.2025-Q4", "section": "cashflow", "metric_id": "cash_start", "label": "Cash and cash equivalents at period start", "period": "2025-Q4", "value": 9556, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_start.2024-Q4", "section": "cashflow", "metric_id": "cash_start", "label": "Cash and cash equivalents at period start", "period": "2024-Q4", "value": 13609, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_start.2025-FY", "section": "cashflow", "metric_id": "cash_start", "label": "Cash and cash equivalents at period start", "period": "2025-FY", "value": 11459, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_start.2024-FY", "section": "cashflow", "metric_id": "cash_start", "label": "Cash and cash equivalents at period start", "period": "2024-FY", "value": 13393, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_end.2025-Q4", "section": "cashflow", "metric_id": "cash_end", "label": "Cash and cash equivalents at December 31", "period": "2025-Q4", "value": 11435, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_end.2024-Q4", "section": "cashflow", "metric_id": "cash_end", "label": "Cash and cash equivalents at December 31", "period": "2024-Q4", "value": 11459, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 23, "pdf_page_index": 22, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_end.2025-FY", "section": "cashflow", "metric_id": "cash_end", "label": "Cash and cash equivalents at December 31", "period": "2025-FY", "value": 11435, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "cashflow.cash_end.2024-FY", "section": "cashflow", "metric_id": "cash_end", "label": "Cash and cash equivalents at December 31", "period": "2024-FY", "value": 11459, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 24, "pdf_page_index": 23, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.inventories.2025-Q4", "section": "working_capital", "metric_id": "inventories", "label": "Decrease/(increase) in inventories", "period": "2025-Q4", "value": 151, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.inventories.2024-Q4", "section": "working_capital", "metric_id": "inventories", "label": "Decrease/(increase) in inventories", "period": "2024-Q4", "value": -169, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.inventories.2025-FY", "section": "working_capital", "metric_id": "inventories", "label": "Decrease/(increase) in inventories", "period": "2025-FY", "value": 34, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.inventories.2024-FY", "section": "working_capital", "metric_id": "inventories", "label": "Decrease/(increase) in inventories", "period": "2024-FY", "value": -225, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_receivables.2025-Q4", "section": "working_capital", "metric_id": "trade_receivables", "label": "Increase/decrease in trade receivables", "period": "2025-Q4", "value": -94, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_receivables.2024-Q4", "section": "working_capital", "metric_id": "trade_receivables", "label": "Increase/decrease in trade receivables", "period": "2024-Q4", "value": 162, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_receivables.2025-FY", "section": "working_capital", "metric_id": "trade_receivables", "label": "Increase/decrease in trade receivables", "period": "2025-FY", "value": -1124, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_receivables.2024-FY", "section": "working_capital", "metric_id": "trade_receivables", "label": "Increase/decrease in trade receivables", "period": "2024-FY", "value": -931, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_payables.2025-Q4", "section": "working_capital", "metric_id": "trade_payables", "label": "Increase/(decrease) in trade payables", "period": "2025-Q4", "value": 102, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_payables.2024-Q4", "section": "working_capital", "metric_id": "trade_payables", "label": "Increase/(decrease) in trade payables", "period": "2024-Q4", "value": 555, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_payables.2025-FY", "section": "working_capital", "metric_id": "trade_payables", "label": "Increase/(decrease) in trade payables", "period": "2025-FY", "value": -273, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.trade_payables.2024-FY", "section": "working_capital", "metric_id": "trade_payables", "label": "Increase/(decrease) in trade payables", "period": "2024-FY", "value": -105, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_assets.2025-Q4", "section": "working_capital", "metric_id": "other_assets", "label": "Change in other current and non-current assets", "period": "2025-Q4", "value": -601, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_assets.2024-Q4", "section": "working_capital", "metric_id": "other_assets", "label": "Change in other current and non-current assets", "period": "2024-Q4", "value": -73, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_assets.2025-FY", "section": "working_capital", "metric_id": "other_assets", "label": "Change in other current and non-current assets", "period": "2025-FY", "value": -461, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_assets.2024-FY", "section": "working_capital", "metric_id": "other_assets", "label": "Change in other current and non-current assets", "period": "2024-FY", "value": -502, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_liabilities.2025-Q4", "section": "working_capital", "metric_id": "other_liabilities", "label": "Change in other current liabilities", "period": "2025-Q4", "value": -1145, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_liabilities.2024-Q4", "section": "working_capital", "metric_id": "other_liabilities", "label": "Change in other current liabilities", "period": "2024-Q4", "value": -470, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_liabilities.2025-FY", "section": "working_capital", "metric_id": "other_liabilities", "label": "Change in other current liabilities", "period": "2025-FY", "value": 247, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.other_liabilities.2024-FY", "section": "working_capital", "metric_id": "other_liabilities", "label": "Change in other current liabilities", "period": "2024-FY", "value": 1057, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.total.2025-Q4", "section": "working_capital", "metric_id": "total", "label": "Total working-capital and other operating items", "period": "2025-Q4", "value": -1587, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.total.2024-Q4", "section": "working_capital", "metric_id": "total", "label": "Total working-capital and other operating items", "period": "2024-Q4", "value": 5, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.total.2025-FY", "section": "working_capital", "metric_id": "total", "label": "Total working-capital and other operating items", "period": "2025-FY", "value": -1577, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "working_capital.total.2024-FY", "section": "working_capital", "metric_id": "total", "label": "Total working-capital and other operating items", "period": "2024-FY", "value": -706, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 32, "pdf_page_index": 31, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.us.2025-Q4", "section": "regions", "metric_id": "us", "label": "United States", "period": "2025-Q4", "value": 5334, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.us.2024-Q4", "section": "regions", "metric_id": "us", "label": "United States", "period": "2024-Q4", "value": 6002, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.us.2025-FY", "section": "regions", "metric_id": "us", "label": "United States", "period": "2025-FY", "value": 23331, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.us.2024-FY", "section": "regions", "metric_id": "us", "label": "United States", "period": "2024-FY", "value": 21146, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.europe.2025-Q4", "section": "regions", "metric_id": "europe", "label": "Europe", "period": "2025-Q4", "value": 4403, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.europe.2024-Q4", "section": "regions", "metric_id": "europe", "label": "Europe", "period": "2024-Q4", "value": 3962, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.europe.2025-FY", "section": "regions", "metric_id": "europe", "label": "Europe", "period": "2025-FY", "value": 16729, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.europe.2024-FY", "section": "regions", "metric_id": "europe", "label": "Europe", "period": "2024-FY", "value": 15557, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.asia_africa_australasia.2025-Q4", "section": "regions", "metric_id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "period": "2025-Q4", "value": 2646, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.asia_africa_australasia.2024-Q4", "section": "regions", "metric_id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "period": "2024-Q4", "value": 2313, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.asia_africa_australasia.2025-FY", "section": "regions", "metric_id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "period": "2025-FY", "value": 10797, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.asia_africa_australasia.2024-FY", "section": "regions", "metric_id": "asia_africa_australasia", "label": "Asia / Africa / Australasia", "period": "2024-FY", "value": 10021, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.canada_latin_america.2025-Q4", "section": "regions", "metric_id": "canada_latin_america", "label": "Canada and Latin America", "period": "2025-Q4", "value": 953, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.canada_latin_america.2024-Q4", "section": "regions", "metric_id": "canada_latin_america", "label": "Canada and Latin America", "period": "2024-Q4", "value": 876, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.canada_latin_america.2025-FY", "section": "regions", "metric_id": "canada_latin_america", "label": "Canada and Latin America", "period": "2025-FY", "value": 3675, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "regions.canada_latin_america.2024-FY", "section": "regions", "metric_id": "canada_latin_america", "label": "Canada and Latin America", "period": "2024-FY", "value": 3593, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.established.2025-Q4", "section": "market_groups", "metric_id": "established", "label": "Established markets", "period": "2025-Q4", "value": 9860, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.established.2024-Q4", "section": "market_groups", "metric_id": "established", "label": "Established markets", "period": "2024-Q4", "value": 10209, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.established.2025-FY", "section": "market_groups", "metric_id": "established", "label": "Established markets", "period": "2025-FY", "value": 40555, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.established.2024-FY", "section": "market_groups", "metric_id": "established", "label": "Established markets", "period": "2024-FY", "value": 37371, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.emerging.2025-Q4", "section": "market_groups", "metric_id": "emerging", "label": "Emerging growth markets", "period": "2025-Q4", "value": 3476, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.emerging.2024-Q4", "section": "market_groups", "metric_id": "emerging", "label": "Emerging growth markets", "period": "2024-Q4", "value": 2944, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.emerging.2025-FY", "section": "market_groups", "metric_id": "emerging", "label": "Emerging growth markets", "period": "2025-FY", "value": 13977, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "market_groups.emerging.2024-FY", "section": "market_groups", "metric_id": "emerging", "label": "Emerging growth markets", "period": "2024-FY", "value": 12946, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 36, "pdf_page_index": 35, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.cardiovascular.2025-Q4", "section": "therapeutic_areas", "metric_id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "period": "2025-Q4", "value": 1601, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.cardiovascular.2024-Q4", "section": "therapeutic_areas", "metric_id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "period": "2024-Q4", "value": 2403, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.cardiovascular.2025-FY", "section": "therapeutic_areas", "metric_id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "period": "2025-FY", "value": 8959, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.cardiovascular.2024-FY", "section": "therapeutic_areas", "metric_id": "cardiovascular", "label": "Cardiovascular, renal and metabolic", "period": "2024-FY", "value": 8576, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.immunology.2025-Q4", "section": "therapeutic_areas", "metric_id": "immunology", "label": "Immunology", "period": "2025-Q4", "value": 2724, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.immunology.2024-Q4", "section": "therapeutic_areas", "metric_id": "immunology", "label": "Immunology", "period": "2024-Q4", "value": 2408, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.immunology.2025-FY", "section": "therapeutic_areas", "metric_id": "immunology", "label": "Immunology", "period": "2025-FY", "value": 10293, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.immunology.2024-FY", "section": "therapeutic_areas", "metric_id": "immunology", "label": "Immunology", "period": "2024-FY", "value": 9293, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.neuroscience.2025-Q4", "section": "therapeutic_areas", "metric_id": "neuroscience", "label": "Neuroscience", "period": "2025-Q4", "value": 1625, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.neuroscience.2024-Q4", "section": "therapeutic_areas", "metric_id": "neuroscience", "label": "Neuroscience", "period": "2024-Q4", "value": 1292, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.neuroscience.2025-FY", "section": "therapeutic_areas", "metric_id": "neuroscience", "label": "Neuroscience", "period": "2025-FY", "value": 5993, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.neuroscience.2024-FY", "section": "therapeutic_areas", "metric_id": "neuroscience", "label": "Neuroscience", "period": "2024-FY", "value": 4750, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.oncology.2025-Q4", "section": "therapeutic_areas", "metric_id": "oncology", "label": "Oncology", "period": "2025-Q4", "value": 4256, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.oncology.2024-Q4", "section": "therapeutic_areas", "metric_id": "oncology", "label": "Oncology", "period": "2024-Q4", "value": 3824, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.oncology.2025-FY", "section": "therapeutic_areas", "metric_id": "oncology", "label": "Oncology", "period": "2025-FY", "value": 16830, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.oncology.2024-FY", "section": "therapeutic_areas", "metric_id": "oncology", "label": "Oncology", "period": "2024-FY", "value": 14297, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.established.2025-Q4", "section": "therapeutic_areas", "metric_id": "established", "label": "Established brands", "period": "2025-Q4", "value": 3130, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.established.2024-Q4", "section": "therapeutic_areas", "metric_id": "established", "label": "Established brands", "period": "2024-Q4", "value": 3226, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.established.2025-FY", "section": "therapeutic_areas", "metric_id": "established", "label": "Established brands", "period": "2025-FY", "value": 12457, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "therapeutic_areas.established.2024-FY", "section": "therapeutic_areas", "metric_id": "established", "label": "Established brands", "period": "2024-FY", "value": 13401, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "products.entresto.2025-Q4", "section": "products", "metric_id": "entresto", "label": "Entresto", "period": "2025-Q4", "value": 1253, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.entresto.2024-Q4", "section": "products", "metric_id": "entresto", "label": "Entresto", "period": "2024-Q4", "value": 2180, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.entresto.2025-FY", "section": "products", "metric_id": "entresto", "label": "Entresto", "period": "2025-FY", "value": 7748, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.entresto.2024-FY", "section": "products", "metric_id": "entresto", "label": "Entresto", "period": "2024-FY", "value": 7822, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.leqvio.2025-Q4", "section": "products", "metric_id": "leqvio", "label": "Leqvio", "period": "2025-Q4", "value": 335, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.leqvio.2024-Q4", "section": "products", "metric_id": "leqvio", "label": "Leqvio", "period": "2024-Q4", "value": 223, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.leqvio.2025-FY", "section": "products", "metric_id": "leqvio", "label": "Leqvio", "period": "2025-FY", "value": 1198, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.leqvio.2024-FY", "section": "products", "metric_id": "leqvio", "label": "Leqvio", "period": "2024-FY", "value": 754, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.vanrafia.2025-Q4", "section": "products", "metric_id": "vanrafia", "label": "Vanrafia", "period": "2025-Q4", "value": 13, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.vanrafia.2024-Q4", "section": "products", "metric_id": "vanrafia", "label": "Vanrafia", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.vanrafia.2025-FY", "section": "products", "metric_id": "vanrafia", "label": "Vanrafia", "period": "2025-FY", "value": 13, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.vanrafia.2024-FY", "section": "products", "metric_id": "vanrafia", "label": "Vanrafia", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "cardiovascular" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.cosentyx.2025-Q4", "section": "products", "metric_id": "cosentyx", "label": "Cosentyx", "period": "2025-Q4", "value": 1807, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.cosentyx.2024-Q4", "section": "products", "metric_id": "cosentyx", "label": "Cosentyx", "period": "2024-Q4", "value": 1596, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.cosentyx.2025-FY", "section": "products", "metric_id": "cosentyx", "label": "Cosentyx", "period": "2025-FY", "value": 6668, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.cosentyx.2024-FY", "section": "products", "metric_id": "cosentyx", "label": "Cosentyx", "period": "2024-FY", "value": 6141, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.ilaris.2025-Q4", "section": "products", "metric_id": "ilaris", "label": "Ilaris", "period": "2025-Q4", "value": 514, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.ilaris.2024-Q4", "section": "products", "metric_id": "ilaris", "label": "Ilaris", "period": "2024-Q4", "value": 413, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.ilaris.2025-FY", "section": "products", "metric_id": "ilaris", "label": "Ilaris", "period": "2025-FY", "value": 1883, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.ilaris.2024-FY", "section": "products", "metric_id": "ilaris", "label": "Ilaris", "period": "2024-FY", "value": 1509, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.xolair.2025-Q4", "section": "products", "metric_id": "xolair", "label": "Xolair", "period": "2025-Q4", "value": 384, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.xolair.2024-Q4", "section": "products", "metric_id": "xolair", "label": "Xolair", "period": "2024-Q4", "value": 399, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.xolair.2025-FY", "section": "products", "metric_id": "xolair", "label": "Xolair", "period": "2025-FY", "value": 1723, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.xolair.2024-FY", "section": "products", "metric_id": "xolair", "label": "Xolair", "period": "2024-FY", "value": 1643, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.rhapsido.2025-Q4", "section": "products", "metric_id": "rhapsido", "label": "Rhapsido", "period": "2025-Q4", "value": 19, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.rhapsido.2024-Q4", "section": "products", "metric_id": "rhapsido", "label": "Rhapsido", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.rhapsido.2025-FY", "section": "products", "metric_id": "rhapsido", "label": "Rhapsido", "period": "2025-FY", "value": 19, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.rhapsido.2024-FY", "section": "products", "metric_id": "rhapsido", "label": "Rhapsido", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "immunology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "Prior-year blank is retained as unavailable; no zero or growth rate inferred." }, { "id": "products.kesimpta.2025-Q4", "section": "products", "metric_id": "kesimpta", "label": "Kesimpta", "period": "2025-Q4", "value": 1228, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kesimpta.2024-Q4", "section": "products", "metric_id": "kesimpta", "label": "Kesimpta", "period": "2024-Q4", "value": 950, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kesimpta.2025-FY", "section": "products", "metric_id": "kesimpta", "label": "Kesimpta", "period": "2025-FY", "value": 4426, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kesimpta.2024-FY", "section": "products", "metric_id": "kesimpta", "label": "Kesimpta", "period": "2024-FY", "value": 3224, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.zolgensma.2025-Q4", "section": "products", "metric_id": "zolgensma", "label": "Zolgensma Group", "period": "2025-Q4", "value": 307, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.zolgensma.2024-Q4", "section": "products", "metric_id": "zolgensma", "label": "Zolgensma Group", "period": "2024-Q4", "value": 262, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.zolgensma.2025-FY", "section": "products", "metric_id": "zolgensma", "label": "Zolgensma Group", "period": "2025-FY", "value": 1232, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.zolgensma.2024-FY", "section": "products", "metric_id": "zolgensma", "label": "Zolgensma Group", "period": "2024-FY", "value": 1214, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.aimovig.2025-Q4", "section": "products", "metric_id": "aimovig", "label": "Aimovig", "period": "2025-Q4", "value": 90, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.aimovig.2024-Q4", "section": "products", "metric_id": "aimovig", "label": "Aimovig", "period": "2024-Q4", "value": 80, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.aimovig.2025-FY", "section": "products", "metric_id": "aimovig", "label": "Aimovig", "period": "2025-FY", "value": 335, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.aimovig.2024-FY", "section": "products", "metric_id": "aimovig", "label": "Aimovig", "period": "2024-FY", "value": 312, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "neuroscience" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kisqali.2025-Q4", "section": "products", "metric_id": "kisqali", "label": "Kisqali", "period": "2025-Q4", "value": 1321, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kisqali.2024-Q4", "section": "products", "metric_id": "kisqali", "label": "Kisqali", "period": "2024-Q4", "value": 902, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kisqali.2025-FY", "section": "products", "metric_id": "kisqali", "label": "Kisqali", "period": "2025-FY", "value": 4783, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kisqali.2024-FY", "section": "products", "metric_id": "kisqali", "label": "Kisqali", "period": "2024-FY", "value": 3033, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tafinlar_mekinist.2025-Q4", "section": "products", "metric_id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "period": "2025-Q4", "value": 540, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tafinlar_mekinist.2024-Q4", "section": "products", "metric_id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "period": "2024-Q4", "value": 527, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tafinlar_mekinist.2025-FY", "section": "products", "metric_id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "period": "2025-FY", "value": 2215, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tafinlar_mekinist.2024-FY", "section": "products", "metric_id": "tafinlar_mekinist", "label": "Tafinlar + Mekinist", "period": "2024-FY", "value": 2058, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.jakavi.2025-Q4", "section": "products", "metric_id": "jakavi", "label": "Jakavi", "period": "2025-Q4", "value": 555, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.jakavi.2024-Q4", "section": "products", "metric_id": "jakavi", "label": "Jakavi", "period": "2024-Q4", "value": 487, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.jakavi.2025-FY", "section": "products", "metric_id": "jakavi", "label": "Jakavi", "period": "2025-FY", "value": 2110, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.jakavi.2024-FY", "section": "products", "metric_id": "jakavi", "label": "Jakavi", "period": "2024-FY", "value": 1936, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.pluvicto.2025-Q4", "section": "products", "metric_id": "pluvicto", "label": "Pluvicto", "period": "2025-Q4", "value": 605, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.pluvicto.2024-Q4", "section": "products", "metric_id": "pluvicto", "label": "Pluvicto", "period": "2024-Q4", "value": 351, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.pluvicto.2025-FY", "section": "products", "metric_id": "pluvicto", "label": "Pluvicto", "period": "2025-FY", "value": 1994, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.pluvicto.2024-FY", "section": "products", "metric_id": "pluvicto", "label": "Pluvicto", "period": "2024-FY", "value": 1392, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.promacta.2025-Q4", "section": "products", "metric_id": "promacta", "label": "Promacta / Revolade", "period": "2025-Q4", "value": 226, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.promacta.2024-Q4", "section": "products", "metric_id": "promacta", "label": "Promacta / Revolade", "period": "2024-Q4", "value": 583, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.promacta.2025-FY", "section": "products", "metric_id": "promacta", "label": "Promacta / Revolade", "period": "2025-FY", "value": 1636, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.promacta.2024-FY", "section": "products", "metric_id": "promacta", "label": "Promacta / Revolade", "period": "2024-FY", "value": 2216, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.scemblix.2025-Q4", "section": "products", "metric_id": "scemblix", "label": "Scemblix", "period": "2025-Q4", "value": 391, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.scemblix.2024-Q4", "section": "products", "metric_id": "scemblix", "label": "Scemblix", "period": "2024-Q4", "value": 207, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.scemblix.2025-FY", "section": "products", "metric_id": "scemblix", "label": "Scemblix", "period": "2025-FY", "value": 1285, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.scemblix.2024-FY", "section": "products", "metric_id": "scemblix", "label": "Scemblix", "period": "2024-FY", "value": 689, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tasigna.2025-Q4", "section": "products", "metric_id": "tasigna", "label": "Tasigna", "period": "2025-Q4", "value": 179, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tasigna.2024-Q4", "section": "products", "metric_id": "tasigna", "label": "Tasigna", "period": "2024-Q4", "value": 411, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tasigna.2025-FY", "section": "products", "metric_id": "tasigna", "label": "Tasigna", "period": "2025-FY", "value": 1104, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.tasigna.2024-FY", "section": "products", "metric_id": "tasigna", "label": "Tasigna", "period": "2024-FY", "value": 1671, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lutathera.2025-Q4", "section": "products", "metric_id": "lutathera", "label": "Lutathera", "period": "2025-Q4", "value": 203, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lutathera.2024-Q4", "section": "products", "metric_id": "lutathera", "label": "Lutathera", "period": "2024-Q4", "value": 190, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lutathera.2025-FY", "section": "products", "metric_id": "lutathera", "label": "Lutathera", "period": "2025-FY", "value": 816, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lutathera.2024-FY", "section": "products", "metric_id": "lutathera", "label": "Lutathera", "period": "2024-FY", "value": 724, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.fabhalta.2025-Q4", "section": "products", "metric_id": "fabhalta", "label": "Fabhalta", "period": "2025-Q4", "value": 155, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.fabhalta.2024-Q4", "section": "products", "metric_id": "fabhalta", "label": "Fabhalta", "period": "2024-Q4", "value": 57, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.fabhalta.2025-FY", "section": "products", "metric_id": "fabhalta", "label": "Fabhalta", "period": "2025-FY", "value": 505, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.fabhalta.2024-FY", "section": "products", "metric_id": "fabhalta", "label": "Fabhalta", "period": "2024-FY", "value": 129, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.piqray_vijoice.2025-Q4", "section": "products", "metric_id": "piqray_vijoice", "label": "Piqray / Vijoice", "period": "2025-Q4", "value": 81, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.piqray_vijoice.2024-Q4", "section": "products", "metric_id": "piqray_vijoice", "label": "Piqray / Vijoice", "period": "2024-Q4", "value": 109, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.piqray_vijoice.2025-FY", "section": "products", "metric_id": "piqray_vijoice", "label": "Piqray / Vijoice", "period": "2025-FY", "value": 382, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.piqray_vijoice.2024-FY", "section": "products", "metric_id": "piqray_vijoice", "label": "Piqray / Vijoice", "period": "2024-FY", "value": 449, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "oncology" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.sandostatin.2025-Q4", "section": "products", "metric_id": "sandostatin", "label": "Sandostatin Group", "period": "2025-Q4", "value": 291, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.sandostatin.2024-Q4", "section": "products", "metric_id": "sandostatin", "label": "Sandostatin Group", "period": "2024-Q4", "value": 306, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.sandostatin.2025-FY", "section": "products", "metric_id": "sandostatin", "label": "Sandostatin Group", "period": "2025-FY", "value": 1213, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.sandostatin.2024-FY", "section": "products", "metric_id": "sandostatin", "label": "Sandostatin Group", "period": "2024-FY", "value": 1279, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.exforge.2025-Q4", "section": "products", "metric_id": "exforge", "label": "Exforge Group", "period": "2025-Q4", "value": 181, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.exforge.2024-Q4", "section": "products", "metric_id": "exforge", "label": "Exforge Group", "period": "2024-Q4", "value": 159, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.exforge.2025-FY", "section": "products", "metric_id": "exforge", "label": "Exforge Group", "period": "2025-FY", "value": 727, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.exforge.2024-FY", "section": "products", "metric_id": "exforge", "label": "Exforge Group", "period": "2024-FY", "value": 703, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lucentis.2025-Q4", "section": "products", "metric_id": "lucentis", "label": "Lucentis", "period": "2025-Q4", "value": 133, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lucentis.2024-Q4", "section": "products", "metric_id": "lucentis", "label": "Lucentis", "period": "2024-Q4", "value": 210, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lucentis.2025-FY", "section": "products", "metric_id": "lucentis", "label": "Lucentis", "period": "2025-FY", "value": 643, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.lucentis.2024-FY", "section": "products", "metric_id": "lucentis", "label": "Lucentis", "period": "2024-FY", "value": 1044, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.diovan.2025-Q4", "section": "products", "metric_id": "diovan", "label": "Diovan Group", "period": "2025-Q4", "value": 157, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.diovan.2024-Q4", "section": "products", "metric_id": "diovan", "label": "Diovan Group", "period": "2024-Q4", "value": 140, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.diovan.2025-FY", "section": "products", "metric_id": "diovan", "label": "Diovan Group", "period": "2025-FY", "value": 604, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.diovan.2024-FY", "section": "products", "metric_id": "diovan", "label": "Diovan Group", "period": "2024-FY", "value": 590, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.galvus.2025-Q4", "section": "products", "metric_id": "galvus", "label": "Galvus Group", "period": "2025-Q4", "value": 114, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.galvus.2024-Q4", "section": "products", "metric_id": "galvus", "label": "Galvus Group", "period": "2024-Q4", "value": 144, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.galvus.2025-FY", "section": "products", "metric_id": "galvus", "label": "Galvus Group", "period": "2025-FY", "value": 487, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.galvus.2024-FY", "section": "products", "metric_id": "galvus", "label": "Galvus Group", "period": "2024-FY", "value": 602, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kymriah.2025-Q4", "section": "products", "metric_id": "kymriah", "label": "Kymriah", "period": "2025-Q4", "value": 85, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kymriah.2024-Q4", "section": "products", "metric_id": "kymriah", "label": "Kymriah", "period": "2024-Q4", "value": 108, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kymriah.2025-FY", "section": "products", "metric_id": "kymriah", "label": "Kymriah", "period": "2025-FY", "value": 381, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.kymriah.2024-FY", "section": "products", "metric_id": "kymriah", "label": "Kymriah", "period": "2024-FY", "value": 443, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.contract_manufacturing.2025-Q4", "section": "products", "metric_id": "contract_manufacturing", "label": "Contract manufacturing", "period": "2025-Q4", "value": 404, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.contract_manufacturing.2024-Q4", "section": "products", "metric_id": "contract_manufacturing", "label": "Contract manufacturing", "period": "2024-Q4", "value": 323, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.contract_manufacturing.2025-FY", "section": "products", "metric_id": "contract_manufacturing", "label": "Contract manufacturing", "period": "2025-FY", "value": 1419, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.contract_manufacturing.2024-FY", "section": "products", "metric_id": "contract_manufacturing", "label": "Contract manufacturing", "period": "2024-FY", "value": 1152, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.other.2025-Q4", "section": "products", "metric_id": "other", "label": "Other portfolio", "period": "2025-Q4", "value": 1765, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.other.2024-Q4", "section": "products", "metric_id": "other", "label": "Other portfolio", "period": "2024-Q4", "value": 1836, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 37, "pdf_page_index": 36, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.other.2025-FY", "section": "products", "metric_id": "other", "label": "Other portfolio", "period": "2025-FY", "value": 6983, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "products.other.2024-FY", "section": "products", "metric_id": "other", "label": "Other portfolio", "period": "2024-FY", "value": 7588, "unit": "USD million", "basis": "IFRS reported", "dimensions": { "therapeutic_area": "established" }, "source_page": 38, "pdf_page_index": 37, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2024 classifications conform to the 2025 presentation." }, { "id": "product_geography.entresto_us.2025-Q4", "section": "product_geography", "metric_id": "entresto_us", "label": "Entresto / US", "period": "2025-Q4", "value": 95, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_us.2024-Q4", "section": "product_geography", "metric_id": "entresto_us", "label": "Entresto / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_us.2025-FY", "section": "product_geography", "metric_id": "entresto_us", "label": "Entresto / US", "period": "2025-FY", "value": 3285, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_us.2024-FY", "section": "product_geography", "metric_id": "entresto_us", "label": "Entresto / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_row.2025-Q4", "section": "product_geography", "metric_id": "entresto_row", "label": "Entresto / rest of world", "period": "2025-Q4", "value": 1158, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_row.2024-Q4", "section": "product_geography", "metric_id": "entresto_row", "label": "Entresto / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_row.2025-FY", "section": "product_geography", "metric_id": "entresto_row", "label": "Entresto / rest of world", "period": "2025-FY", "value": 4463, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.entresto_row.2024-FY", "section": "product_geography", "metric_id": "entresto_row", "label": "Entresto / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_us.2025-Q4", "section": "product_geography", "metric_id": "cosentyx_us", "label": "Cosentyx / US", "period": "2025-Q4", "value": 1098, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_us.2024-Q4", "section": "product_geography", "metric_id": "cosentyx_us", "label": "Cosentyx / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_us.2025-FY", "section": "product_geography", "metric_id": "cosentyx_us", "label": "Cosentyx / US", "period": "2025-FY", "value": 3839, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_us.2024-FY", "section": "product_geography", "metric_id": "cosentyx_us", "label": "Cosentyx / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_row.2025-Q4", "section": "product_geography", "metric_id": "cosentyx_row", "label": "Cosentyx / rest of world", "period": "2025-Q4", "value": 709, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_row.2024-Q4", "section": "product_geography", "metric_id": "cosentyx_row", "label": "Cosentyx / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_row.2025-FY", "section": "product_geography", "metric_id": "cosentyx_row", "label": "Cosentyx / rest of world", "period": "2025-FY", "value": 2829, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.cosentyx_row.2024-FY", "section": "product_geography", "metric_id": "cosentyx_row", "label": "Cosentyx / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_us.2025-Q4", "section": "product_geography", "metric_id": "kisqali_us", "label": "Kisqali / US", "period": "2025-Q4", "value": 795, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_us.2024-Q4", "section": "product_geography", "metric_id": "kisqali_us", "label": "Kisqali / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_us.2025-FY", "section": "product_geography", "metric_id": "kisqali_us", "label": "Kisqali / US", "period": "2025-FY", "value": 2975, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_us.2024-FY", "section": "product_geography", "metric_id": "kisqali_us", "label": "Kisqali / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_row.2025-Q4", "section": "product_geography", "metric_id": "kisqali_row", "label": "Kisqali / rest of world", "period": "2025-Q4", "value": 526, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_row.2024-Q4", "section": "product_geography", "metric_id": "kisqali_row", "label": "Kisqali / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_row.2025-FY", "section": "product_geography", "metric_id": "kisqali_row", "label": "Kisqali / rest of world", "period": "2025-FY", "value": 1808, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kisqali_row.2024-FY", "section": "product_geography", "metric_id": "kisqali_row", "label": "Kisqali / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_us.2025-Q4", "section": "product_geography", "metric_id": "kesimpta_us", "label": "Kesimpta / US", "period": "2025-Q4", "value": 815, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_us.2024-Q4", "section": "product_geography", "metric_id": "kesimpta_us", "label": "Kesimpta / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_us.2025-FY", "section": "product_geography", "metric_id": "kesimpta_us", "label": "Kesimpta / US", "period": "2025-FY", "value": 2943, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_us.2024-FY", "section": "product_geography", "metric_id": "kesimpta_us", "label": "Kesimpta / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_row.2025-Q4", "section": "product_geography", "metric_id": "kesimpta_row", "label": "Kesimpta / rest of world", "period": "2025-Q4", "value": 413, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_row.2024-Q4", "section": "product_geography", "metric_id": "kesimpta_row", "label": "Kesimpta / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_row.2025-FY", "section": "product_geography", "metric_id": "kesimpta_row", "label": "Kesimpta / rest of world", "period": "2025-FY", "value": 1483, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.kesimpta_row.2024-FY", "section": "product_geography", "metric_id": "kesimpta_row", "label": "Kesimpta / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_us.2025-Q4", "section": "product_geography", "metric_id": "tafinlar_mekinist_us", "label": "Tafinlar + Mekinist / US", "period": "2025-Q4", "value": 181, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_us.2024-Q4", "section": "product_geography", "metric_id": "tafinlar_mekinist_us", "label": "Tafinlar + Mekinist / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_us.2025-FY", "section": "product_geography", "metric_id": "tafinlar_mekinist_us", "label": "Tafinlar + Mekinist / US", "period": "2025-FY", "value": 867, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_us.2024-FY", "section": "product_geography", "metric_id": "tafinlar_mekinist_us", "label": "Tafinlar + Mekinist / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_row.2025-Q4", "section": "product_geography", "metric_id": "tafinlar_mekinist_row", "label": "Tafinlar + Mekinist / rest of world", "period": "2025-Q4", "value": 359, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_row.2024-Q4", "section": "product_geography", "metric_id": "tafinlar_mekinist_row", "label": "Tafinlar + Mekinist / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_row.2025-FY", "section": "product_geography", "metric_id": "tafinlar_mekinist_row", "label": "Tafinlar + Mekinist / rest of world", "period": "2025-FY", "value": 1348, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tafinlar_mekinist_row.2024-FY", "section": "product_geography", "metric_id": "tafinlar_mekinist_row", "label": "Tafinlar + Mekinist / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_us.2025-Q4", "section": "product_geography", "metric_id": "jakavi_us", "label": "Jakavi / US", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_us.2024-Q4", "section": "product_geography", "metric_id": "jakavi_us", "label": "Jakavi / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_us.2025-FY", "section": "product_geography", "metric_id": "jakavi_us", "label": "Jakavi / US", "period": "2025-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_us.2024-FY", "section": "product_geography", "metric_id": "jakavi_us", "label": "Jakavi / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_row.2025-Q4", "section": "product_geography", "metric_id": "jakavi_row", "label": "Jakavi / rest of world", "period": "2025-Q4", "value": 555, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_row.2024-Q4", "section": "product_geography", "metric_id": "jakavi_row", "label": "Jakavi / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_row.2025-FY", "section": "product_geography", "metric_id": "jakavi_row", "label": "Jakavi / rest of world", "period": "2025-FY", "value": 2110, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.jakavi_row.2024-FY", "section": "product_geography", "metric_id": "jakavi_row", "label": "Jakavi / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_us.2025-Q4", "section": "product_geography", "metric_id": "pluvicto_us", "label": "Pluvicto / US", "period": "2025-Q4", "value": 491, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_us.2024-Q4", "section": "product_geography", "metric_id": "pluvicto_us", "label": "Pluvicto / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_us.2025-FY", "section": "product_geography", "metric_id": "pluvicto_us", "label": "Pluvicto / US", "period": "2025-FY", "value": 1596, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_us.2024-FY", "section": "product_geography", "metric_id": "pluvicto_us", "label": "Pluvicto / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_row.2025-Q4", "section": "product_geography", "metric_id": "pluvicto_row", "label": "Pluvicto / rest of world", "period": "2025-Q4", "value": 114, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_row.2024-Q4", "section": "product_geography", "metric_id": "pluvicto_row", "label": "Pluvicto / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_row.2025-FY", "section": "product_geography", "metric_id": "pluvicto_row", "label": "Pluvicto / rest of world", "period": "2025-FY", "value": 398, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.pluvicto_row.2024-FY", "section": "product_geography", "metric_id": "pluvicto_row", "label": "Pluvicto / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_us.2025-Q4", "section": "product_geography", "metric_id": "ilaris_us", "label": "Ilaris / US", "period": "2025-Q4", "value": 294, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_us.2024-Q4", "section": "product_geography", "metric_id": "ilaris_us", "label": "Ilaris / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_us.2025-FY", "section": "product_geography", "metric_id": "ilaris_us", "label": "Ilaris / US", "period": "2025-FY", "value": 1041, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_us.2024-FY", "section": "product_geography", "metric_id": "ilaris_us", "label": "Ilaris / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_row.2025-Q4", "section": "product_geography", "metric_id": "ilaris_row", "label": "Ilaris / rest of world", "period": "2025-Q4", "value": 220, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_row.2024-Q4", "section": "product_geography", "metric_id": "ilaris_row", "label": "Ilaris / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_row.2025-FY", "section": "product_geography", "metric_id": "ilaris_row", "label": "Ilaris / rest of world", "period": "2025-FY", "value": 842, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.ilaris_row.2024-FY", "section": "product_geography", "metric_id": "ilaris_row", "label": "Ilaris / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_us.2025-Q4", "section": "product_geography", "metric_id": "xolair_us", "label": "Xolair / US", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_us.2024-Q4", "section": "product_geography", "metric_id": "xolair_us", "label": "Xolair / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_us.2025-FY", "section": "product_geography", "metric_id": "xolair_us", "label": "Xolair / US", "period": "2025-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_us.2024-FY", "section": "product_geography", "metric_id": "xolair_us", "label": "Xolair / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_row.2025-Q4", "section": "product_geography", "metric_id": "xolair_row", "label": "Xolair / rest of world", "period": "2025-Q4", "value": 384, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_row.2024-Q4", "section": "product_geography", "metric_id": "xolair_row", "label": "Xolair / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_row.2025-FY", "section": "product_geography", "metric_id": "xolair_row", "label": "Xolair / rest of world", "period": "2025-FY", "value": 1723, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.xolair_row.2024-FY", "section": "product_geography", "metric_id": "xolair_row", "label": "Xolair / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_us.2025-Q4", "section": "product_geography", "metric_id": "promacta_us", "label": "Promacta / US", "period": "2025-Q4", "value": 33, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_us.2024-Q4", "section": "product_geography", "metric_id": "promacta_us", "label": "Promacta / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_us.2025-FY", "section": "product_geography", "metric_id": "promacta_us", "label": "Promacta / US", "period": "2025-FY", "value": 636, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_us.2024-FY", "section": "product_geography", "metric_id": "promacta_us", "label": "Promacta / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_row.2025-Q4", "section": "product_geography", "metric_id": "promacta_row", "label": "Promacta / rest of world", "period": "2025-Q4", "value": 193, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_row.2024-Q4", "section": "product_geography", "metric_id": "promacta_row", "label": "Promacta / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_row.2025-FY", "section": "product_geography", "metric_id": "promacta_row", "label": "Promacta / rest of world", "period": "2025-FY", "value": 1000, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.promacta_row.2024-FY", "section": "product_geography", "metric_id": "promacta_row", "label": "Promacta / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_us.2025-Q4", "section": "product_geography", "metric_id": "scemblix_us", "label": "Scemblix / US", "period": "2025-Q4", "value": 246, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_us.2024-Q4", "section": "product_geography", "metric_id": "scemblix_us", "label": "Scemblix / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_us.2025-FY", "section": "product_geography", "metric_id": "scemblix_us", "label": "Scemblix / US", "period": "2025-FY", "value": 824, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_us.2024-FY", "section": "product_geography", "metric_id": "scemblix_us", "label": "Scemblix / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_row.2025-Q4", "section": "product_geography", "metric_id": "scemblix_row", "label": "Scemblix / rest of world", "period": "2025-Q4", "value": 145, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_row.2024-Q4", "section": "product_geography", "metric_id": "scemblix_row", "label": "Scemblix / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_row.2025-FY", "section": "product_geography", "metric_id": "scemblix_row", "label": "Scemblix / rest of world", "period": "2025-FY", "value": 461, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.scemblix_row.2024-FY", "section": "product_geography", "metric_id": "scemblix_row", "label": "Scemblix / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_us.2025-Q4", "section": "product_geography", "metric_id": "zolgensma_us", "label": "Zolgensma / US", "period": "2025-Q4", "value": 91, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_us.2024-Q4", "section": "product_geography", "metric_id": "zolgensma_us", "label": "Zolgensma / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_us.2025-FY", "section": "product_geography", "metric_id": "zolgensma_us", "label": "Zolgensma / US", "period": "2025-FY", "value": 413, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_us.2024-FY", "section": "product_geography", "metric_id": "zolgensma_us", "label": "Zolgensma / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_row.2025-Q4", "section": "product_geography", "metric_id": "zolgensma_row", "label": "Zolgensma / rest of world", "period": "2025-Q4", "value": 216, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_row.2024-Q4", "section": "product_geography", "metric_id": "zolgensma_row", "label": "Zolgensma / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_row.2025-FY", "section": "product_geography", "metric_id": "zolgensma_row", "label": "Zolgensma / rest of world", "period": "2025-FY", "value": 819, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.zolgensma_row.2024-FY", "section": "product_geography", "metric_id": "zolgensma_row", "label": "Zolgensma / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_us.2025-Q4", "section": "product_geography", "metric_id": "sandostatin_us", "label": "Sandostatin / US", "period": "2025-Q4", "value": 169, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_us.2024-Q4", "section": "product_geography", "metric_id": "sandostatin_us", "label": "Sandostatin / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_us.2025-FY", "section": "product_geography", "metric_id": "sandostatin_us", "label": "Sandostatin / US", "period": "2025-FY", "value": 729, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_us.2024-FY", "section": "product_geography", "metric_id": "sandostatin_us", "label": "Sandostatin / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_row.2025-Q4", "section": "product_geography", "metric_id": "sandostatin_row", "label": "Sandostatin / rest of world", "period": "2025-Q4", "value": 122, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_row.2024-Q4", "section": "product_geography", "metric_id": "sandostatin_row", "label": "Sandostatin / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_row.2025-FY", "section": "product_geography", "metric_id": "sandostatin_row", "label": "Sandostatin / rest of world", "period": "2025-FY", "value": 484, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.sandostatin_row.2024-FY", "section": "product_geography", "metric_id": "sandostatin_row", "label": "Sandostatin / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_us.2025-Q4", "section": "product_geography", "metric_id": "leqvio_us", "label": "Leqvio / US", "period": "2025-Q4", "value": 164, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_us.2024-Q4", "section": "product_geography", "metric_id": "leqvio_us", "label": "Leqvio / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_us.2025-FY", "section": "product_geography", "metric_id": "leqvio_us", "label": "Leqvio / US", "period": "2025-FY", "value": 575, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_us.2024-FY", "section": "product_geography", "metric_id": "leqvio_us", "label": "Leqvio / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_row.2025-Q4", "section": "product_geography", "metric_id": "leqvio_row", "label": "Leqvio / rest of world", "period": "2025-Q4", "value": 171, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_row.2024-Q4", "section": "product_geography", "metric_id": "leqvio_row", "label": "Leqvio / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_row.2025-FY", "section": "product_geography", "metric_id": "leqvio_row", "label": "Leqvio / rest of world", "period": "2025-FY", "value": 623, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.leqvio_row.2024-FY", "section": "product_geography", "metric_id": "leqvio_row", "label": "Leqvio / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_us.2025-Q4", "section": "product_geography", "metric_id": "tasigna_us", "label": "Tasigna / US", "period": "2025-Q4", "value": 48, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_us.2024-Q4", "section": "product_geography", "metric_id": "tasigna_us", "label": "Tasigna / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_us.2025-FY", "section": "product_geography", "metric_id": "tasigna_us", "label": "Tasigna / US", "period": "2025-FY", "value": 486, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_us.2024-FY", "section": "product_geography", "metric_id": "tasigna_us", "label": "Tasigna / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_row.2025-Q4", "section": "product_geography", "metric_id": "tasigna_row", "label": "Tasigna / rest of world", "period": "2025-Q4", "value": 131, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_row.2024-Q4", "section": "product_geography", "metric_id": "tasigna_row", "label": "Tasigna / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_row.2025-FY", "section": "product_geography", "metric_id": "tasigna_row", "label": "Tasigna / rest of world", "period": "2025-FY", "value": 618, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.tasigna_row.2024-FY", "section": "product_geography", "metric_id": "tasigna_row", "label": "Tasigna / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_us.2025-Q4", "section": "product_geography", "metric_id": "lutathera_us", "label": "Lutathera / US", "period": "2025-Q4", "value": 147, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_us.2024-Q4", "section": "product_geography", "metric_id": "lutathera_us", "label": "Lutathera / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_us.2025-FY", "section": "product_geography", "metric_id": "lutathera_us", "label": "Lutathera / US", "period": "2025-FY", "value": 588, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_us.2024-FY", "section": "product_geography", "metric_id": "lutathera_us", "label": "Lutathera / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_row.2025-Q4", "section": "product_geography", "metric_id": "lutathera_row", "label": "Lutathera / rest of world", "period": "2025-Q4", "value": 56, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_row.2024-Q4", "section": "product_geography", "metric_id": "lutathera_row", "label": "Lutathera / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_row.2025-FY", "section": "product_geography", "metric_id": "lutathera_row", "label": "Lutathera / rest of world", "period": "2025-FY", "value": 228, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lutathera_row.2024-FY", "section": "product_geography", "metric_id": "lutathera_row", "label": "Lutathera / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_us.2025-Q4", "section": "product_geography", "metric_id": "exforge_us", "label": "Exforge / US", "period": "2025-Q4", "value": 1, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_us.2024-Q4", "section": "product_geography", "metric_id": "exforge_us", "label": "Exforge / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_us.2025-FY", "section": "product_geography", "metric_id": "exforge_us", "label": "Exforge / US", "period": "2025-FY", "value": 5, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_us.2024-FY", "section": "product_geography", "metric_id": "exforge_us", "label": "Exforge / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_row.2025-Q4", "section": "product_geography", "metric_id": "exforge_row", "label": "Exforge / rest of world", "period": "2025-Q4", "value": 180, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_row.2024-Q4", "section": "product_geography", "metric_id": "exforge_row", "label": "Exforge / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_row.2025-FY", "section": "product_geography", "metric_id": "exforge_row", "label": "Exforge / rest of world", "period": "2025-FY", "value": 722, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.exforge_row.2024-FY", "section": "product_geography", "metric_id": "exforge_row", "label": "Exforge / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_us.2025-Q4", "section": "product_geography", "metric_id": "lucentis_us", "label": "Lucentis / US", "period": "2025-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_us.2024-Q4", "section": "product_geography", "metric_id": "lucentis_us", "label": "Lucentis / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_us.2025-FY", "section": "product_geography", "metric_id": "lucentis_us", "label": "Lucentis / US", "period": "2025-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_us.2024-FY", "section": "product_geography", "metric_id": "lucentis_us", "label": "Lucentis / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_row.2025-Q4", "section": "product_geography", "metric_id": "lucentis_row", "label": "Lucentis / rest of world", "period": "2025-Q4", "value": 133, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_row.2024-Q4", "section": "product_geography", "metric_id": "lucentis_row", "label": "Lucentis / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_row.2025-FY", "section": "product_geography", "metric_id": "lucentis_row", "label": "Lucentis / rest of world", "period": "2025-FY", "value": 643, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.lucentis_row.2024-FY", "section": "product_geography", "metric_id": "lucentis_row", "label": "Lucentis / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_us.2025-Q4", "section": "product_geography", "metric_id": "diovan_us", "label": "Diovan / US", "period": "2025-Q4", "value": 8, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_us.2024-Q4", "section": "product_geography", "metric_id": "diovan_us", "label": "Diovan / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_us.2025-FY", "section": "product_geography", "metric_id": "diovan_us", "label": "Diovan / US", "period": "2025-FY", "value": 35, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_us.2024-FY", "section": "product_geography", "metric_id": "diovan_us", "label": "Diovan / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_row.2025-Q4", "section": "product_geography", "metric_id": "diovan_row", "label": "Diovan / rest of world", "period": "2025-Q4", "value": 149, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_row.2024-Q4", "section": "product_geography", "metric_id": "diovan_row", "label": "Diovan / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_row.2025-FY", "section": "product_geography", "metric_id": "diovan_row", "label": "Diovan / rest of world", "period": "2025-FY", "value": 569, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.diovan_row.2024-FY", "section": "product_geography", "metric_id": "diovan_row", "label": "Diovan / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_us.2025-Q4", "section": "product_geography", "metric_id": "fabhalta_us", "label": "Fabhalta / US", "period": "2025-Q4", "value": 95, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_us.2024-Q4", "section": "product_geography", "metric_id": "fabhalta_us", "label": "Fabhalta / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_us.2025-FY", "section": "product_geography", "metric_id": "fabhalta_us", "label": "Fabhalta / US", "period": "2025-FY", "value": 317, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_us.2024-FY", "section": "product_geography", "metric_id": "fabhalta_us", "label": "Fabhalta / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_row.2025-Q4", "section": "product_geography", "metric_id": "fabhalta_row", "label": "Fabhalta / rest of world", "period": "2025-Q4", "value": 60, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_row.2024-Q4", "section": "product_geography", "metric_id": "fabhalta_row", "label": "Fabhalta / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_row.2025-FY", "section": "product_geography", "metric_id": "fabhalta_row", "label": "Fabhalta / rest of world", "period": "2025-FY", "value": 188, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.fabhalta_row.2024-FY", "section": "product_geography", "metric_id": "fabhalta_row", "label": "Fabhalta / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_us.2025-Q4", "section": "product_geography", "metric_id": "top20_us", "label": "Top 20 brands / US", "period": "2025-Q4", "value": 4771, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_us.2024-Q4", "section": "product_geography", "metric_id": "top20_us", "label": "Top 20 brands / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_us.2025-FY", "section": "product_geography", "metric_id": "top20_us", "label": "Top 20 brands / US", "period": "2025-FY", "value": 21154, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_us.2024-FY", "section": "product_geography", "metric_id": "top20_us", "label": "Top 20 brands / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_row.2025-Q4", "section": "product_geography", "metric_id": "top20_row", "label": "Top 20 brands / rest of world", "period": "2025-Q4", "value": 5994, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_row.2024-Q4", "section": "product_geography", "metric_id": "top20_row", "label": "Top 20 brands / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_row.2025-FY", "section": "product_geography", "metric_id": "top20_row", "label": "Top 20 brands / rest of world", "period": "2025-FY", "value": 23359, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_row.2024-FY", "section": "product_geography", "metric_id": "top20_row", "label": "Top 20 brands / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_total.2025-Q4", "section": "product_geography", "metric_id": "top20_total", "label": "Top 20 brands / total", "period": "2025-Q4", "value": 10765, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_total.2024-Q4", "section": "product_geography", "metric_id": "top20_total", "label": "Top 20 brands / total", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_total.2025-FY", "section": "product_geography", "metric_id": "top20_total", "label": "Top 20 brands / total", "period": "2025-FY", "value": 44513, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.top20_total.2024-FY", "section": "product_geography", "metric_id": "top20_total", "label": "Top 20 brands / total", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_us.2025-Q4", "section": "product_geography", "metric_id": "rest_portfolio_us", "label": "Rest of portfolio / US", "period": "2025-Q4", "value": 563, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_us.2024-Q4", "section": "product_geography", "metric_id": "rest_portfolio_us", "label": "Rest of portfolio / US", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_us.2025-FY", "section": "product_geography", "metric_id": "rest_portfolio_us", "label": "Rest of portfolio / US", "period": "2025-FY", "value": 2177, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_us.2024-FY", "section": "product_geography", "metric_id": "rest_portfolio_us", "label": "Rest of portfolio / US", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_row.2025-Q4", "section": "product_geography", "metric_id": "rest_portfolio_row", "label": "Rest of portfolio / rest of world", "period": "2025-Q4", "value": 2008, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_row.2024-Q4", "section": "product_geography", "metric_id": "rest_portfolio_row", "label": "Rest of portfolio / rest of world", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_row.2025-FY", "section": "product_geography", "metric_id": "rest_portfolio_row", "label": "Rest of portfolio / rest of world", "period": "2025-FY", "value": 7842, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_row.2024-FY", "section": "product_geography", "metric_id": "rest_portfolio_row", "label": "Rest of portfolio / rest of world", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_total.2025-Q4", "section": "product_geography", "metric_id": "rest_portfolio_total", "label": "Rest of portfolio / total", "period": "2025-Q4", "value": 2571, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_total.2024-Q4", "section": "product_geography", "metric_id": "rest_portfolio_total", "label": "Rest of portfolio / total", "period": "2024-Q4", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 39, "pdf_page_index": 38, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_total.2025-FY", "section": "product_geography", "metric_id": "rest_portfolio_total", "label": "Rest of portfolio / total", "period": "2025-FY", "value": 10019, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "product_geography.rest_portfolio_total.2024-FY", "section": "product_geography", "metric_id": "rest_portfolio_total", "label": "Rest of portfolio / total", "period": "2024-FY", "value": null, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 40, "pdf_page_index": 39, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "not_disclosed", "note": "2025 geographic amounts only; no exact prior-year geographic amount is disclosed in this table. Blank cells remain unavailable." }, { "id": "other_revenues.profit_sharing.2025-Q4", "section": "other_revenues", "metric_id": "profit_sharing", "label": "Profit sharing income", "period": "2025-Q4", "value": 373, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.profit_sharing.2024-Q4", "section": "other_revenues", "metric_id": "profit_sharing", "label": "Profit sharing income", "period": "2024-Q4", "value": 305, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.profit_sharing.2025-FY", "section": "other_revenues", "metric_id": "profit_sharing", "label": "Profit sharing income", "period": "2025-FY", "value": 1341, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.profit_sharing.2024-FY", "section": "other_revenues", "metric_id": "profit_sharing", "label": "Profit sharing income", "period": "2024-FY", "value": 1063, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.royalties.2025-Q4", "section": "other_revenues", "metric_id": "royalties", "label": "Royalty income", "period": "2025-Q4", "value": 27, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.royalties.2024-Q4", "section": "other_revenues", "metric_id": "royalties", "label": "Royalty income", "period": "2024-Q4", "value": 7, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.royalties.2025-FY", "section": "other_revenues", "metric_id": "royalties", "label": "Royalty income", "period": "2025-FY", "value": 379, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.royalties.2024-FY", "section": "other_revenues", "metric_id": "royalties", "label": "Royalty income", "period": "2024-FY", "value": 37, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.milestones.2025-Q4", "section": "other_revenues", "metric_id": "milestones", "label": "Milestone income", "period": "2025-Q4", "value": 21, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.milestones.2024-Q4", "section": "other_revenues", "metric_id": "milestones", "label": "Milestone income", "period": "2024-Q4", "value": 2, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.milestones.2025-FY", "section": "other_revenues", "metric_id": "milestones", "label": "Milestone income", "period": "2025-FY", "value": 117, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.milestones.2024-FY", "section": "other_revenues", "metric_id": "milestones", "label": "Milestone income", "period": "2024-FY", "value": 28, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.other.2025-Q4", "section": "other_revenues", "metric_id": "other", "label": "Other revenue", "period": "2025-Q4", "value": 103, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.other.2024-Q4", "section": "other_revenues", "metric_id": "other", "label": "Other revenue", "period": "2024-Q4", "value": 91, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.other.2025-FY", "section": "other_revenues", "metric_id": "other", "label": "Other revenue", "period": "2025-FY", "value": 305, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.other.2024-FY", "section": "other_revenues", "metric_id": "other", "label": "Other revenue", "period": "2024-FY", "value": 277, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.total.2025-Q4", "section": "other_revenues", "metric_id": "total", "label": "Total other revenues", "period": "2025-Q4", "value": 524, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.total.2024-Q4", "section": "other_revenues", "metric_id": "total", "label": "Total other revenues", "period": "2024-Q4", "value": 405, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.total.2025-FY", "section": "other_revenues", "metric_id": "total", "label": "Total other revenues", "period": "2025-FY", "value": 2142, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "other_revenues.total.2024-FY", "section": "other_revenues", "metric_id": "total", "label": "Total other revenues", "period": "2024-FY", "value": 1405, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 41, "pdf_page_index": 40, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_sales.2025-Q4", "section": "core", "metric_id": "net_sales", "label": "Net sales", "period": "2025-Q4", "value": 13336, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_sales.2024-Q4", "section": "core", "metric_id": "net_sales", "label": "Net sales", "period": "2024-Q4", "value": 13153, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 17, "pdf_page_index": 16, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_sales.2025-FY", "section": "core", "metric_id": "net_sales", "label": "Net sales", "period": "2025-FY", "value": 54532, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_sales.2024-FY", "section": "core", "metric_id": "net_sales", "label": "Net sales", "period": "2024-FY", "value": 50317, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 18, "pdf_page_index": 17, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_revenues.2025-Q4", "section": "core", "metric_id": "other_revenues", "label": "Other revenues", "period": "2025-Q4", "value": 524, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_revenues.2024-Q4", "section": "core", "metric_id": "other_revenues", "label": "Other revenues", "period": "2024-Q4", "value": 405, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_revenues.2025-FY", "section": "core", "metric_id": "other_revenues", "label": "Other revenues", "period": "2025-FY", "value": 1798, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_revenues.2024-FY", "section": "core", "metric_id": "other_revenues", "label": "Other revenues", "period": "2024-FY", "value": 1405, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.cost_of_goods_sold.2025-Q4", "section": "core", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2025-Q4", "value": -2853, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.cost_of_goods_sold.2024-Q4", "section": "core", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2024-Q4", "value": -2584, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.cost_of_goods_sold.2025-FY", "section": "core", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2025-FY", "value": -10815, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.cost_of_goods_sold.2024-FY", "section": "core", "metric_id": "cost_of_goods_sold", "label": "Cost of goods sold", "period": "2024-FY", "value": -9850, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.gross_profit.2025-Q4", "section": "core", "metric_id": "gross_profit", "label": "Gross profit", "period": "2025-Q4", "value": 11007, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.gross_profit.2024-Q4", "section": "core", "metric_id": "gross_profit", "label": "Gross profit", "period": "2024-Q4", "value": 10974, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.gross_profit.2025-FY", "section": "core", "metric_id": "gross_profit", "label": "Gross profit", "period": "2025-FY", "value": 45515, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.gross_profit.2024-FY", "section": "core", "metric_id": "gross_profit", "label": "Gross profit", "period": "2024-FY", "value": 41872, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.selling_general_administration.2025-Q4", "section": "core", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2025-Q4", "value": -3436, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.selling_general_administration.2024-Q4", "section": "core", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2024-Q4", "value": -3501, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.selling_general_administration.2025-FY", "section": "core", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2025-FY", "value": -13238, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.selling_general_administration.2024-FY", "section": "core", "metric_id": "selling_general_administration", "label": "Selling, general and administration", "period": "2024-FY", "value": -12564, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.research_and_development.2025-Q4", "section": "core", "metric_id": "research_and_development", "label": "Research and development", "period": "2025-Q4", "value": -2763, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.research_and_development.2024-Q4", "section": "core", "metric_id": "research_and_development", "label": "Research and development", "period": "2024-Q4", "value": -2502, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.research_and_development.2025-FY", "section": "core", "metric_id": "research_and_development", "label": "Research and development", "period": "2025-FY", "value": -10295, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.research_and_development.2024-FY", "section": "core", "metric_id": "research_and_development", "label": "Research and development", "period": "2024-FY", "value": -9302, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_income.2025-Q4", "section": "core", "metric_id": "other_income", "label": "Other income", "period": "2025-Q4", "value": 298, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_income.2024-Q4", "section": "core", "metric_id": "other_income", "label": "Other income", "period": "2024-Q4", "value": 26, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_income.2025-FY", "section": "core", "metric_id": "other_income", "label": "Other income", "period": "2025-FY", "value": 667, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_income.2024-FY", "section": "core", "metric_id": "other_income", "label": "Other income", "period": "2024-FY", "value": 273, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_expense.2025-Q4", "section": "core", "metric_id": "other_expense", "label": "Other expense", "period": "2025-Q4", "value": -177, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_expense.2024-Q4", "section": "core", "metric_id": "other_expense", "label": "Other expense", "period": "2024-Q4", "value": -138, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_expense.2025-FY", "section": "core", "metric_id": "other_expense", "label": "Other expense", "period": "2025-FY", "value": -760, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.other_expense.2024-FY", "section": "core", "metric_id": "other_expense", "label": "Other expense", "period": "2024-FY", "value": -785, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.operating_income.2025-Q4", "section": "core", "metric_id": "operating_income", "label": "Core operating income", "period": "2025-Q4", "value": 4929, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.operating_income.2024-Q4", "section": "core", "metric_id": "operating_income", "label": "Core operating income", "period": "2024-Q4", "value": 4859, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.operating_income.2025-FY", "section": "core", "metric_id": "operating_income", "label": "Core operating income", "period": "2025-FY", "value": 21889, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.operating_income.2024-FY", "section": "core", "metric_id": "operating_income", "label": "Core operating income", "period": "2024-FY", "value": 19494, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_before_taxes.2025-Q4", "section": "core", "metric_id": "income_before_taxes", "label": "Core income before taxes", "period": "2025-Q4", "value": 4641, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_before_taxes.2024-Q4", "section": "core", "metric_id": "income_before_taxes", "label": "Core income before taxes", "period": "2024-Q4", "value": 4664, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_before_taxes.2025-FY", "section": "core", "metric_id": "income_before_taxes", "label": "Core income before taxes", "period": "2025-FY", "value": 20777, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_before_taxes.2024-FY", "section": "core", "metric_id": "income_before_taxes", "label": "Core income before taxes", "period": "2024-FY", "value": 18771, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_taxes.2025-Q4", "section": "core", "metric_id": "income_taxes", "label": "Core income taxes", "period": "2025-Q4", "value": -752, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_taxes.2024-Q4", "section": "core", "metric_id": "income_taxes", "label": "Core income taxes", "period": "2024-Q4", "value": -731, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_taxes.2025-FY", "section": "core", "metric_id": "income_taxes", "label": "Core income taxes", "period": "2025-FY", "value": -3366, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.income_taxes.2024-FY", "section": "core", "metric_id": "income_taxes", "label": "Core income taxes", "period": "2024-FY", "value": -3016, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income.2025-Q4", "section": "core", "metric_id": "net_income", "label": "Core net income", "period": "2025-Q4", "value": 3889, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income.2024-Q4", "section": "core", "metric_id": "net_income", "label": "Core net income", "period": "2024-Q4", "value": 3933, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income.2025-FY", "section": "core", "metric_id": "net_income", "label": "Core net income", "period": "2025-FY", "value": 17411, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income.2024-FY", "section": "core", "metric_id": "net_income", "label": "Core net income", "period": "2024-FY", "value": 15755, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income_shareholders.2025-Q4", "section": "core", "metric_id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "period": "2025-Q4", "value": 3894, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income_shareholders.2024-Q4", "section": "core", "metric_id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "period": "2024-Q4", "value": 3932, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income_shareholders.2025-FY", "section": "core", "metric_id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "period": "2025-FY", "value": 17411, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.net_income_shareholders.2024-FY", "section": "core", "metric_id": "net_income_shareholders", "label": "Core net income attributable to Novartis AG shareholders", "period": "2024-FY", "value": 15757, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.non_controlling_interests.2025-Q4", "section": "core", "metric_id": "non_controlling_interests", "label": "Core non-controlling interests", "period": "2025-Q4", "value": -5, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.non_controlling_interests.2024-Q4", "section": "core", "metric_id": "non_controlling_interests", "label": "Core non-controlling interests", "period": "2024-Q4", "value": 1, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.non_controlling_interests.2025-FY", "section": "core", "metric_id": "non_controlling_interests", "label": "Core non-controlling interests", "period": "2025-FY", "value": 0, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.non_controlling_interests.2024-FY", "section": "core", "metric_id": "non_controlling_interests", "label": "Core non-controlling interests", "period": "2024-FY", "value": -2, "unit": "USD million", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.basic_eps.2025-Q4", "section": "core", "metric_id": "basic_eps", "label": "Core basic earnings per share", "period": "2025-Q4", "value": 2.03, "unit": "USD per share", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.basic_eps.2024-Q4", "section": "core", "metric_id": "basic_eps", "label": "Core basic earnings per share", "period": "2024-Q4", "value": 1.98, "unit": "USD per share", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 47, "pdf_page_index": 46, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.basic_eps.2025-FY", "section": "core", "metric_id": "basic_eps", "label": "Core basic earnings per share", "period": "2025-FY", "value": 8.98, "unit": "USD per share", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core.basic_eps.2024-FY", "section": "core", "metric_id": "basic_eps", "label": "Core basic earnings per share", "period": "2024-FY", "value": 7.81, "unit": "USD per share", "basis": "Core non-IFRS", "dimensions": {}, "source_page": 48, "pdf_page_index": 47, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.amortization.2025-Q4", "section": "core_adjustments", "metric_id": "amortization", "label": "Amortization of intangible assets", "period": "2025-Q4", "value": 763, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.amortization.2024-Q4", "section": "core_adjustments", "metric_id": "amortization", "label": "Amortization of intangible assets", "period": "2024-Q4", "value": 800, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.amortization.2025-FY", "section": "core_adjustments", "metric_id": "amortization", "label": "Amortization of intangible assets", "period": "2025-FY", "value": 3197, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.amortization.2024-FY", "section": "core_adjustments", "metric_id": "amortization", "label": "Amortization of intangible assets", "period": "2024-FY", "value": 3174, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.impairments.2025-Q4", "section": "core_adjustments", "metric_id": "impairments", "label": "Total impairment charges", "period": "2025-Q4", "value": 364, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.impairments.2024-Q4", "section": "core_adjustments", "metric_id": "impairments", "label": "Total impairment charges", "period": "2024-Q4", "value": 425, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.impairments.2025-FY", "section": "core_adjustments", "metric_id": "impairments", "label": "Total impairment charges", "period": "2025-FY", "value": 552, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.impairments.2024-FY", "section": "core_adjustments", "metric_id": "impairments", "label": "Total impairment charges", "period": "2024-FY", "value": 1428, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.acquisition_divestment.2025-Q4", "section": "core_adjustments", "metric_id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "period": "2025-Q4", "value": 50, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.acquisition_divestment.2024-Q4", "section": "core_adjustments", "metric_id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "period": "2024-Q4", "value": -15, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.acquisition_divestment.2025-FY", "section": "core_adjustments", "metric_id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "period": "2025-FY", "value": 71, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.acquisition_divestment.2024-FY", "section": "core_adjustments", "metric_id": "acquisition_divestment", "label": "Acquisition/divestment and related items, net", "period": "2024-FY", "value": 25, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.other_adjustments.2025-Q4", "section": "core_adjustments", "metric_id": "other_adjustments", "label": "Total other adjustment items", "period": "2025-Q4", "value": 136, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.other_adjustments.2024-Q4", "section": "core_adjustments", "metric_id": "other_adjustments", "label": "Total other adjustment items", "period": "2024-Q4", "value": 119, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.other_adjustments.2025-FY", "section": "core_adjustments", "metric_id": "other_adjustments", "label": "Total other adjustment items", "period": "2025-FY", "value": 425, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.other_adjustments.2024-FY", "section": "core_adjustments", "metric_id": "other_adjustments", "label": "Total other adjustment items", "period": "2024-FY", "value": 323, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.total_adjustments.2025-Q4", "section": "core_adjustments", "metric_id": "total_adjustments", "label": "Total adjustments", "period": "2025-Q4", "value": 1313, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.total_adjustments.2024-Q4", "section": "core_adjustments", "metric_id": "total_adjustments", "label": "Total adjustments", "period": "2024-Q4", "value": 1329, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.total_adjustments.2025-FY", "section": "core_adjustments", "metric_id": "total_adjustments", "label": "Total adjustments", "period": "2025-FY", "value": 4245, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "core_adjustments.total_adjustments.2024-FY", "section": "core_adjustments", "metric_id": "total_adjustments", "label": "Total adjustments", "period": "2024-FY", "value": 4950, "unit": "USD million", "basis": "Core adjustment (non-IFRS)", "dimensions": {}, "source_page": 46, "pdf_page_index": 45, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "free_cash_flow.free_cash_flow.2025-Q4", "section": "free_cash_flow", "metric_id": "free_cash_flow", "label": "Free cash flow", "period": "2025-Q4", "value": 1655, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "dimensions": {}, "source_page": 49, "pdf_page_index": 48, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=49", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "free_cash_flow.free_cash_flow.2024-Q4", "section": "free_cash_flow", "metric_id": "free_cash_flow", "label": "Free cash flow", "period": "2024-Q4", "value": 3635, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "dimensions": {}, "source_page": 49, "pdf_page_index": 48, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=49", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "free_cash_flow.free_cash_flow.2025-FY", "section": "free_cash_flow", "metric_id": "free_cash_flow", "label": "Free cash flow", "period": "2025-FY", "value": 17596, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "dimensions": {}, "source_page": 50, "pdf_page_index": 49, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=50", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "free_cash_flow.free_cash_flow.2024-FY", "section": "free_cash_flow", "metric_id": "free_cash_flow", "label": "Free cash flow", "period": "2024-FY", "value": 16253, "unit": "USD million", "basis": "Company-defined free cash flow (non-IFRS)", "dimensions": {}, "source_page": 50, "pdf_page_index": 49, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=50", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.noncurrent_debts.2025-12-31", "section": "net_debt", "metric_id": "noncurrent_debts", "label": "Non-current financial debts", "period": "2025-12-31", "value": -27935, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.noncurrent_debts.2024-12-31", "section": "net_debt", "metric_id": "noncurrent_debts", "label": "Non-current financial debts", "period": "2024-12-31", "value": -21366, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.current_debts.2025-12-31", "section": "net_debt", "metric_id": "current_debts", "label": "Current financial debts and derivatives", "period": "2025-12-31", "value": -5602, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.current_debts.2024-12-31", "section": "net_debt", "metric_id": "current_debts", "label": "Current financial debts and derivatives", "period": "2024-12-31", "value": -8232, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.financial_debts.2025-12-31", "section": "net_debt", "metric_id": "financial_debts", "label": "Total financial debts", "period": "2025-12-31", "value": -33537, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.financial_debts.2024-12-31", "section": "net_debt", "metric_id": "financial_debts", "label": "Total financial debts", "period": "2024-12-31", "value": -29598, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.cash.2025-12-31", "section": "net_debt", "metric_id": "cash", "label": "Cash and cash equivalents", "period": "2025-12-31", "value": 11435, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.cash.2024-12-31", "section": "net_debt", "metric_id": "cash", "label": "Cash and cash equivalents", "period": "2024-12-31", "value": 11459, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.marketable_securities.2025-12-31", "section": "net_debt", "metric_id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "period": "2025-12-31", "value": 155, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.marketable_securities.2024-12-31", "section": "net_debt", "metric_id": "marketable_securities", "label": "Marketable securities, time deposits and derivatives", "period": "2024-12-31", "value": 1998, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.liquidity.2025-12-31", "section": "net_debt", "metric_id": "liquidity", "label": "Total liquidity", "period": "2025-12-31", "value": 11590, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.liquidity.2024-12-31", "section": "net_debt", "metric_id": "liquidity", "label": "Total liquidity", "period": "2024-12-31", "value": 13457, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.signed_net_debt.2025-12-31", "section": "net_debt", "metric_id": "signed_net_debt", "label": "Signed net debt", "period": "2025-12-31", "value": -21947, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "net_debt.signed_net_debt.2024-12-31", "section": "net_debt", "metric_id": "signed_net_debt", "label": "Signed net debt", "period": "2024-12-31", "value": -16141, "unit": "USD million", "basis": "Company net-debt definition (additional information)", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_start.2025-Q4", "section": "equity", "metric_id": "equity_start", "label": "Total equity at start of period", "period": "2025-Q4", "value": 44752, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_start.2024-Q4", "section": "equity", "metric_id": "equity_start", "label": "Total equity at start of period", "period": "2024-Q4", "value": 43441, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_start.2025-FY", "section": "equity", "metric_id": "equity_start", "label": "Total equity at start of period", "period": "2025-FY", "value": 44126, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_start.2024-FY", "section": "equity", "metric_id": "equity_start", "label": "Total equity at start of period", "period": "2024-FY", "value": 46750, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.net_income.2025-Q4", "section": "equity", "metric_id": "net_income", "label": "Net income", "period": "2025-Q4", "value": 2404, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.net_income.2024-Q4", "section": "equity", "metric_id": "net_income", "label": "Net income", "period": "2024-Q4", "value": 2820, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.net_income.2025-FY", "section": "equity", "metric_id": "net_income", "label": "Net income", "period": "2025-FY", "value": 13967, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.net_income.2024-FY", "section": "equity", "metric_id": "net_income", "label": "Net income", "period": "2024-FY", "value": 11939, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_comprehensive_income.2025-Q4", "section": "equity", "metric_id": "other_comprehensive_income", "label": "Other comprehensive income", "period": "2025-Q4", "value": 595, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_comprehensive_income.2024-Q4", "section": "equity", "metric_id": "other_comprehensive_income", "label": "Other comprehensive income", "period": "2024-Q4", "value": 477, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_comprehensive_income.2025-FY", "section": "equity", "metric_id": "other_comprehensive_income", "label": "Other comprehensive income", "period": "2025-FY", "value": 3990, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_comprehensive_income.2024-FY", "section": "equity", "metric_id": "other_comprehensive_income", "label": "Other comprehensive income", "period": "2024-FY", "value": 589, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_movements.2025-Q4", "section": "equity", "metric_id": "other_movements", "label": "Total other equity movements", "period": "2025-Q4", "value": -1202, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_movements.2024-Q4", "section": "equity", "metric_id": "other_movements", "label": "Total other equity movements", "period": "2024-Q4", "value": -2612, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_movements.2025-FY", "section": "equity", "metric_id": "other_movements", "label": "Total other equity movements", "period": "2025-FY", "value": -15534, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.other_movements.2024-FY", "section": "equity", "metric_id": "other_movements", "label": "Total other equity movements", "period": "2024-FY", "value": -15152, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_end.2025-Q4", "section": "equity", "metric_id": "equity_end", "label": "Total equity at end of period", "period": "2025-Q4", "value": 46549, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_end.2024-Q4", "section": "equity", "metric_id": "equity_end", "label": "Total equity at end of period", "period": "2024-Q4", "value": 44126, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 21, "pdf_page_index": 20, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_end.2025-FY", "section": "equity", "metric_id": "equity_end", "label": "Total equity at end of period", "period": "2025-FY", "value": 46549, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "equity.equity_end.2024-FY", "section": "equity", "metric_id": "equity_end", "label": "Total equity at end of period", "period": "2024-FY", "value": 44126, "unit": "USD million", "basis": "IFRS reported", "dimensions": {}, "source_page": 22, "pdf_page_index": 21, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2025-Q4", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2025-Q4", "value": 1.251, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2024-Q4", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2024-Q4", "value": 1.14, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2025-FY", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2025-FY", "value": 1.205, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2024-FY", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2024-FY", "value": 1.136, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2025-12-31", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2025-12-31", "value": 1.261, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.chf.2024-12-31", "section": "currency_rates", "metric_id": "chf", "label": "CHF", "period": "2024-12-31", "value": 1.107, "unit": "USD per 1 CHF", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2025-Q4", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2025-Q4", "value": 0.141, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2024-Q4", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2024-Q4", "value": 0.139, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2025-FY", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2025-FY", "value": 0.139, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2024-FY", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2024-FY", "value": 0.139, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2025-12-31", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2025-12-31", "value": 0.143, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.cny.2024-12-31", "section": "currency_rates", "metric_id": "cny", "label": "CNY", "period": "2024-12-31", "value": 0.137, "unit": "USD per 1 CNY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2025-Q4", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2025-Q4", "value": 1.164, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2024-Q4", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2024-Q4", "value": 1.067, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2025-FY", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2025-FY", "value": 1.129, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2024-FY", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2024-FY", "value": 1.082, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2025-12-31", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2025-12-31", "value": 1.174, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.eur.2024-12-31", "section": "currency_rates", "metric_id": "eur", "label": "EUR", "period": "2024-12-31", "value": 1.041, "unit": "USD per 1 EUR", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2025-Q4", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2025-Q4", "value": 1.329, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2024-Q4", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2024-Q4", "value": 1.282, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2025-FY", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2025-FY", "value": 1.318, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2024-FY", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2024-FY", "value": 1.278, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2025-12-31", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2025-12-31", "value": 1.346, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.gbp.2024-12-31", "section": "currency_rates", "metric_id": "gbp", "label": "GBP", "period": "2024-12-31", "value": 1.256, "unit": "USD per 1 GBP", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2025-Q4", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2025-Q4", "value": 0.649, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2024-Q4", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2024-Q4", "value": 0.657, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2025-FY", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2025-FY", "value": 0.669, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2024-FY", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2024-FY", "value": 0.661, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2025-12-31", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2025-12-31", "value": 0.639, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.jpy100.2024-12-31", "section": "currency_rates", "metric_id": "jpy100", "label": "100 JPY", "period": "2024-12-31", "value": 0.64, "unit": "USD per 100 JPY", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2025-Q4", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2025-Q4", "value": 1.252, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2024-Q4", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2024-Q4", "value": 0.997, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2025-FY", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2025-FY", "value": 1.2, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2024-FY", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2024-FY", "value": 1.08, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2025-12-31", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2025-12-31", "value": 1.255, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "currency_rates.rub100.2024-12-31", "section": "currency_rates", "metric_id": "rub100", "label": "100 RUB", "period": "2024-12-31", "value": 0.889, "unit": "USD per 100 RUB", "basis": "Reported currency translation rate", "dimensions": {}, "source_page": 52, "pdf_page_index": 51, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.shares_outstanding.2025-12-31", "section": "share_information", "metric_id": "shares_outstanding", "label": "Number of shares outstanding", "period": "2025-12-31", "value": 1908151679, "unit": "shares", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.shares_outstanding.2024-12-31", "section": "share_information", "metric_id": "shares_outstanding", "label": "Number of shares outstanding", "period": "2024-12-31", "value": 1975089248, "unit": "shares", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.registered_share_price.2025-12-31", "section": "share_information", "metric_id": "registered_share_price", "label": "Registered share price", "period": "2025-12-31", "value": 109.6, "unit": "CHF per share", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.registered_share_price.2024-12-31", "section": "share_information", "metric_id": "registered_share_price", "label": "Registered share price", "period": "2024-12-31", "value": 88.7, "unit": "CHF per share", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.adr_price.2025-12-31", "section": "share_information", "metric_id": "adr_price", "label": "ADR price", "period": "2025-12-31", "value": 137.87, "unit": "USD per ADR", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.adr_price.2024-12-31", "section": "share_information", "metric_id": "adr_price", "label": "ADR price", "period": "2024-12-31", "value": 97.31, "unit": "USD per ADR", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.market_cap_usd.2025-12-31", "section": "share_information", "metric_id": "market_cap_usd", "label": "Market capitalization, USD", "period": "2025-12-31", "value": 263.7, "unit": "USD billion", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.market_cap_usd.2024-12-31", "section": "share_information", "metric_id": "market_cap_usd", "label": "Market capitalization, USD", "period": "2024-12-31", "value": 193.9, "unit": "USD billion", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.market_cap_chf.2025-12-31", "section": "share_information", "metric_id": "market_cap_chf", "label": "Market capitalization, CHF", "period": "2025-12-31", "value": 209.1, "unit": "CHF billion", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null }, { "id": "share_information.market_cap_chf.2024-12-31", "section": "share_information", "metric_id": "market_cap_chf", "label": "Market capitalization, CHF", "period": "2024-12-31", "value": 175.2, "unit": "CHF billion", "basis": "Reported year-end market information", "dimensions": {}, "source_page": 51, "pdf_page_index": 50, "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51", "capture_method": "Reviewed transcription assisted by local PDF text extraction; no general PDF ingestion claim.", "availability": "reported", "note": null } ], "sources": [ { "id": "p1", "title": "Cover", "page": 1, "pdf_page_index": 0, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=1" }, { "id": "p2", "title": "Index", "page": 2, "pdf_page_index": 1, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=2" }, { "id": "p3", "title": "Key figures", "page": 3, "pdf_page_index": 2, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=3" }, { "id": "p4", "title": "Strategy and Q 4 sales drivers", "page": 4, "pdf_page_index": 3, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=4" }, { "id": "p5", "title": "Q 4 income, tax and cash-flow narrative", "page": 5, "pdf_page_index": 4, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=5" }, { "id": "p6", "title": "Full-year financial review", "page": 6, "pdf_page_index": 5, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=6" }, { "id": "p7", "title": "Annual tax/cash and cardiovascular products", "page": 7, "pdf_page_index": 6, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=7" }, { "id": "p8", "title": "Immunology and neuroscience products", "page": 8, "pdf_page_index": 7, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=8" }, { "id": "p9", "title": "Oncology products", "page": 9, "pdf_page_index": 8, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=9" }, { "id": "p10", "title": "Established brands", "page": 10, "pdf_page_index": 9, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=10" }, { "id": "p11", "title": "Cash flow Q 4 and FY", "page": 11, "pdf_page_index": 10, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=11" }, { "id": "p12", "title": "Annual financing and free cash flow", "page": 12, "pdf_page_index": 11, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=12" }, { "id": "p13", "title": "Balance-sheet movement", "page": 13, "pdf_page_index": 12, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=13" }, { "id": "p14", "title": "Equity and net debt narrative", "page": 14, "pdf_page_index": 13, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=14" }, { "id": "p15", "title": "Innovation approvals and pipeline", "page": 15, "pdf_page_index": 14, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=15" }, { "id": "p16", "title": "Innovation pipeline continued", "page": 16, "pdf_page_index": 15, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=16" }, { "id": "p17", "title": "Q 4 consolidated income statement", "page": 17, "pdf_page_index": 16, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17" }, { "id": "p18", "title": "FY consolidated income statement", "page": 18, "pdf_page_index": 17, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18" }, { "id": "p19", "title": "Comprehensive income", "page": 19, "pdf_page_index": 18, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=19" }, { "id": "p20", "title": "Consolidated balance sheet", "page": 20, "pdf_page_index": 19, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20" }, { "id": "p21", "title": "Q 4 changes in equity", "page": 21, "pdf_page_index": 20, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21" }, { "id": "p22", "title": "FY changes in equity", "page": 22, "pdf_page_index": 21, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22" }, { "id": "p23", "title": "Q 4 cash-flow statement", "page": 23, "pdf_page_index": 22, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23" }, { "id": "p24", "title": "FY cash-flow statement", "page": 24, "pdf_page_index": 23, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24" }, { "id": "p25", "title": "Basis of preparation and policies", "page": 25, "pdf_page_index": 24, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=25" }, { "id": "p26", "title": "Policies and business combinations", "page": 26, "pdf_page_index": 25, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=26" }, { "id": "p27", "title": "MorphoSys acquisition/impairment", "page": 27, "pdf_page_index": 26, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=27" }, { "id": "p28", "title": "Business combination assets and 2025 acquisitions", "page": 28, "pdf_page_index": 27, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=28" }, { "id": "p29", "title": "Regulus/Anthos and asset acquisitions", "page": 29, "pdf_page_index": 28, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=29" }, { "id": "p30", "title": "Shareholder equity summary", "page": 30, "pdf_page_index": 29, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=30" }, { "id": "p31", "title": "Financial instruments fair-value hierarchy", "page": 31, "pdf_page_index": 30, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=31" }, { "id": "p32", "title": "Cash-flow detail and working capital", "page": 32, "pdf_page_index": 31, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32" }, { "id": "p33", "title": "Acquisition cash-flow detail", "page": 33, "pdf_page_index": 32, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=33" }, { "id": "p34", "title": "Legal proceedings", "page": 34, "pdf_page_index": 33, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=34" }, { "id": "p35", "title": "Legal proceedings and operating segment", "page": 35, "pdf_page_index": 34, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=35" }, { "id": "p36", "title": "Geographic sales", "page": 36, "pdf_page_index": 35, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36" }, { "id": "p37", "title": "Q 4 therapeutic and brand sales", "page": 37, "pdf_page_index": 36, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37" }, { "id": "p38", "title": "FY therapeutic and brand sales", "page": 38, "pdf_page_index": 37, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38" }, { "id": "p39", "title": "Q 4 top 20 brands geographic split", "page": 39, "pdf_page_index": 38, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39" }, { "id": "p40", "title": "FY top 20 brands geographic split", "page": 40, "pdf_page_index": 39, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40" }, { "id": "p41", "title": "Other revenues and interim disclosures", "page": 41, "pdf_page_index": 40, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41" }, { "id": "p42", "title": "Taxes, commitments and pending transactions", "page": 42, "pdf_page_index": 41, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=42" }, { "id": "p43", "title": "Subsequent events", "page": 43, "pdf_page_index": 42, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=43" }, { "id": "p44", "title": "Non-IFRS definitions", "page": 44, "pdf_page_index": 43, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=44" }, { "id": "p45", "title": "Non-IFRS definitions continued", "page": 45, "pdf_page_index": 44, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=45" }, { "id": "p46", "title": "IFRS-to-core reconciliation overview", "page": 46, "pdf_page_index": 45, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46" }, { "id": "p47", "title": "Q 4 core income reconciliation", "page": 47, "pdf_page_index": 46, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47" }, { "id": "p48", "title": "FY core income reconciliation", "page": 48, "pdf_page_index": 47, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48" }, { "id": "p49", "title": "Free-cash-flow reconciliation", "page": 49, "pdf_page_index": 48, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=49" }, { "id": "p50", "title": "FY free-cash-flow summary", "page": 50, "pdf_page_index": 49, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=50" }, { "id": "p51", "title": "Net debt and share information", "page": 51, "pdf_page_index": 50, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51" }, { "id": "p52", "title": "Currency translation and impact", "page": 52, "pdf_page_index": 51, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52" }, { "id": "p53", "title": "Disclaimer and SEC transaction information", "page": 53, "pdf_page_index": 52, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=53" }, { "id": "p54", "title": "Solicitation, company and event dates", "page": 54, "pdf_page_index": 53, "url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=54" } ], "coverage": { "total_pages": 54, "reviewed_pages": 54, "extracted_pages": 21, "source_tables": 17, "reported_values": 753, "unavailable_cells": 115, "pages": [ { "page": 1, "pdf_page_index": 0, "title": "Cover", "classification": "Document identity", "coverage": "context_reviewed", "notes": "No numeric extraction; report identity reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=1" }, { "page": 2, "pdf_page_index": 1, "title": "Index", "classification": "Navigation", "coverage": "context_reviewed", "notes": "All 54 pages inventoried; financial statements and notes located.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=2" }, { "page": 3, "pdf_page_index": 2, "title": "Key figures", "classification": "Financial overview", "coverage": "context_reviewed", "notes": "Summary duplicates canonical statement/core/FCF tables; canonical pages used.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=3" }, { "page": 4, "pdf_page_index": 3, "title": "Strategy and Q 4 sales drivers", "classification": "Company narrative", "coverage": "context_reviewed", "notes": "Reported volume, price, competition and geographic explanations; not independent causal findings.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=4" }, { "page": 5, "pdf_page_index": 4, "title": "Q 4 income, tax and cash-flow narrative", "classification": "Company narrative", "coverage": "context_reviewed", "notes": "Supports original E 1 attribution; IFRS/core and effective-tax context reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=5" }, { "page": 6, "pdf_page_index": 5, "title": "Full-year financial review", "classification": "Company narrative", "coverage": "context_reviewed", "notes": "Annual reported sales, expenses and operating performance context.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=6" }, { "page": 7, "pdf_page_index": 6, "title": "Annual tax/cash and cardiovascular products", "classification": "Product commentary", "coverage": "context_reviewed", "notes": "Narrative and duplicate sales table; canonical products taken from p 37/38.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=7" }, { "page": 8, "pdf_page_index": 7, "title": "Immunology and neuroscience products", "classification": "Product commentary", "coverage": "context_reviewed", "notes": "Commercial scope restrictions for Xolair/Aimovig; duplicate tables not recounted.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=8" }, { "page": 9, "pdf_page_index": 8, "title": "Oncology products", "classification": "Product commentary", "coverage": "context_reviewed", "notes": "Reported launch/competition context; duplicate product amounts not recounted.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=9" }, { "page": 10, "pdf_page_index": 9, "title": "Established brands", "classification": "Product commentary", "coverage": "context_reviewed", "notes": "Duplicate brand table and narrative; canonical rows taken from p 37/38.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=10" }, { "page": 11, "pdf_page_index": 10, "title": "Cash flow Q 4 and FY", "classification": "Cash-flow narrative", "coverage": "context_reviewed", "notes": "Acquisitions and capital/financing explanations; exact amounts use p 23/24.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=11" }, { "page": 12, "pdf_page_index": 11, "title": "Annual financing and free cash flow", "classification": "Cash-flow narrative", "coverage": "context_reviewed", "notes": "Annual dividends/share transactions and company-defined FCF context.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=12" }, { "page": 13, "pdf_page_index": 12, "title": "Balance-sheet movement", "classification": "Balance-sheet narrative", "coverage": "context_reviewed", "notes": "Asset/liability movement descriptions; exact dated balances use p 20.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=13" }, { "page": 14, "pdf_page_index": 13, "title": "Equity and net debt narrative", "classification": "Balance-sheet narrative", "coverage": "context_reviewed", "notes": "Equity and liquidity definitions reviewed; exact components use p 20/51.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=14" }, { "page": 15, "pdf_page_index": 14, "title": "Innovation approvals and pipeline", "classification": "Non-financial context", "coverage": "context_reviewed", "notes": "Read in full; no pipeline values converted into forecasts/revenue.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=15" }, { "page": 16, "pdf_page_index": 15, "title": "Innovation pipeline continued", "classification": "Non-financial context", "coverage": "context_reviewed", "notes": "Read in full; no financial forecast or probability inferred.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=16" }, { "page": 17, "pdf_page_index": 16, "title": "Q 4 consolidated income statement", "classification": "Income statement", "coverage": "extracted", "notes": "Extracted all selected monetary lines, attributable income, EPS and weighted shares.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=17" }, { "page": 18, "pdf_page_index": 17, "title": "FY consolidated income statement", "classification": "Income statement", "coverage": "extracted", "notes": "Comparable annual figures; audited annual versus unaudited quarter explicit.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=18" }, { "page": 19, "pdf_page_index": 18, "title": "Comprehensive income", "classification": "Financial statement", "coverage": "context_reviewed", "notes": "Reviewed detailed OCI; selected total OCI/total equity movements sourced from p 21/22 instead.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=19" }, { "page": 20, "pdf_page_index": 19, "title": "Consolidated balance sheet", "classification": "Balance sheet", "coverage": "extracted", "notes": "Extracted full dated main balance-sheet rows; not a quarterly flow.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=20" }, { "page": 21, "pdf_page_index": 20, "title": "Q 4 changes in equity", "classification": "Equity statement", "coverage": "extracted", "notes": "Extracted total-equity start, net income, OCI, other movements and end; component columns not all normalized.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=21" }, { "page": 22, "pdf_page_index": 21, "title": "FY changes in equity", "classification": "Equity statement", "coverage": "extracted", "notes": "Extracted total-equity rollforward; shareholder-only column kept separate from total equity.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=22" }, { "page": 23, "pdf_page_index": 22, "title": "Q 4 cash-flow statement", "classification": "Cash flow", "coverage": "extracted", "notes": "Extracted main IFRS cash-flow rows including investing/financing and exchange-rate effects.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=23" }, { "page": 24, "pdf_page_index": 23, "title": "FY cash-flow statement", "classification": "Cash flow", "coverage": "extracted", "notes": "Extracted comparable annual cash flows; dividends and acquisitions preserve reported classification.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=24" }, { "page": 25, "pdf_page_index": 24, "title": "Basis of preparation and policies", "classification": "Accounting context", "coverage": "context_reviewed", "notes": "IFRS/IAS 34 basis, estimation limits and IFRS 18 adoption context reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=25" }, { "page": 26, "pdf_page_index": 25, "title": "Policies and business combinations", "classification": "Accounting context", "coverage": "context_reviewed", "notes": "Future presentation changes;2024 business combinations distinct from 2025 asset acquisitions.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=26" }, { "page": 27, "pdf_page_index": 26, "title": "MorphoSys acquisition/impairment", "classification": "Acquisition note", "coverage": "context_reviewed", "notes": "Read in full; no unsourced acquisition-causality claims.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=27" }, { "page": 28, "pdf_page_index": 27, "title": "Business combination assets and 2025 acquisitions", "classification": "Acquisition note", "coverage": "context_reviewed", "notes": "Tables reviewed; not all purchase-price allocations normalized.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=28" }, { "page": 29, "pdf_page_index": 28, "title": "Regulus/Anthos and asset acquisitions", "classification": "Acquisition note", "coverage": "context_reviewed", "notes": "Optional concentration test assets differ from business combinations; allocation table reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=29" }, { "page": 30, "pdf_page_index": 29, "title": "Shareholder equity summary", "classification": "Equity note", "coverage": "context_reviewed", "notes": "Reviewed outstanding-share and shareholder-only equity movements; not mixed with total equity.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=30" }, { "page": 31, "pdf_page_index": 30, "title": "Financial instruments fair-value hierarchy", "classification": "Financial-risk note", "coverage": "context_reviewed", "notes": "Hierarchy and hedges reviewed; not all Level 1/2/3 cells normalized.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=31" }, { "page": 32, "pdf_page_index": 31, "title": "Cash-flow detail and working capital", "classification": "Cash-flow note", "coverage": "extracted", "notes": "Extracted five working-capital components plus total; non-cash detailed components reviewed only.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=32" }, { "page": 33, "pdf_page_index": 32, "title": "Acquisition cash-flow detail", "classification": "Acquisition note", "coverage": "context_reviewed", "notes": "Business versus asset-acquisition cash classification reviewed; statement rows provide dataset amounts.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=33" }, { "page": 34, "pdf_page_index": 33, "title": "Legal proceedings", "classification": "Legal context", "coverage": "context_reviewed", "notes": "Read in full; contingencies are not added to reported expenses/liabilities.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=34" }, { "page": 35, "pdf_page_index": 34, "title": "Legal proceedings and operating segment", "classification": "Segment context", "coverage": "context_reviewed", "notes": "Company reports one global operating segment; therapeutic areas are sales classifications, not IFRS segments.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=35" }, { "page": 36, "pdf_page_index": 35, "title": "Geographic sales", "classification": "Geography", "coverage": "extracted", "notes": "Extracted four geographic regions and separate established/emerging market partition; customer location basis.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=36" }, { "page": 37, "pdf_page_index": 36, "title": "Q 4 therapeutic and brand sales", "classification": "Product sales", "coverage": "extracted", "notes": "Extracted five non-overlapping groups and 28 leafrows; subtotals not double-counted.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=37" }, { "page": 38, "pdf_page_index": 37, "title": "FY therapeutic and brand sales", "classification": "Product sales", "coverage": "extracted", "notes": "Extracted comparable annual figures;2024 group presentation conformed to 2025 per note.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=38" }, { "page": 39, "pdf_page_index": 38, "title": "Q 4 top 20 brands geographic split", "classification": "Product geography", "coverage": "extracted", "notes": "Extracted 2025 US/rest-of-world amounts and top 20/restportfolio totals; prior amounts unavailable.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=39" }, { "page": 40, "pdf_page_index": 39, "title": "FY top 20 brands geographic split", "classification": "Product geography", "coverage": "extracted", "notes": "Same 2025 top 20 cohort; annual current geographic amounts only, not inferred historical splits.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=40" }, { "page": 41, "pdf_page_index": 40, "title": "Other revenues and interim disclosures", "classification": "Revenue/accounting note", "coverage": "extracted", "notes": "Extracted other-revenue components; impairment/addition/bond notes reviewed but not every cell normalized.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=41" }, { "page": 42, "pdf_page_index": 41, "title": "Taxes, commitments and pending transactions", "classification": "Commitments context", "coverage": "context_reviewed", "notes": "Undiscounted conditional milestones/pending Avidity transaction reviewed; not booked as actual acquisition cash.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=42" }, { "page": 43, "pdf_page_index": 42, "title": "Subsequent events", "classification": "Subsequent-event context", "coverage": "context_reviewed", "notes": "Proposed dividend and post-period agreement are not 2025 cashpayments.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=43" }, { "page": 44, "pdf_page_index": 43, "title": "Non-IFRS definitions", "classification": "Definitions", "coverage": "context_reviewed", "notes": "Read core and constant-currency definitions/limitations; bases remain separate.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=44" }, { "page": 45, "pdf_page_index": 44, "title": "Non-IFRS definitions continued", "classification": "Definitions", "coverage": "context_reviewed", "notes": "FCF=CFO less PP&E purchases; expense-growth sign convention and net-debt definition reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=45" }, { "page": 46, "pdf_page_index": 45, "title": "IFRS-to-core reconciliation overview", "classification": "Core reconciliation", "coverage": "extracted", "notes": "Extracted four non-overlapping operating-income adjustment groups and total; no child/subtotal double count.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=46" }, { "page": 47, "pdf_page_index": 46, "title": "Q 4 core income reconciliation", "classification": "Core reconciliation", "coverage": "extracted", "notes": "Extracted core income rows; detailed tax/adjustment footnotes reviewed.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=47" }, { "page": 48, "pdf_page_index": 47, "title": "FY core income reconciliation", "classification": "Core reconciliation", "coverage": "extracted", "notes": "Extracted annual core income rows; core revenue adjustment retained.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=48" }, { "page": 49, "pdf_page_index": 48, "title": "Free-cash-flow reconciliation", "classification": "Free cash flow", "coverage": "extracted", "notes": "Extracted quarterly FCF and reviewed all three IFRS cash-category reconciliation blocks.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=49" }, { "page": 50, "pdf_page_index": 49, "title": "FY free-cash-flow summary", "classification": "Free cash flow", "coverage": "extracted", "notes": "Extracted annual FCF; confirms CFO less PP&E purchases; intangibles not deducted in company definition.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=50" }, { "page": 51, "pdf_page_index": 50, "title": "Net debt and share information", "classification": "Net debt/market information", "coverage": "extracted", "notes": "Extracted dated net-debt components and share information; signed debt, shares and billions units explicit.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=51" }, { "page": 52, "pdf_page_index": 51, "title": "Currency translation and impact", "classification": "Currency context", "coverage": "extracted", "notes": "Extracted principal rates with per 100 JPY/RUB distinction; reported cc impacts reviewed, not recomputed from spotrates.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=52" }, { "page": 53, "pdf_page_index": 52, "title": "Disclaimer and SEC transaction information", "classification": "Legal context", "coverage": "context_reviewed", "notes": "Forward-looking statement boundaries reviewed; narrative not treated as forecast ground truth.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=53" }, { "page": 54, "pdf_page_index": 53, "title": "Solicitation, company and event dates", "classification": "Legal/company context", "coverage": "context_reviewed", "notes": "Read final page; document-date event announcements not current verified schedule.", "source_url": "https://www.novartis.com/sites/novartiscom/files/q4-2025-interim-financial-report-en.pdf#page=54" } ], "note": "All pages read; selected financial values extracted. Coverage is not a claim that every cell was normalized or that an automated parser was validated." }, "trace": { "source_dataset_hash": "2d17662dd9275c80520c1c020ea0856b35fbdf5214c8feb897412ab1ffaedb3a", "source_pdf_hash": "96b1174acff58ba1cb1212ad7b9f74aecfbf966c126c437a65928f0ab2908543", "hash_scope": "Canonical reviewed table JSON, distinct from source PDF bytes and generated artifact bytes.", "steps": [ { "id": "curate", "label": "Review report", "kind": "manual", "detail": "Read all 54 pages; transcribe selected tables with source pages and original units." }, { "id": "normalize", "label": "Normalize facts", "kind": "python", "detail": "Pydantic checks table periods, rows, values and source pages; emit uniquely keyed fact records." }, { "id": "calculate", "label": "Calculate comparisons", "kind": "python", "detail": "Build ratios, shares, year-on-year contributions and cash/core/equity reconciliations." }, { "id": "validate", "label": "Check identities", "kind": "python", "detail": "Reconcile statement totals and partitions; retain blank comparatives and basis boundaries." }, { "id": "serve", "label": "Serve JSON and saved exports", "kind": "fastapi", "detail": "GET /api/report returns the same financial calculation as the saved JSON artifact. No inference." } ] }, "cost": { "currency": "USD", "actual": 0, "model_calls": 0, "label": "Real local deterministic calculations; no paid model or data call." }, "limitations": [ "New independent portfolio experiment using public disclosures; no employer engagement or historical delivery is implied.", "Reviewed table transcription is the input; a general PDF extraction system, database warehouse and live ingestion are not implemented.", "The report supports Q4 and full-year comparisons for 2025/2024 plus two year-end balance sheets. It does not supply a multi-quarter forecast training dataset or internal budget.", "Reported IFRS results, company-defined core/non-IFRS measures, dated stocks and period flows remain separate.", "Calculated growth and shares use displayed rounded amounts; reported constant-currency growth is a different non-IFRS measure.", "Unknown/blank cells remain null. They are never inferred from rounded growth rates or substituted with measured zeros.", "The explorer covers selected financial tables plus an inventory of all 54 pages, not every cell or narrative claim.", "No LLM-quality, forecasting accuracy, autonomous-agent performance or business savings have been measured." ], "evaluation": { "passed": 101, "failed": 0, "total": 101, "cases": [ { "id": "2025-Q4.gross_profit", "label": "IFRS gross profit identity", "expected": 10249, "actual": 10249, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.operating_income", "label": "IFRS operating-income identity", "expected": 3616, "actual": 3616, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.pretax", "label": "IFRS pretax-income identity", "expected": 3218, "actual": 3218, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.net_income", "label": "Net income after tax", "expected": 2404, "actual": 2404, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.attribution", "label": "Attributable income and non-controlling interests", "expected": 2404, "actual": 2404, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.regions", "label": "Four geographic regions reconcile to company sales", "expected": 13336, "actual": 13336, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.market_groups", "label": "Separate market-group partition reconciles", "expected": 13336, "actual": 13336, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.areas", "label": "Five sales classifications reconcile", "expected": 13336, "actual": 13336, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "expected": 13336, "actual": 13336, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.other_revenue", "label": "Other-revenue components reconcile", "expected": 524, "actual": 524, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.working_capital", "label": "Working-capital components reconcile", "expected": -1587, "actual": -1587, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.operating_cash", "label": "Operating cash-flow stages reconcile", "expected": 2264, "actual": 2264, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "expected": 11435, "actual": 11435, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "expected": 1655, "actual": 1655, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.core_adjustments", "label": "Four non-overlapping core adjustment groups", "expected": 1313, "actual": 1313, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "expected": 4929, "actual": 4929, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.core_pnl", "label": "Core P&L subtotal identity", "expected": 4929, "actual": 4929, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-Q4.equity", "label": "Total-equity rollforward", "expected": 46549, "actual": 46549, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.gross_profit", "label": "IFRS gross profit identity", "expected": 10234, "actual": 10234, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.operating_income", "label": "IFRS operating-income identity", "expected": 3530, "actual": 3530, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.pretax", "label": "IFRS pretax-income identity", "expected": 3285, "actual": 3285, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.net_income", "label": "Net income after tax", "expected": 2820, "actual": 2820, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.attribution", "label": "Attributable income and non-controlling interests", "expected": 2820, "actual": 2820, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.regions", "label": "Four geographic regions reconcile to company sales", "expected": 13153, "actual": 13153, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.market_groups", "label": "Separate market-group partition reconciles", "expected": 13153, "actual": 13153, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.areas", "label": "Five sales classifications reconcile", "expected": 13153, "actual": 13153, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "expected": 13153, "actual": 13153, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.other_revenue", "label": "Other-revenue components reconcile", "expected": 405, "actual": 405, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.working_capital", "label": "Working-capital components reconcile", "expected": 5, "actual": 5, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.operating_cash", "label": "Operating cash-flow stages reconcile", "expected": 4193, "actual": 4193, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "expected": 11459, "actual": 11459, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "expected": 3635, "actual": 3635, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.core_adjustments", "label": "Four non-overlapping core adjustment groups", "expected": 1329, "actual": 1329, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "expected": 4859, "actual": 4859, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.core_pnl", "label": "Core P&L subtotal identity", "expected": 4859, "actual": 4859, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-Q4.equity", "label": "Total-equity rollforward", "expected": 44126, "actual": 44126, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.gross_profit", "label": "IFRS gross profit identity", "expected": 42975, "actual": 42975, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.operating_income", "label": "IFRS operating-income identity", "expected": 17644, "actual": 17644, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.pretax", "label": "IFRS pretax-income identity", "expected": 16352, "actual": 16352, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.net_income", "label": "Net income after tax", "expected": 13967, "actual": 13967, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.attribution", "label": "Attributable income and non-controlling interests", "expected": 13967, "actual": 13967, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.regions", "label": "Four geographic regions reconcile to company sales", "expected": 54532, "actual": 54532, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.market_groups", "label": "Separate market-group partition reconciles", "expected": 54532, "actual": 54532, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.areas", "label": "Five sales classifications reconcile", "expected": 54532, "actual": 54532, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "expected": 54532, "actual": 54532, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.other_revenue", "label": "Other-revenue components reconcile", "expected": 2142, "actual": 2142, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.working_capital", "label": "Working-capital components reconcile", "expected": -1577, "actual": -1577, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.operating_cash", "label": "Operating cash-flow stages reconcile", "expected": 19144, "actual": 19144, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "expected": 11435, "actual": 11435, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "expected": 17596, "actual": 17596, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.core_adjustments", "label": "Four non-overlapping core adjustment groups", "expected": 4245, "actual": 4245, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "expected": 21889, "actual": 21889, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.core_pnl", "label": "Core P&L subtotal identity", "expected": 21889, "actual": 21889, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-FY.equity", "label": "Total-equity rollforward", "expected": 46549, "actual": 46549, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.gross_profit", "label": "IFRS gross profit identity", "expected": 38895, "actual": 38895, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.operating_income", "label": "IFRS operating-income identity", "expected": 14544, "actual": 14544, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.pretax", "label": "IFRS pretax-income identity", "expected": 13640, "actual": 13640, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.net_income", "label": "Net income after tax", "expected": 11939, "actual": 11939, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.attribution", "label": "Attributable income and non-controlling interests", "expected": 11939, "actual": 11939, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.regions", "label": "Four geographic regions reconcile to company sales", "expected": 50317, "actual": 50317, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.market_groups", "label": "Separate market-group partition reconciles", "expected": 50317, "actual": 50317, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.areas", "label": "Five sales classifications reconcile", "expected": 50317, "actual": 50317, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "expected": 50317, "actual": 50317, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.other_revenue", "label": "Other-revenue components reconcile", "expected": 1405, "actual": 1405, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.working_capital", "label": "Working-capital components reconcile", "expected": -706, "actual": -706, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.operating_cash", "label": "Operating cash-flow stages reconcile", "expected": 17619, "actual": 17619, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "expected": 11459, "actual": 11459, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "expected": 16253, "actual": 16253, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.core_adjustments", "label": "Four non-overlapping core adjustment groups", "expected": 4950, "actual": 4950, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "expected": 19494, "actual": 19494, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.core_pnl", "label": "Core P&L subtotal identity", "expected": 19494, "actual": 19494, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-FY.equity", "label": "Total-equity rollforward", "expected": 44126, "actual": 44126, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-12-31.assets", "label": "Balance-sheet assets reconcile", "expected": 110949, "actual": 110949, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-12-31.liabilities", "label": "Current and non-current liabilities reconcile", "expected": 64400, "actual": 64400, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-12-31.balance", "label": "Assets equal equity plus liabilities", "expected": 110949, "actual": 110949, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2025-12-31.net_debt", "label": "Signed net debt equals signed financial debts plus liquidity", "expected": -21947, "actual": -21947, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-12-31.assets", "label": "Balance-sheet assets reconcile", "expected": 102246, "actual": 102246, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-12-31.liabilities", "label": "Current and non-current liabilities reconcile", "expected": 58120, "actual": 58120, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-12-31.balance", "label": "Assets equal equity plus liabilities", "expected": 102246, "actual": 102246, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "2024-12-31.net_debt", "label": "Signed net debt equals signed financial debts plus liquidity", "expected": -16141, "actual": -16141, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.income_delta", "label": "Expected reported operating-income movement", "expected": 86, "actual": 86, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.top20", "label": "Sum of twenty brand amounts matches source top-20 total", "expected": 10765, "actual": 10765, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.income.bridge", "label": "Selected-view bridge residual: income", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.operating_cash.bridge", "label": "Selected-view bridge residual: operating_cash", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.cash_rollforward.bridge", "label": "Selected-view bridge residual: cash_rollforward", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.free_cash.bridge", "label": "Selected-view bridge residual: free_cash", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.core.bridge", "label": "Selected-view bridge residual: core", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "quarter.equity.bridge", "label": "Selected-view bridge residual: equity", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.income_delta", "label": "Expected reported operating-income movement", "expected": 3100, "actual": 3100, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.top20", "label": "Sum of twenty brand amounts matches source top-20 total", "expected": 44513, "actual": 44513, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.income.bridge", "label": "Selected-view bridge residual: income", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.operating_cash.bridge", "label": "Selected-view bridge residual: operating_cash", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.cash_rollforward.bridge", "label": "Selected-view bridge residual: cash_rollforward", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.free_cash.bridge", "label": "Selected-view bridge residual: free_cash", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.core.bridge", "label": "Selected-view bridge residual: core", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "full_year.equity.bridge", "label": "Selected-view bridge residual: equity", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "page_inventory", "label": "All 54 pages inventoried exactly once", "expected": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 ], "actual": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 ], "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "unique_fact_ids", "label": "Normalized fact IDs are unique", "expected": 868, "actual": 868, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "sources", "label": "All facts have exact page anchors and correct PDF indices", "expected": true, "actual": true, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "blank_prior", "label": "Blank new-brand prior remains unavailable", "expected": null, "actual": null, "passed": true, "tolerance": 0, "source_pages": [] }, { "id": "no_model_calls", "label": "No LLM call was made", "expected": 0, "actual": 0, "passed": true, "tolerance": 0, "source_pages": [] } ], "scope": "Deterministic accounting identities, source linkage and view-contract checks on reviewed source tables. Not an extraction or LLM-quality benchmark." }, "checks": [ { "id": "2025-Q4.gross_profit", "label": "IFRS gross profit identity", "passed": true, "detail": "Expected 10249; observed 10249" }, { "id": "2025-Q4.operating_income", "label": "IFRS operating-income identity", "passed": true, "detail": "Expected 3616; observed 3616" }, { "id": "2025-Q4.pretax", "label": "IFRS pretax-income identity", "passed": true, "detail": "Expected 3218; observed 3218" }, { "id": "2025-Q4.net_income", "label": "Net income after tax", "passed": true, "detail": "Expected 2404; observed 2404" }, { "id": "2025-Q4.attribution", "label": "Attributable income and non-controlling interests", "passed": true, "detail": "Expected 2404; observed 2404" }, { "id": "2025-Q4.regions", "label": "Four geographic regions reconcile to company sales", "passed": true, "detail": "Expected 13336; observed 13336" }, { "id": "2025-Q4.market_groups", "label": "Separate market-group partition reconciles", "passed": true, "detail": "Expected 13336; observed 13336" }, { "id": "2025-Q4.areas", "label": "Five sales classifications reconcile", "passed": true, "detail": "Expected 13336; observed 13336" }, { "id": "2025-Q4.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "passed": true, "detail": "Expected 13336; observed 13336" }, { "id": "2025-Q4.other_revenue", "label": "Other-revenue components reconcile", "passed": true, "detail": "Expected 524; observed 524" }, { "id": "2025-Q4.working_capital", "label": "Working-capital components reconcile", "passed": true, "detail": "Expected -1587; observed -1587" }, { "id": "2025-Q4.operating_cash", "label": "Operating cash-flow stages reconcile", "passed": true, "detail": "Expected 2264; observed 2264" }, { "id": "2025-Q4.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "passed": true, "detail": "Expected 11435; observed 11435" }, { "id": "2025-Q4.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "passed": true, "detail": "Expected 1655; observed 1655" }, { "id": "2025-Q4.core_adjustments", "label": "Four non-overlapping core adjustment groups", "passed": true, "detail": "Expected 1313; observed 1313" }, { "id": "2025-Q4.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "passed": true, "detail": "Expected 4929; observed 4929" }, { "id": "2025-Q4.core_pnl", "label": "Core P&L subtotal identity", "passed": true, "detail": "Expected 4929; observed 4929" }, { "id": "2025-Q4.equity", "label": "Total-equity rollforward", "passed": true, "detail": "Expected 46549; observed 46549" }, { "id": "2024-Q4.gross_profit", "label": "IFRS gross profit identity", "passed": true, "detail": "Expected 10234; observed 10234" }, { "id": "2024-Q4.operating_income", "label": "IFRS operating-income identity", "passed": true, "detail": "Expected 3530; observed 3530" }, { "id": "2024-Q4.pretax", "label": "IFRS pretax-income identity", "passed": true, "detail": "Expected 3285; observed 3285" }, { "id": "2024-Q4.net_income", "label": "Net income after tax", "passed": true, "detail": "Expected 2820; observed 2820" }, { "id": "2024-Q4.attribution", "label": "Attributable income and non-controlling interests", "passed": true, "detail": "Expected 2820; observed 2820" }, { "id": "2024-Q4.regions", "label": "Four geographic regions reconcile to company sales", "passed": true, "detail": "Expected 13153; observed 13153" }, { "id": "2024-Q4.market_groups", "label": "Separate market-group partition reconciles", "passed": true, "detail": "Expected 13153; observed 13153" }, { "id": "2024-Q4.areas", "label": "Five sales classifications reconcile", "passed": true, "detail": "Expected 13153; observed 13153" }, { "id": "2024-Q4.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "passed": true, "detail": "Expected 13153; observed 13153" }, { "id": "2024-Q4.other_revenue", "label": "Other-revenue components reconcile", "passed": true, "detail": "Expected 405; observed 405" }, { "id": "2024-Q4.working_capital", "label": "Working-capital components reconcile", "passed": true, "detail": "Expected 5; observed 5" }, { "id": "2024-Q4.operating_cash", "label": "Operating cash-flow stages reconcile", "passed": true, "detail": "Expected 4193; observed 4193" }, { "id": "2024-Q4.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "passed": true, "detail": "Expected 11459; observed 11459" }, { "id": "2024-Q4.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "passed": true, "detail": "Expected 3635; observed 3635" }, { "id": "2024-Q4.core_adjustments", "label": "Four non-overlapping core adjustment groups", "passed": true, "detail": "Expected 1329; observed 1329" }, { "id": "2024-Q4.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "passed": true, "detail": "Expected 4859; observed 4859" }, { "id": "2024-Q4.core_pnl", "label": "Core P&L subtotal identity", "passed": true, "detail": "Expected 4859; observed 4859" }, { "id": "2024-Q4.equity", "label": "Total-equity rollforward", "passed": true, "detail": "Expected 44126; observed 44126" }, { "id": "2025-FY.gross_profit", "label": "IFRS gross profit identity", "passed": true, "detail": "Expected 42975; observed 42975" }, { "id": "2025-FY.operating_income", "label": "IFRS operating-income identity", "passed": true, "detail": "Expected 17644; observed 17644" }, { "id": "2025-FY.pretax", "label": "IFRS pretax-income identity", "passed": true, "detail": "Expected 16352; observed 16352" }, { "id": "2025-FY.net_income", "label": "Net income after tax", "passed": true, "detail": "Expected 13967; observed 13967" }, { "id": "2025-FY.attribution", "label": "Attributable income and non-controlling interests", "passed": true, "detail": "Expected 13967; observed 13967" }, { "id": "2025-FY.regions", "label": "Four geographic regions reconcile to company sales", "passed": true, "detail": "Expected 54532; observed 54532" }, { "id": "2025-FY.market_groups", "label": "Separate market-group partition reconciles", "passed": true, "detail": "Expected 54532; observed 54532" }, { "id": "2025-FY.areas", "label": "Five sales classifications reconcile", "passed": true, "detail": "Expected 54532; observed 54532" }, { "id": "2025-FY.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "passed": true, "detail": "Expected 54532; observed 54532" }, { "id": "2025-FY.other_revenue", "label": "Other-revenue components reconcile", "passed": true, "detail": "Expected 2142; observed 2142" }, { "id": "2025-FY.working_capital", "label": "Working-capital components reconcile", "passed": true, "detail": "Expected -1577; observed -1577" }, { "id": "2025-FY.operating_cash", "label": "Operating cash-flow stages reconcile", "passed": true, "detail": "Expected 19144; observed 19144" }, { "id": "2025-FY.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "passed": true, "detail": "Expected 11435; observed 11435" }, { "id": "2025-FY.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "passed": true, "detail": "Expected 17596; observed 17596" }, { "id": "2025-FY.core_adjustments", "label": "Four non-overlapping core adjustment groups", "passed": true, "detail": "Expected 4245; observed 4245" }, { "id": "2025-FY.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "passed": true, "detail": "Expected 21889; observed 21889" }, { "id": "2025-FY.core_pnl", "label": "Core P&L subtotal identity", "passed": true, "detail": "Expected 21889; observed 21889" }, { "id": "2025-FY.equity", "label": "Total-equity rollforward", "passed": true, "detail": "Expected 46549; observed 46549" }, { "id": "2024-FY.gross_profit", "label": "IFRS gross profit identity", "passed": true, "detail": "Expected 38895; observed 38895" }, { "id": "2024-FY.operating_income", "label": "IFRS operating-income identity", "passed": true, "detail": "Expected 14544; observed 14544" }, { "id": "2024-FY.pretax", "label": "IFRS pretax-income identity", "passed": true, "detail": "Expected 13640; observed 13640" }, { "id": "2024-FY.net_income", "label": "Net income after tax", "passed": true, "detail": "Expected 11939; observed 11939" }, { "id": "2024-FY.attribution", "label": "Attributable income and non-controlling interests", "passed": true, "detail": "Expected 11939; observed 11939" }, { "id": "2024-FY.regions", "label": "Four geographic regions reconcile to company sales", "passed": true, "detail": "Expected 50317; observed 50317" }, { "id": "2024-FY.market_groups", "label": "Separate market-group partition reconciles", "passed": true, "detail": "Expected 50317; observed 50317" }, { "id": "2024-FY.areas", "label": "Five sales classifications reconcile", "passed": true, "detail": "Expected 50317; observed 50317" }, { "id": "2024-FY.products", "label": "Disclosed non-null leaf amounts reconcile; blanks remain unavailable", "passed": true, "detail": "Expected 50317; observed 50317" }, { "id": "2024-FY.other_revenue", "label": "Other-revenue components reconcile", "passed": true, "detail": "Expected 1405; observed 1405" }, { "id": "2024-FY.working_capital", "label": "Working-capital components reconcile", "passed": true, "detail": "Expected -706; observed -706" }, { "id": "2024-FY.operating_cash", "label": "Operating cash-flow stages reconcile", "passed": true, "detail": "Expected 17619; observed 17619" }, { "id": "2024-FY.cash_rollforward", "label": "Cash rollforward includes foreign-exchange effects", "passed": true, "detail": "Expected 11459; observed 11459" }, { "id": "2024-FY.fcf", "label": "Company FCF equals operating cash flow plus signed PP&E purchases", "passed": true, "detail": "Expected 16253; observed 16253" }, { "id": "2024-FY.core_adjustments", "label": "Four non-overlapping core adjustment groups", "passed": true, "detail": "Expected 4950; observed 4950" }, { "id": "2024-FY.ifrs_to_core", "label": "IFRS to core operating-income reconciliation", "passed": true, "detail": "Expected 19494; observed 19494" }, { "id": "2024-FY.core_pnl", "label": "Core P&L subtotal identity", "passed": true, "detail": "Expected 19494; observed 19494" }, { "id": "2024-FY.equity", "label": "Total-equity rollforward", "passed": true, "detail": "Expected 44126; observed 44126" }, { "id": "2025-12-31.assets", "label": "Balance-sheet assets reconcile", "passed": true, "detail": "Expected 110949; observed 110949" }, { "id": "2025-12-31.liabilities", "label": "Current and non-current liabilities reconcile", "passed": true, "detail": "Expected 64400; observed 64400" }, { "id": "2025-12-31.balance", "label": "Assets equal equity plus liabilities", "passed": true, "detail": "Expected 110949; observed 110949" }, { "id": "2025-12-31.net_debt", "label": "Signed net debt equals signed financial debts plus liquidity", "passed": true, "detail": "Expected -21947; observed -21947" }, { "id": "2024-12-31.assets", "label": "Balance-sheet assets reconcile", "passed": true, "detail": "Expected 102246; observed 102246" }, { "id": "2024-12-31.liabilities", "label": "Current and non-current liabilities reconcile", "passed": true, "detail": "Expected 58120; observed 58120" }, { "id": "2024-12-31.balance", "label": "Assets equal equity plus liabilities", "passed": true, "detail": "Expected 102246; observed 102246" }, { "id": "2024-12-31.net_debt", "label": "Signed net debt equals signed financial debts plus liquidity", "passed": true, "detail": "Expected -16141; observed -16141" }, { "id": "quarter.income_delta", "label": "Expected reported operating-income movement", "passed": true, "detail": "Expected 86; observed 86" }, { "id": "quarter.top20", "label": "Sum of twenty brand amounts matches source top-20 total", "passed": true, "detail": "Expected 10765; observed 10765" }, { "id": "quarter.income.bridge", "label": "Selected-view bridge residual: income", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "quarter.operating_cash.bridge", "label": "Selected-view bridge residual: operating_cash", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "quarter.cash_rollforward.bridge", "label": "Selected-view bridge residual: cash_rollforward", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "quarter.free_cash.bridge", "label": "Selected-view bridge residual: free_cash", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "quarter.core.bridge", "label": "Selected-view bridge residual: core", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "quarter.equity.bridge", "label": "Selected-view bridge residual: equity", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.income_delta", "label": "Expected reported operating-income movement", "passed": true, "detail": "Expected 3100; observed 3100" }, { "id": "full_year.top20", "label": "Sum of twenty brand amounts matches source top-20 total", "passed": true, "detail": "Expected 44513; observed 44513" }, { "id": "full_year.income.bridge", "label": "Selected-view bridge residual: income", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.operating_cash.bridge", "label": "Selected-view bridge residual: operating_cash", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.cash_rollforward.bridge", "label": "Selected-view bridge residual: cash_rollforward", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.free_cash.bridge", "label": "Selected-view bridge residual: free_cash", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.core.bridge", "label": "Selected-view bridge residual: core", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "full_year.equity.bridge", "label": "Selected-view bridge residual: equity", "passed": true, "detail": "Expected 0; observed 0" }, { "id": "page_inventory", "label": "All 54 pages inventoried exactly once", "passed": true, "detail": "Expected [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54]; observed [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54]" }, { "id": "unique_fact_ids", "label": "Normalized fact IDs are unique", "passed": true, "detail": "Expected 868; observed 868" }, { "id": "sources", "label": "All facts have exact page anchors and correct PDF indices", "passed": true, "detail": "Expected True; observed True" }, { "id": "blank_prior", "label": "Blank new-brand prior remains unavailable", "passed": true, "detail": "Expected None; observed None" }, { "id": "no_model_calls", "label": "No LLM call was made", "passed": true, "detail": "Expected 0; observed 0" } ] }